Cancer Metastases of 202 Kinds of Cancers via Cytocapsular Tubes

Tingfang Yi^{1,2,3*}, PhD, Gerhard Wagner^{1,2,3,4}, PhD

1. Cytocapsula Research Institute, 245 First Street, Cambridge, MA, 02142 USA
2. Cellmig Biolabs Inc., 790 Memorial Drive, Cambridge, MA, 02139 USA
3. Celldim Therapeutics Inc., 790 Memorial Drive, Cambridge, MA, 02139 USA
4. Department of Biological Chemistry and Molecular Pharmacology of Harvard Medical School, 240 Longwood, Boston, MA, 02115 USA

* Address reprint requests to Dr. Tingfang Yi, Cytocapsula Research Institute, 245 First Street, Cambridge, MA, 02142 USA, or at tyi@cytocapsula.com.

BACKGROUND Cancer metastasis is the primary source of solid cancer lethality, but the underlying mechanisms have essentially remained elusive. Recently, we found that cytocapsular tubes, a newly discovered organelle of mammalian cells, conduct cell translocation, suggesting an efficient pathway for cancer cell metastases.

METHODS We performed immunohistochemistry staining and fluorescence microscope imaging analyses of 6 kinds of normal organs (n=14 patients), 38 subtypes of benign tumors (n=126 patients), and 8,061 clinical solid cancer tissue samples (covering 202 types and subtypes of cancers, and including cancers, paracancer tissues and metastatic cancers) taken from 7,125 cancer patients. These solid cancers cover 30 types of organs. We characterized cytocapsular tubes (CTs), cell migration in CTs, and CT quantity, density, network, superstructures and lifecycle in clinical samples of normal tissues, benign tumors, cancers, paracancer tissues, and metastatic cancers.

RESULTS There is no cytocapsular tubes (CTs) in normal organ tissues. Among the 126 benign tumor samples (covering 38 subtypes) from 126 patients, 86.6% do not have CTs and the other 13.4% show benign-to-malignancy transitions with CTs. Of the 8,061 solid cancer tissue

and paracancer samples from 7,125 patients, 100% of cancers (including carcinomas *in situ*), 100% of paracancer tissues, and 100% of metastatic cancer tissues/organs, harbor large quantities (from thousands to hundreds of thousands) of CTs with many cancer cells in migration inside.

CONCLUSION

Cytocapsular tubes and networks provide membrane-enclosed physical freeway systems for clinical cancer cell metastasis to neighboring and far-distance tissues and organs.

Introduction

Cancer is a leading cause of human mortality¹. It has been estimated that approximately 19.3 million new cancer cases and approximately 10 million cancer deaths occurred worldwide in 2020 alone¹. Cancer metastasis is the major source of cancer lethality²⁻⁶. The verifiable identification of cancer metastasis mechanisms is a prerequisite for the effective prognosis, diagnosis, pharmacotherapy and treatment for patients with suspicious, progressive, symptomatic, metastatic and recurrent cancers, for effective drug development, for minimizing side effects and sufferings, and for reliably determining the benefits of treatments. Prognosis, diagnosis and treatment responses are usually assessed with the application of radiographic/ MRI imaging at millimeter (mm) level, which fails to detect the cancer metastasis pathways at micrometer (μm) level⁷⁻⁹. The methods of precise identification of initial cancerous transformation at μm level in tissues are absent. Therefore, there is an urgent need for verifiable identification of cancer metastasis mechanisms and biomarkers that effectively detect cancer metastasis physical pathways with high sensitivity and specificity.

Cancer cell metastasis proceeding unprotected through tissues *in vivo* would encounter numerous heterogeneous neighbor cells and diverse extracellular matrices (ECM), all of which function as both migration clues and substantial environmental obstacles impeding the migration and long distance translocation of cancer cells. Although a number of hypotheses have been proposed¹⁰⁻¹⁶, consistent models are still missing that could explain the mechanisms underlying cancer metastasis to different sites.

Recently, we discovered that previously unknown membrane-enclosed organelles, dubbed cytocapsular tubes (CTs)¹⁷, can conduct efficient cell translocation (**Fig. S1A; Movies S1-2**). We developed anti-CM-01 antibodies that recognize a CT membrane protein marker *in-vitro* (**Fig. S1A**). We have now used the same membrane protein marker, to investigate CTs in 8,061 solid cancer and paracancer tissues from 7,125 cancer patients (covering 202 kinds of cancers, and including cancers, paracancer and metastatic cancer tissues). We found that the cancer cells in all examined 202 kinds of cancers employ a similar mechanism for near- and long-distance metastases based on CT networks.

Methods

Patients and Sample Collection

The sources of clinical samples are described in **Fig. 1**. The patients providing formalin-fixed paraffin-embedded (FFPE) tissue samples gave informed consent that indicated that they understood that the biopsies (needle biopsy or surgical biopsy) were performed for research purposes only. Comparative deidentified samples of normal tissues, benign tissues, carcinoma *in situ*, cancer, paracancer, metastatic tissues with their cancer stages identified according to the TNM system (cancer stages: 0, I, II, III, IV) were obtained from archival materials. The cancer,

paracancer and metastatic cancer tissues, in which the original cancer niches were identified by indicated cancer specific molecular markers, were identified by hospital pathology laboratories and obtained from archival materials.

Histology and Immunohistochemical testing

Cancer lesion samples were obtained from the index patients from clinical hospitals in USA (8,036 specimens from 7,088 patients, US Biomax; others samples directly from clinical hospitals). Samples were processed for histopathological evaluation with the use of hematoxylin and eosin (H&E) staining. Immunohistochemical (IHC) fluorescence tests were performed to stain CTs using rabbit anti-CM-01 monoclonal and polyclonal primary antibodies (self-made), mouse anti-gamma-actin monoclonal primary antibodies (Abcam, ab123034) (**Fig. S1**).

Data collection

Cytocapsular tubes (not sectioned, longitudinally sectioned, and cross sectioned) without degradation (3~6 μ m in measured diameter) were counted using a fluorescence microscope and ImageJ. The presence of CTs degrading into thick strands (1~2 μ m in measured diameter), thin strands (0.2~1 μ m in measured diameter), or the disintegration state were reported without quantification.

Statistical analysis

For each specimen, the number of fully intact cytocapsular tubes was counted in 5 areas (0.35mm x 0.35mm, length x width) of the sample (top, bottom, left, right, and center), and the CT density (CT/mm²) was calculated and determined for each area. The average CT density across the 5 sites was treated as the specimen's overall CT density.

Results

Cancer metastasis via cytocapsular tubes in 202 kinds of cancers

Normal tissues: In the 6 types of normal tissues analyzed immunohistochemically (breast, colon, liver, lung, prostate, and stomach; n=1 to 3 patients for each type, n=14 patients in total), no cytocapsular tubes were found (CT, 0%) (**Fig. 2A and Fig. S2A, 2D,**).

Benign tumors: Of the 6 types (breast, lung, prostate, stomach, liver, colon; covering 38 subtypes) of clinical benign tumor samples (n= 1 to 15 patients of each subtype, n=126 patients in total), approximately 86.6% don't present CTs; however, approximately 13.4% harbor CTs, displaying the transition of a benign tumor to a malignant tumor (**Fig. 2A, and Fig. S2B, 2E and Table S1**). CTs are invisible in conventional hematoxylin & eosin staining assay or in IHC staining assays with multiple popular cancer protein marker antibodies (such as anti-ER, anti-PR and anti-HER2 antibodies for breast cancer; anti-MSH-2 antibody for colon cancer) (**Figs.S2-3**), but visible in IHC staining assays with anti-CM-01 antibodies in multiple types of cancers, including cancers in breast, colon, oral and thyroid (**Figs. S2-S5**).

Carcinoma in situ: This is the early stage before spreading. In breast carcinoma in situ tissues (n=12), 100% of them have plenty of CTs and the average CT density is high up to 106 CT/mm² (**Excel S1**).

202 subtypes of cancer: Next, we performed CT analyses in 202 subtypes of cancers. In the 6, 837 cancer tissue samples from 6,795 cancer patients (covering 202 subtypes of cancer tissues), all of them (100%) harbor CTs with various CT densities, and cancer cells were found in migration inside the CTs (**Figs.2-3, S2, Tables 1-2, Excel S1-2**). These 202 subtypes of cancers cover up to 30 kinds of organs: adrenal gland, bladder, bone, brain, breast, cervix uteri, colon, esophagus, gallbladder, head/neck, intestine, kidney, liver, lung, lymph node, oesophagus, oral

cavity, ovary, pancreas, penis, prostate, rectum, skin, spleen, stomach, testis, thymus, thyroid, uterus, and vulva (n=3~2774 patients per type of organ). The CT densities in cancers of these 30 kinds of organs vary in a range from 6 to 111 CT/mm² (**Figs.2-3, Excel S1-2**).

Paracancer: This is a state tissues must pass towards solid cancer metastasis. We performed IHC staining analyses with clinical paracancer tissues (namely “normal adjacent tissue, NAT”) of breast and prostate cancers, and found that these paracancer tissues contain plenty of CTs and CT networks with many cancer cells migrating in CTs (**Fig.2**). Next, we performed IHC staining analyses with paracancer tissues of 12 types of cancers (covering 64 subtypes of cancers) in bladder, breast, esophagus, colon, intestine, kidney, liver, lung, ovary, pancreas, stomach and uterus (**Fig. 4**). In these paracancer tissues of 64 subtypes of cancers (n=3~365 samples per subtype), 100% paracancer tissues harbor plenty of CTs. The CT densities of these paracancer tissues range from 67 to 114CT/mm² (**Fig. 4**). There are many cancer cells migrating in all the CTs in paracancer tissues of all the 64 cancer subtypes (**Fig. 4**).

Metastatic cancers: Subsequently, we investigated CTs in clinical metastatic mucinous adenocarcinoma from colon in liver, metastatic adenocarcinoma from ovary in epiploon, metastatic breast adenocarcinoma in lymph node, and metastatic mucinous adenocarcinoma from unknown sites in epiploon, 100% of them harbor numerous CTs with many cancer cells migrating in CTs (**Fig. S6**). We performed CT analyses in 9 types of metastatic cancer tissues in multiple metastatic sites, and found that 100% of these clinical metastatic cancers harbor a lot of CTs with many cancer cells in migration in CTs (**Fig.5A**). We performed CT analyses in more metastatic cancers with successive cancer-paracancer-metastatic sites in breast, colon, pancreas and ovary, 100% of these samples along the cancer-paracancer-metastatic site axis harbor plenty

of CTs with increased CT density in paracancer tissues comparing to cancer original niches and metastatic cancers (**Fig.5B**).

Lifecycle of cytocapsular tubes in clinical tissues

We analyzed the acquired >60,000 frames of IHC fluorescence microscope images of the examined 8,061 cancer/paracancer/metastatic samples taken from 7,125 patients covering 202 kinds of cancers, and found variations in CT quantity, density, morphologies, distribution, CT networks, stages in CT life cycle, and superstructure textures, displaying a huge diversity of CTs and networks in all kinds of clinical cancers. Thus, based on the comprehensive analyses of these images, we can identify a lifecycle of cytocapsular tubes in clinical cancers. It can be categorized into 5 successive stages: 1) CT initiation; 2) CT elongation, network formation and cancer cell migration inside; 3) CTs and networks invasion into and pass through paracancer tissues; 4) CTs and CT networks cross tissues and organs and reach neighboring and far-distance destinations; 5) CT degradation and decomposition.

In the initiation phase, individual cancer cells generate cytocapsulas that envelope the cancer cells. Cancer cells migrate inside and generate elongated CTs. The rear part of the CTs display shrunk and thin-tailed morphologies as they are not well anchored in the ECM (**Fig.S7A**). CTs continue to elongate and form long CTs with consistent diameter/width (2~6 μ m in diameter). Individual elongated CTs aggressively invade into neighboring loose and compact tissues, even invade through the tightly-connected and thickness-enhanced epithelial layer of terminal ducts in breast cancer (**Fig.S7B**). Membrane-enclosed CTs interconnect to each other and form superlarge 3D CT networks and provide membrane-enclosed 3D freeway systems that allow multiple migration directions for CT-conducted cancer cell dissemination in tissues (**Fig.S8**).

Elongated CTs generate curved and entangled CT masses that occupy spaces and create CT mass cavities (CMCs). Locally, still-free cancer cells invade into CTs and migrate away via CTs , which creates free (liquid-filled) spaces and cavities that grow in size (**Figs.S9A-B**). After CT masses degrade and decompose, the empty but liquid filled CT mass cavities (CMCs) are left in the compact cancer tissues (**Figs. S9C**). Numerous CTs align together and form CT bundles and invade into compact tissues (**Fig.S10A**). Nearby cancer cells invade into CTs and migrate away, CT masses occupy the spaces while few/no cancer cells remain outside of CTs (**Fig. S10B**). Cancer cells generate highly curved and coiled CTs, and invade into compact tissues in multiple directions, providing more freeways for cancer cell metastasis (**Fig. S11**). Free cancer cells invade into CTs generated by other cancer cells, make more CTs and CT networks, and escape to neighboring and far-distance destinations, leaving no free cancer cells beyond CT masses (**Figs.S12-13**). Cancer cells can generate highly curved CT masses and big curved CT masses, which provide more closed CT freeways for cancer cell invasion into CTs for metastasis (**Fig.S14**). Cancer cells generate multiple layered, highly curved, coiled superstructures invading into compact tissues, providing large CT contacting surfaces for cancer cell invasion into CT networks for cancer cell metastasis (**Fig.S15**). During CT conducted cancer metastasis, cancer cells engender many kinds of different complex superstructures for invading into and pass through diverse compact tissues (**Fig.S16**), huge, dozens-layers complex superstructures invading into tissues with diverse densities (**Fig. S17**), highly compact cone-shaped superstructure (**Fig. S18A**), or multiple layered complex superstructures (**Fig.S18B**). Massive CT clusters can powerfully invade into all kinds of loose and compact tissues (**Figs.S19-20**). Straight, curved and coiled CTs interconnect together and form large CT networks for cancer metastasis. Even though some parts of CT networks decompose due to CT degradation, the left

CT networks remain capable of providing CT efficient freeway systems for cancer cell metastasis progression. Thus, CT networks display potent damage resistance capacities and provide efficient CT freeway systems for cancer metastasis (**Fig.S21**). Subsequent CT degradation employs a multiple-step format: 1) numerous dot membranes on CT surfaces collapse, 2) CTs form a thin CT strand-interconnected network in tube shapes; 3) thin CT strands decompose, disconnect and form individual CT strands; 4) disconnected thin CT strands, decompose and disappear in a complex manner (**Figs.S22-24**).

The numbers of CTs are always much larger than those of circulating system vessels (blood/lymph vessels) (**Fig. S25A**). In most instances, plenty of CTs pass through, surround and embed circulating system vessels (blood vessels and lymph vessels) without invading into blood vessels and lymph vessels (**Fig. S25A**). In the examined 8 kinds of organs, the average number ratio of CTs versus blood and lymph vessels in cancers, paracancer tissues and metastatic cancers is around 1000 (**Fig. S25B**). In the late (but not early) stage cancers (stage III or IV), CTs invade into the tightly connected endothelial layers of approximately 1 in 10^4 blood/lymph vessels and release cancer cells into circulation system vessels (**Fig.S26A**). Approximately 1% of CT invaded blood/lymph vessels present leak/disassembly followed by local blood cell spreading (**Figs.S26B-C**). CT analyses with needle biopsy samples provide a linear CT scan in multiple-layer tissues (**Fig.S27**).

Cytocapsular tube based cancer metastasis grading

Based on the above observations and data of cancer CT numbers, density, degradation, and metastasis situations of the 8,061 solid cancer and paracancer tissue samples from 7,125 cancer patients (covering 202 kinds of cancers), we suggest a five stage CT-based cancer metastasis

(CM) grading reference: CM0, CM1, CM2, CM3, and CM4 (**Table S3**). On the basis of the comprehensive analyses of the cancer stages and CT based CM grade of 7251 benign tumor and cancer patients, we found relationships between cancer stages and CT based CM grades listed in **Table S4**.

Discussion

It is vital to understand the long-term elusive mechanics underlying cancer metastasis¹⁸⁻²⁵. Here, we investigated the metastasis mechanics of 202 kinds of clinical cancers, and evidenced that cancer cells generate substantial membrane-enclosed freeway systems formed by cytocapsular tubes and CT networks that conduct cancer-cell metastases to neighboring and far-distant tissues and organs; this was found to be the case in all 202 kinds of solid cancers tested.

Our data indicate that cancerous cells upon becoming malignant decide to generate extra-cellular cytocapsular tubes initiated by a not-yet-known mechanism. CTs are used by the originator cells and other cancer cells. From there on, cancer cells can migrate in large quantity CTs and protected from outside attacks. CTs can be very long consistent with far-distance metastasis. While most of our data shown here are obtained from snapshots of clinical cancers samples received from cancer tissue banks, the emerging picture is confirmed by clinal data from live cancer patients with cancers in 9 kinds of organs: breast, colon, lung, oral, pancreas, prostate, skin, testis, and thyroid.

It was unforeseen that cytocapsular tubes would be ubiquitously used as physical freeways for cancer metastasis in all 202 kinds of examined solid cancers. Membrane-enclosed homogeneous CTs shield cancer cells from external heterogeneous obstacles of neighbor cells and ECM, and

significantly facilitate efficient cancer cell dissemination. 3D CT networks provide substantial physical freeways leading in multiple and expanding directions for cancer cell metastases to far-distance tissues and organs. Collective and self-organization activities of long CTs, large networks and superstructures augment collective cancer metastasis through dense, compacted and diverse tissues, cross organs and reach far-distance destinations. The number of cancer cell-filled CTs is approximately 1000-fold larger than that of blood and lymph vessels, and only approximately one 1 of 10,000 blood/lymph vessels present CT-vessel invasion in late stage cancers where cancer cells are released into the circulation systems. This is consistent with clinical observations that there are rare circulating cancer cells (CTCs) in the circulation system²⁶⁻²⁸. These above observations evidenced that the ubiquitous and large quantities of CT networks provide the major physical pathways for neighboring and far-distance cancer metastases in cancer patients.

It is essential to precisely evaluate the cancer metastasis status in prognosis, before and after treatments, and during cancer management to achieve better outcomes for patients. So far, a quantitative and precise cancer metastasis evaluation system is absent^{2-3, 29}. The cytocapsular tube-based cancer metastasis (CM) grading described here may facilitate the accurate evaluation of cancer cell status and metastasis, thereby improving therapy outcomes. To take advantage of the possibilities for the precise and qualitative evaluation of CT-based cancer metastasis, more clinical analyses are required. In the future, we expect that CT-based drug and technology development will significantly improve cancer pharmacotherapy and management.

Supported by a grant (to Dr. Yi) from Cytocapsula Research Institute Fund for Cytocapsular Tube Conducted Cancer Metastasis Research, and a grant (to Dr. Yi) from Cellmig Biolabs Inc Fund for Cytocapsular Tube Cancer Metastasis Research.

We greatly acknowledge Dr. Ed Harlow, Harvard Medical School (USA) and Cancer Institute of University of Cambridge (UK), Dr. Jon Aster, Harvard Medical School, Dr. Jelle Wesseling, Leiden University (Netherlands), Dr. David Golan of Harvard Medical School (USA), and Steven Ganshirt, MD of Northwestern University Medical School for their help and meaningful discussion in the study.

Reference:

1. Sung H, et al, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021; Online ahead of print.
2. Chaffer CL, Weinberg RA. A Perspective on Cancer Cell Metastasis. *Science* 2011; 331:1559-64
3. Friedl P, Wolf K. Tumour-cell invasion and migration: Diversity and escape mechanisms. *Nat Rev Cancer* 2003; 3:362–374.
4. Steeg PS. Targeting metastasis. *Nat Rev Cancer*. 2016 Apr; 16: 201–218.
5. Massagué J, Obenauf AC. Metastatic Colonization. *Nature* 2016; 529: 298–306
6. Barbolina MV, et al. Microenvironmental regulation of ovarian cancer metastasis. *Cancer Treat Res* 2009; 149:319–334.
7. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell* 2009; 139:871–890.
8. Franz CM, Jones GE, Ridley AJ. Cell migration in development and disease. *Dev Cell* 2002; 2:153–158.
9. Mehlen P, Puisieux A. Metastasis: a question of life or death. *Nat Rev Cancer* 2006; 6:449–58
10. Stephen Paget. The distribution of secondary growths in cancer of the breast. *The Lancet* 1889; 133:571-573.
11. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. *Nat Rev Cancer* 2003; 3:453–8
12. Erler JT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. *Nature* 2006; 440:1222–6.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; 144:646-74.
14. Turajlic S, Swanton C. Metastasis as an evolutionary process. *Science* 2016; 352:169-75.
15. Chiang AC, Massagué J. Molecular basis of metastasis. *N Engl J Med* 2008;359:2814-23.
16. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. *Cell* 2011; 147: 275–292.
17. Yi F, Wagner G. Cytocapsular tubes conduct cell translocation. *Proc Natl Acad Sci U S A* 2018; 115: E1137-E1146.
18. Sporn, M.B. The war on cancer. *Lancet* 1996; 347, 1377–1381.
19. Kinzler, K.W., and Vogelstein, B. Landscaping the cancer terrain. *Science* 1998; 280, 1036–1037.
20. Chambers, A.F., and Matrisian, L.M. Changing views of the role of matrix metalloproteinases in metastasis. *J. Natl. Cancer Inst* 1997; 89, 1260–1270.
21. Johnson, J.P. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. *Cancer Metastasis Rev* 1991; 10, 11–22.
22. Chiang AC, Massagué J. Molecular basis of metastasis. *N Engl J Med* 2008; 359:2814-23.
23. Zetter BR. The cellular basis of site-specific tumor metastasis. *N Engl J Med* 1990; 322:605-12.
24. Roodman GD. Mechanisms of bone metastasis. *N Engl J Med* 2004; 350:1655-64.
25. Birkbak NJ, McGranahan N. Cancer genome evolutionary trajectories in metastasis. *Cancer Cell* 2020; 13;37(1):8-19.
26. Ashworth TR.. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. *Med J Aust.* 1869;14:146–7.
27. Nowell PC.. The clonal evolution of tumor cell populations. *Science.* 1976;194:23–8.
28. Dawson S, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med.* 2013;368:1199–209.
29. Boire A, et al. Brain metastasis. *Nat Rev Cancer* 2020; 20:4-11.

Figure legends:

Figure 1. Origen and Enrollment of Clinical Samples from 7,253 Patients.

In the 7,253 cancer patients, 846 cancer patients provided both cancer and paracancer tissues, 42 cancer patients provided 84 samples (2 tissue samples per patient), and 5,907 cancer patients provided one tissue sample each. In the 24 cancer patients, each provided with 1 original cancer sample, 1 paracancer sample and 1 metastatic cancer sample.

Figure 2. Cytocapsular tubes that are ubiquitously present in clinical solid cancer tissues (but not in normal tissues or benign tumors) are membrane-enclosed, physical freeways of cancer cell metastasis.

A: Comprehensive analyses of 6 kinds of normal human tissues, 38 kinds of benign tumors in 6 kinds of tissues, and 202 types/subtypes of solid cancers in 30 kinds of tissues evidence that CTs, which are ubiquitously distributed in solid cancers but not in normal tissues or non-transformed benign tumors, are physical freeways of cancer cell metastasis and dissemination. **B:** Representative fluorescence microscope image of a clinical pancreas carcinoma stained with DAPI, anti-CM-01 and anti- γ -actin antibodies in immunohistochemistry (IHC) assays. A long and highly curved, membrane-enclosed cytocapsular tube (CT) with many hairpins, turns and coils (white arrows, measured length is approximately 5400 μ m in the sectioned specimen analyzed by ImageJ), forming a super-large structure in an irregular morphology. Outer side that

well-formed structure, there are many CT strands (CTS) degraded from another layer of super-large CT structure(s). **C:** Representative fluorescence microscope image of a clinical breast cancer with many aligned CTs (white arrows) and CT bunches. Breast cancer cells (yellow and orange arrows) migrate in the long and membrane enclosed freeways of CTs. Indicated are: longitudinally sectioned CT fragments with longitudinally sectioned cells migrating in CTs (yellow arrows, in a thin and long morphology shaped by CT membranes), cross sectioned CTs with cross sectioned cells in migration in CTs (orange arrows), and cross sectioned CT surfaces without cells (purple arrows). Scale bar, 10 μ m.

Figure 3. Characterization of cytocapsular tubes in 202 kinds of clinical cancers in 30 types of human organs.

The cancer patient and tissue sample collection underwent randomization. The cytocapsular tube presence, percentages and densities in all the 6,837 examined cancer tissue samples from 6,795 cancer patients (covering 202 kinds of solid cancers and 30 types of organs).

Figure 4. Cytocapsular tubes are massively distributed in paracancer tissues.

A: Representative fluorescence microscope image of paracancer or “normal adjacent tissues (NAT)” of a breast cancer with massive long, curved and entangled CTs (green color, white arrows) conducting cancer cell metastasis. There are many breast cancer cells in migration (orange arrows, the nuclei are in blue color) in the thousands of thousands of massive CTs. These images show that previously thought “normal adjacent tissues” are not real normal tissues, but harbor thousands or millions of membrane-enclosed highways of CTs conducting massive cancer

cell dissemination. **B:** Table of characterization of CTs in the examined clinical paracancer tissues of 64 subtypes of cancers in 12 kinds of organs.

Figure 5. Cytocapsular tubes (CTs) conduct crossing-organ cancer metastasis in solid cancers.

A: Characterization of CTs in crossing-organ cancer metastasis from original cancer niches (in 9 kinds of organs) to multiple far-distance and crossing-organ dissemination. **B:** Characterization of CTs in 8 kinds of cancers with crossing-organ metastasis from examining CTs in original cancer niches, paracancer tissues, and metastatic cancer tissues.

Supplementary Methods

Proteome characterization of cancer cell cytocapsulas and cytocapsular tubes and cytocapsular tube protein marker identification.

Multiple stable dual SILAC labeled human cancer cells (100% SILAC labeling with $^{13}\text{C}_6$, $^{15}\text{N}_2$ -Lys and $^{13}\text{C}_6$, $^{15}\text{N}_4$ -Arg) of pancreas cancer cell Bxpc3, non-small cell lung cancer cell A-427, breast cancer cell MCF-7, and colon cancer cell SK-CO-1 cells were cultured on 3D-Matrigel matrix to grow cytocapsulas and cytocapsular tubes¹. With cytocapsulae and cytocapsular tube ecellularization and ecellularized cytocapsulae and cytocapsular tube collection methods, SILAC labeled, ecellularized, and cell-free cytocapsulas and cytocapsular tubes were collected, followed

by SDS-gel purification and LC-MS/MS proteome analyses. We identified 412 cytocapsula and cytocapsular tube proteins. Protein marker candidate screenings were performed in cancer cell cytocapsulae and cytocapsular tubes *in vitro* with antibodies and IHC-fluorescence microscope analyses. An identified cytocapsular tube membrane protein marker named as CM-01 (Cancer Metastasis-01, an established membrane protein) was used for cytocapsular tube analyses in clinical tissues *in vivo*.

Supplementary Figure Legends:

Figure S1. Verification of a cytocapsular tube protein marker in cancer cell cytocapsular membranes *in vitro* and *in vivo*.

A: Representative fluorescence microscope images of pancreas cancer cell Bxpc3 cytocapsulae with anti-CM-01 and anti- γ -actin antibodies in immunohistochemistry (IHC) assays. Bxpc3 cells were implanted onto and cultured on a 3D-Matrigel matrix. Bxpc3 pancreas cancer cells grow cytocapsulas. After ecellulation, Bxpc3 cells existed and left ecellulated cytocapsulas (EC, orange arrows). Cytocapsular membranes (CM, white arrows) of single Bxpc3 cells, Cytocapsular membranes enclosing two or more Bxpc3 cells (CM, purple arrows), and cells outside CMs (cyan arrows) are shown. Panels of DAPI staining, anti-CM-01 antibody staining, anti- γ -actin antibody staining, and merge are shown. **B:** Representative image of collective thyroid cancer cytocapsular tubes (CTs) invading into compact thyroid cancer tissues. The bright green color specific for cytocapsular tubes, and the very low green background color in non-cytocapsular tube thyroid cancer tissues document the relative enhanced abundance of the protein marker CM-01 recognized by anti-CM-01 antibody and the specific binding ability of

anti-CM-01 antibodies. Longitudinally-sectioned CTs (white arrows) and cross-sectioned CTs (purple arrows) are shown. Scale bar, 10 μ m.

Figure S2. Cytocapsular tubes are present in clinical cancer tissues, but not in normal tissues or benign tumor tissues.

A-C: Representative images of H&E stained samples of normal clinical breast tissue, clinical breast benign tumor and clinical malignant breast cancer. **D-F:** Representative images of IHC fluorescence images of anti-CM-01 (green), anti- γ -actin (red) and DAPI (blue) stained samples of clinical normal tissue, breast benign tumor and malignant breast cancer, respectively. Conventional H&E staining method does not clearly show cytocapsular tubes (CTs) in malignant breast cancer tissues, while immunohistochemistry (IHC) staining with anti-CM-01 antibodies shows numerous CTs (white arrows) in malignant breast cancer tissues. Scale bar, 10 μ m.

Figure S3. Anti-CM-01 antibodies, but not conventional popular cancer cell marker antibodies or H&E staining, show cytocapsular tubes in clinical cancer tissues.

A: Representative images of H&E staining (panel 1) and immunohistochemistry (IHC) staining with antibodies recognize ER (estrogen receptor, panel 2), PR (Progesterone receptor, panel 3) and HER2 (human epidermal growth factor receptor 2, panel 4), and anti-CM-01 antibody (panel 5) with clinical breast cancer tissues. Only IHC staining with anti-CM-01 antibody show that there are many cytocapsular tubes (CTs, white arrow, in curved tube-shaped morphologies with 3-6 μ m in diameter/width, in red-framed areas) in clinical breast cancer tissues, which are invisible in the panels 1-4. These 5 specimen analyzed here are 5 continuously-sectioned

specimens (5µm in thickness, panels 1-5) from the same site of the same clinical breast tumor sample. **B:** Representative images of H&E staining (panel 1) and IHC staining with antibodies recognizing DNA mismatch repair protein MSH-2 (panel 2), and anti-CM-01 antibody (panel 3) in clinical colon cancer tissues. The specimen in the above analyses are three continuously-sectioned specimens (5µm in thickness, panels 1-3) from the same site of the same clinical colon cancer sample.

There are many cytocapsular tubes (CT, white arrows) in clinical breast and colon cancer tissues, which are invisible in conventional methods of H&E staining and IHC staining assay with conventional cancer markers (ER, PR, HER2 for breast cancer, and MSH-2 for colon cancer), but can be clearly detected by anti-CM-01 antibodies in IHC the fluorescence staining assay. There are many colon cancer cells (in cyan color) in migration in CTs in the colon cancer tissue. Scale bar: 10µm.

Figure S4. Individual cytocapsular tubes (CTs) potently invade into and pass through compact tissues.

A: Representative image of compact clinical oral cancer tissue. Individual oral cancer cells are propertyed with potent capacities to generate long and straight CT freeways crossing condensed and highly compacted tissues in CT conducting cancer cell metastasis. Longitudinal sectioned CT (white arrows) and CT strands (CTS, orange arrows) are shown. **B:** Representative image of thyroid cancer. Individual thyroid cancer cells exhibit potent abilities to generate CT freeways invading into dense and compacted tissues for cancer cell metastasis. Longitudinal-sectioned or not-sectioned curved CT (white arrows) and cross-sectioned CT (purple arrows) are shown. The specific binding ability of anti-CM-01 antibodies to the CT protein is shown. Scale bar: 10µm.

Figure S5. Collective cancer cell cytocapsular tubes (CTs) powerfully invade into compact tissues.

A: Representative image of collective and curved breast cancer CTs invading into compacted tissues. Breast cancer cells present powerful abilities in engendering collective curved CTs for massive cancer metastasis in compacted tissues. Curved, longitudinal-sectioned or not-sectioned CT (white arrows), cross-sectioned CT (purple arrows), and CT strands (CTS, orange arrows) are shown. **B:** Representative image of cytocapsular tubes (CTs, white arrows) in clinical pancreas cancer tissues. Massive curved CTs invade into compact tissues. Scale bar: 10µm.

Figure S6. Long distance cancer metastasis crossing organ/tissue via cytocapsular tubes (CTs) and CT networks.

A: Representative image of metastatic mucinous adenocarcinoma from colon via colon cancer cell CT in liver. Many CTs align and entangle together and form compact CT bundles with multiple sharp tips (top of the panel) invading into the liver with many cancer cells in migration inside colon cancer-cell CTs. Large quantities of liver cells surrounding the colon cancer cell CT cluster are apoptotic and disappear, leaving a big area absent of liver tissues. Longitudinally sectioned colon CTs (white arrows) with longitudinally-sectioned cell in migration in colon CTs (purple arrows), and cross-sectioned colon CTs (orange arrows) in liver are shown. **B:** Representative image of metastatic adenocarcinoma from ovary via ovary cancer cell CTs in epiploon. There are many straight and curved ovary cancer cell CTs entangled together, invading into compact epiploon tissues, with many ovary cancer cells migrating in CTs. Longitudinally sectioned ovary CTs (white arrows) with longitudinally sectioned cell in migration in CTs

(purple arrows), and cross-sectioned ovary CTs (orange arrows) in epiploon are shown. **C:** Representative image of metastatic breast adenocarcinoma from breast via breast cancer cell CTs (and CT networks) in lymph node. Many curved breast cancer cell CTs entangled together and interconnected to form a condensed CT cluster powerfully invading into compact lymph node. Several small CT bunches (cyan arrows) invade into lymph node at the right and left sides. **D:** Representative image of mucinous adenocarcinoma from unknown site via CT in epiploon. Longitudinally sectioned ovary CTs (white arrows) with longitudinally sectioned cells migrating in CTs (purple arrows) are shown in epiploon. Scale bar:10 μ m.

Figure S7. Initiation and early elongation of cytocapsular tubes in clinical breast carcinoma in situ.

A: Initiation and early elongation of cytocapsular tube in clinical breast ductal carcinoma in situ. There are plenty of single breast cancer cell cytocapsular tube (CT) in curved morphologies showing shrunk thin tails without CT degradation. The longitudinally sectioned (or not sectioned) CT fragments (white arrows), longitudinal sectioned CT fragments carrying cancer cells (in cyan or blue color and in long and thin morphology) are shown in migration in CTs (cyan arrows), cross sectioned cytocapsula with cell inside (red arrow), and cross sectioned CTs (purple arrows). **B:** Elongation of CTs in clinical breast ductal carcinoma in situ. Breast cancer cell CTs (white arrows) elongate and aggressively invade into terminal ducts and neighboring tissues. The elongated CTs show consistent diameter/width without the shrunk thin tails. Terminal ducts (TDs) are shown. Scale bar:10 μ m.

Figure S8. Cytocapsular tubes (CTs) interconnect and form large 3D CT networks for cancer cell dissemination.

A: Representative image of a part of sectioned network of large and 3D breast cancer cell CT networks with breast cancer cells migrating in CT networks. Cells migrating in CTs can generate new CTs and CT branches in diverse directions. CTs (white arrows) interconnect to each other and form large, 3D and self-organized networks. There are many breast cancer cells (purple arrows) freely migrating in the CT networks, in which most cells are in long and thin morphologies squeezed and shaped by the CT membranes. CT connection node (orange arrows), and longitudinal sectioned CT fragment with longitudinal sectioned cells in CTs (purple arrows) are shown. **B:** Representative image of a part of sectioned 3D colon cancer cell CT networks with colon cancer cells migrating in CT networks. CT (white arrows), CT connection node (cyan arrows), longitudinal sectioned CT fragment with longitudinal sectioned cells in CTs (purple arrows), cross sectioned CT surfaces with exposed round CT membranes with the tiny CT lumen in a dimmed/darkness in the center (yellow arrows), cross sectioned CT surfaces with shrunk CT membrane and without dimmed lumens (orange arrows) are shown. Multiple (3 or more) CTs form a CT hole/grid. In the right part, there is a compact, dense and wide CT network bundle with many long and straight CTs (white brace) align together and interconnect to each other. In a long and straight CT fragment (white brace), there are 5 colon cancer cells (purple arrows) that migrate inside. In the left part, there is a compact and thin CT network bundle with many curved CTs (white thin arrows) entangled together, with many colon cancer cells (purple arrows) in migration in CTs. There is no CT degradation. The grids or holes among CTs in the 3D CT networks are formed during CT interconnection to generate 3D CT networks. Scale bar, 10µm.

Figure S9. Development of cytocapsular tube (CT) mass cavities.

A-B: Highly curved/coiled breast cancer cell CTs (white arrows) entangle together and engender CT masses. CT masses occupy spaces in compact breast cancer tissues and form CT mass cavities (CMCs, yellow arrows). Representative image of cross-sectioned CMCs (**A**) and longitudinally-sectioned CMCs (**B**, yellow braces) in compact breast cancer tissues are shown. These sectioned CMCs interconnect and form CMC clusters or networks distributed in tissues. Cancer cells surrounding the CT mass cavity can invade into the CTs and leave, and the cavity space size will increase, and the cavities grow into bigger ones. **C:** Representative image of empty CMCs after CT degradation and decomposition. After CT degradation, CTs disappear, leaving empty CMCs in the compacted cancer tissues. Scale bar:10μm.

Figure S10. Collective cytocapsular tubes (CTs) align together and form CT bundles for massive cancer cell dissemination.

A: Representative image of breast cancer presents many long and straight breast cancer cell CTs aligning together and form compact CT bundles that conduct cancer metastasis to far distance tissues and organs. **B:** Representative image of breast cancer displays that massive highly curved breast CTs entangled together occupying the space. The cancer cells in that place have invaded into these CTs and relocate to other sites via the CTs, leaving no breast cancer cell here. CT (white arrows), and cell in migration in CTs (purple arrows) are shown. Scale bar:10μm.

Figure S11. Curved cytocapsular tubes (CTs) and CT clusters invade into compact tissues in diverse pathways conducting cancer metastasis in multiple directions.

A: Representative image of breast cancer tissues. Highly curved and coiled breast cancer cell CTs potently invade into and pass through compacted tissues in multiple and diverse pathways, and conduct cancer metastasis in multiple directions. The cancer cells outside of and close to the CTs can invade into the CTs and relocate to other sites via CTs. **B:** A representative image presents that numerous highly curved/coiled breast CT masses conquer the place. The cancer cells in the place have invaded into these curved CTs and relocate to other sites via the CTs, leaving no breast cancer cells. Even with the highly curved morphology, these CTs (without degradation) keep the similar and consistent sizes in diameter/width. CT (white arrows), and cell in migration in CTs (purple arrows) are shown. Scale bar: 10 μ m.

Figure S12. Massive breast cancer cell cytocapsular tubes (CTs) conduct cancer metastasis.

A: Representative image of clinical breast cancer tissues with CT masses. There are many highly curved CTs that pile up and form compact CT masses. The major breast cancer cells in place invade into the CTs and relocate away, leaving very few cells in the center. **B:** Representative image of breast cancer tissues with CT masses. A large quantity of curved CTs pile up and form large CT masses occupying the spaces. The breast cancer cells in this place invade into these CTs and relocate away leaving no cancer cells outside of CTs. At the top right corner, there are two big cavities caused by the CT degradation and decomposition. CT (white arrows), and cell in migration in CTs (purple arrows) are shown. Scale bar: 10 μ m.

Figure S13. Massive breast cancer cell CTs conduct massive cancer metastasis. There are plenty of hairpin-shaped and highly curved CTs (white arrows) in clinical breast carcinoma with

cancer cells (purple arrows) migrating in CTs. Massive cancer cells invaded the CTs leaving no cancer cell outside. Some CTs degrade into CT strands (CTS, orange arrows). Scale bar, 10 μ m.

Figure S14. Highly curved pancreas and lung cancer cell CTs induce cancer metastasis.

A: Representative image of pancreas cancer with plenty of highly curved pancreas cancer cell CTs randomly distributed in clinical pancreas cancer tissues. At the top, there is a long and highly curved pancreas cancer cell CT with many condensed hairpin-shaped turns and a continuously maintained diameter of 4 μ m. **B:** Representative image of lung cancer with multi-layered, highly curved lung cancer cell CTs. At the bottom, there are multiple layers of CT individuals with regular and irregular turns and curves. The highly curved CT repeats significantly increase the area for contacting more cancer cells, providing more close freeways for cancer cell metastasis in an efficient format. Scale bar, 10 μ m.

Figure S15. Cross-section view of highly curved, coiled, multi-layered pancreatic-cancer CT super-structures.

The highly curved and coiled pancreatic cancer cell CTs form multi-layered CT superstructures in pancreas cancer, displaying the powerful capacities of CTs in generating complex superstructures when invading into tissues during the CT conducted cancer metastasis. CT (white arrows), and CT strands (CTS, orange arrows) are shown. Scale bar:10 μ m.

Figure S16. Cross-section view of two big, round, multi-layered, multi-staged, complex colon cancer CT superstructures.

A representative cross-section view of two big and complex CT super-structures of round morphology. The bigger one displays multiple layers: outer side thin layer, in severe degradation

into thin CT strands; middle thick layer, many highly curved CTs distributed in a ring circulating the center; and inner side layer, CTs with severe degradation into cloud-like status. At the bottom left corner, most CTs degrade into CT strands (CTS) in diverse thickness in this big complex CT super-structure. These two complex CT super-structures of round morphology and exhibiting multiple layers of multi-staged CTs display the vigorous abilities of collective CTs in engendering diverse and effective superstructures for efficient invasion during conducting cancer metastasis. CT (white arrows), and CT strands (CTS, orange arrows) are shown. Scale bar:10 μ m.

Figure S17. Cross-section view of huge, flattened and oval shaped, multi-layered, complex prostate cancer CT superstructures.

A: Representative image of cross-section view of a part of a huge, flattened and oval shaped, multi-layered, complex prostate CT superstructure. There are many circulated CTs that form a complex CT superstructure. The purple arrow labeled CT bundle is formed by aligned 4 long and curved CTs with a big hair-pin shaped curve. This huge, multi-layered, complex CT superstructure presents the potent capacities of collective CT invasion in cancer metastasis. Multiple CTs tightly align together and form a CT bundle with enhanced invasion capabilities during conducting cancer cell metastasis in tissues. **B:** Representative image of a part of cross-section view of a huge, multi-layered, irregular-shaped morphology, multi-CT stages, and complex pancreas cancer cell CT superstructures. In the middle, there is a part of a single, long, highly curved pancreas cancer cell CT with many hairpins, turns, coils and irregular curves. In the outside, there are multiple layered CTs degrade into strands in various sizes in width. CT (white arrows), and CT strands (CTS, orange arrows) are shown. Scale bar:10 μ m.

Figure S18. Longitudinal section view of long and big breast cancer CT superstructures in conducting cancer metastasis in compact tissues.

A: Longitudinal section view of a long, big and needle-shaped breast cancer CT superstructure during cancer metastasis. This image shows that many long, curved or straight breast CTs entangle together, and form a long, big, self-organized and needle-shaped CT superstructure, massively and powerfully spur into the highly condensed and compacted tissues, conducting cancer metastasis. There are multiple CTs (orange arrows) extend into the compacted tissue surrounding the CT super-structure including the front. **B:** Longitudinal view of a long, big, sandwiched, irregular CT superstructure in conducting cancer metastasis. Most CTs are degraded into CT strands (CTS, orange arrows). CT (white arrows), and cells in migration in CTs (purple arrows) are shown. Scale bar: 10µm.

Figure S19. Massive invasion of breast cancer CTs into diverse types of tissues during cancer metastasis.

A: A representative image of breast cancer tissue shows that a large quantity of breast cancer CTs massively invade into the neighboring tissue among terminal ducts (TD), and some CTs (purple arrows) even crossed through the tight contacted epithelial cell layers of TD and invade into the TD lumens. **B:** A representative image presents that massive CTs in three different CT lifecycle stages invade into diverse tissues during breast cancer metastasis. The right CT mass in a big round morphology is in a late CT stage with CT degradation into cloud-like status. In the middle CT mass, most CTs are not in degradation, and some CTs cross the tight TD epithelial layer and invade into the TD lumens (purple arrow). In the bottom CT mass, most CTs degrade

into thick and thin strands. Longitudinal sectioned CT (white arrows), cross-sectioned CTs (yellow arrows), and CT strands (CTS, orange arrows) are shown. Scale bar:10 μ m.

Figure S20. Collective CT clusters invade through compact tissues conducting long distance, CT-directed cancer metastasis.

A. Representative fluorescence microscope image shows that many curved and entangled prostate cancer-cell CTs formed a curved cone-shaped CT network cluster that invades through a compact tissue layer during cancer metastasis. **B.** Representative image displays numerous curved, coiled and entangled breast cancer cell CT (white arrows) formed collective CT masses that invade into compact tissues in multiple directions, wrapping compact tissues and separating them into several islands. These images document that collective CT clusters can aggressively invade through compact tissues and reach far distance tissues/organs, conducting cancer metastasis in multiple CT-steered directions. Scale bar, 10 μ m.

Figure S21. Cytocapsular tube networks possess robust capacities to direct cancer cell metastasis-pathway and are network damage resistant.

A: Representative image of compacted straight breast cancer CT network bunches with CT degradation. There are several big holes in the compact CT network bundle caused by CT degradation and partly CT network decomposition, but there are still some CTs that connect between the small bundles, which enables the 3D CT network bundles to keep interconnections, thus allowing cancer cell metastasis among the whole CT networks to continue and provide CT network damage resistance. **B:** Representative image of compacted curved CT network masses with severe CT degradation. In the compact and condensed breast cancer CT network masses formed by highly curved, coiled and entangled CTs, part of CTs degrade and networks

decompose, leaving many big holes in the CT network masses. The remaining 3D CT networks keep interconnections via curved or coiled CTs, which maintains the powerful cancer cell metastasis pathway capacities with CT network damage resistance. Scale bar:10 μ m.

Figure S22. Cytocapsular tube degradation stage I: point array-membrane collapse and decomposition, and CT strand network-tube formation.

A-B: Representative breast cancer CT degradation from a breast cancer specimen with fresh breast cancer tissues and instant FFPE (formalin-fixed, paraffin-embedded) treatment. There are many tiny points (point array, <0.1 μ m in width in measured sizes) in the CT membranes collapse and decompose, leaving plenty of tiny holes (0.05-0.2 μ m in width in measured sizes) in CTs. The remaining CT strands interconnect and form CT strand-network in the CT tubes: the whole CTs transiently remain the outline of the original CT, while the CT surfaces are composed of thin or very thin CT strand networks with many point-shaped tiny holes (point array) inside. Subsequently, the membrane degradation continues, connected CT strand networks in the CT tubes decompose into disconnected thin strands until they completely disappear. The white-line framed area is enlarged and shown in panel B. This enlargement shows not-yet-degraded CTs (white arrows), micro CT strand network tubes (purple arrow), and tiny point CT membrane degradation-generated holes (orange arrows). Scale bar:10 μ m.

Figure S23: Cytocapsular tube degradation stage II: Disconnected CT strands, thin CT strands.

A: Representative image of breast cancer showing degradation of micro CT strand network tubes into CT strands, thin CT strands, and cloud like status. Labeled are: CTs without degradation

(white arrows), CT strands (orange arrows), thin strands (yellow arrows), and cloud-like status (purple arrows). **B:** Representative image of breast cancer cell CT degradation into CT strands and thin CT strands. Linear colon cancer cell CT strands (orange arrows) and thin strands (yellow arrows) sporadically distributed in colon tissues are shown. Scale bar:10μm.

Figure S24. Massive cytocapsular tube degradation.

A: After cancer cells invade into CTs and migrate away, massive CTs degrade into massive thick and thin strands. There are countless CT strands. **B:** CT strands continue to degrade into massive very thin strands, followed by decomposition and disappearance. After CT strands disappear, these sites will leave cavities filled with intercellular fluids. Scale bar:10μm.

Figure S25. Cytocapsular tubes and networks dominate cancer metastasis pathways.

A: Representative fluorescence microscope image of prostate cancer tissue specimen shows that there are several hundreds of CTs (white arrows) and only one micro blood vessel (MBV) in this imaged area. Some CTs degrade into CT strands (CTS, orange arrows). **B:** Comprehensive analyses of ratios of numbers of CTs and circulatory system vessels (blood vessels and lymph vessels) examined in cancer, paracancer and metastatic cancer for 8 types of cancers in breast, colon, lung, liver, ovary, pancreas, prostate and stomach. Scale bar, 10μm.

Figure S26. Cytocapsular tubes invade into micro blood vessels and release cancer cells into circulation systems at late cancer stages.

A. Representative image of rare CT invasion into micro blood vessels (MBV) in stage III prostate cancer. Approximately 1 in 10^4 CTs (white arrows) wrap around micro blood vessels,

aggressively invade into and pass through the tightly connected endothelial layer of micro blood vessel. The cyan arrow labels a CT that protrudes into the micro blood vessel lumen and cancer cells migrate inside. This indicates that cancer cells can be released from the CTs that invade into blood and lymph vessels and subsequently allowing cancer cells release into the circulation systems as circulating tumor cells. There are numerous CTs (white arrow), degraded CT strands (CTS, orange arrows) outside the circulation system vessels. Red blood cells (RBC, purple arrows) are also shown. **B.** Representative image of a micro blood vessel that is leaky due to CT invasion in stage IV lung cancer. The micro blood vessel with leak caused by CT invasion is full of red blood cells (RBC, purple arrows), which spread and distribute around the local neighboring tissues. **C.** Representative image of blood vessels with leaks caused by severe CT invasion. This triggered blood vessel disassembly and decomposition in stage IV prostate cancer. There are many CT strands and fragments (CTS, orange arrows) and red blood cells (RBC, purple arrows). The local prostate cancer cells invaded into CTs (white arrows) and migrate away, leaving spaces without tissue cells. Scale bar:10 μ m.

Figure S27. Continuous multi-layered tissue scanning of cancer cell cytocapsular tube in needle biopsy for cancer prognosis and diagnosis.

Representative images of multiple sites in needle biopsy with suspicious breast cancer tissues by CT analyses for breast cancer diagnosis. In site 3, there are many breast cancer cell CTs without degradation. In sites 4 and 5, there are numerous breast cancer cell CT strands in degradation. Scale bar:10 μ m.

Movie S1: Movie of cancer stem cell (CSC) cytocapsular-tube initiation, generation, and bi-directionally migration in the CSC CT it generated.

A single breast cancer stem cell from the HMLER(CD44^{high}/CD24^{low})^{FA} subpopulation¹ generates a short cytocapsular tube in the 3D Matrigel matrix. Subsequently, it migrates bi-directionally in the CT it engendered. Initially, the cell generates a cytocapsula outside of and disconnected from the plasma membrane. Then the cell moves to the left to elongate the cytocapsular membrane to engender a short cytocapsular tube (CT) in its wake. Then, the cell migrates in the CT to the right. There are several transient spike-like features of still unknown structure dynamically connecting the rear of the cell with the CT membranes. Scale bar:10μm.

Movie S2: Multiple cancer stem cells bi-directionally migrate in a single long CSC cytocapsular tube.

There are 4 breast cancer stem cell HMLER(CD44^{high}/CD24^{low})^{FA} subpopulation cells migrate in a long cytocapsular tube (CT) generated by another breast CSC. The top CSC bi-directionally migrates inside the breast CSC CT. Scale bar:10μm.

References:

1. Yi F, Wagner G. Cytocapsular tubes conduct cell translocation. Proc Natl Acad Sci U S A 2018; 115: E1137-E1146.

Fig. 1

Fig. 2

A

	Number/names of organ types	Benign tumor/cancer subtype number	Patient number	Specimen number	Number of specimens with CT	% with CTs
Normal tissue	Breast		3	3	0	0
	Colon		2	2	0	0
	Liver		2	2	0	0
	Lung		3	3	0	0
	Prostate		1	1	0	0
	Stomach		3	3	0	0
		Total	14	14	0	0
Benign tumor tissue (details in Table S1)	6	38	126	126	17	13.4%
Cancer/malignant tumor (details in Table 2)	30	202	6795	6837	6837	100%

B

Clinical pancreas carcinoma

C

Clinical breast cancer

Fig. 3

	Cancer types by organs, tissues	Cancer subtypes [#]	Tissue specimen number	Patient number	Male	Female	Age range	Cancer stages	Tissues with cytocrapsular tubes (CTs)	% of cancer tissues with CT	CT density (CT/mm ²) range
1	Adrenal Gland	3	23	22	10	12	26-71	I-IV	+	100	6-73
2	Bladder	5	46	46	30	16	36-74	I-IV	+	100	20-102
3	Bone	12	212	210	115	95	21-78	I-IV	+	100	7-78
4	Brain	3	124	122	86	36	24-67	I-IV	+	100	9-109
5	Breast*	27	2786	2774		2774	18-86	I-IV	+	100	6-113
6	Cervix uteri	7	53	51		51	37-55	I-IV	+	100	8-97
7	Colon**	6	586	586	323	263	16-90	I-IV	+	100	18-113
8	Esophagus	5	63	62	41	21	24-65	I-IV	+	100	10-103
9	Gallbladder	3	26	26	20	6	37-62	I-IV	+	100	8-106
10	Head/neck	5	12	12	4	8	41-66	I-IV	+	100	12-111
11	Intestine	3	15	15	10	5	36-68	I-IV	+	100	12-106
12	Kidney	10	123	120	81	39	33-65	I-IV	+	100	5-98
13	Liver	6	362	358	231	127	36-76	I-IV	+	100	23-106
14	Lung	23	683	676	437	239	27-78	I-IV	+	100	45-103
15	Lymph node	9	56	56	31	25	21-73	I-IV	+	100	26-107
16	Oesophagus	2	4	4	3	1	34-54	I-IV	+	100	25-98
17	Oral cavity	5	17	17	10	7	28-69	I-IV	+	100	15-87
18	Ovary	7	83	83		83	32-61	I-IV	+	100	18-107
19	Pancreas	13	222	218	162	56	28-74	I-IV	+	100	29-111
20	Penis	2	3	3	3		45-62	I-IV	+	100	25-104
21	Prostate	5	875	871	871		35-77	I-IV	+	100	35-110
22	Rectum	5	5	5	4	1	32-57	I-IV	+	100	45-97
23	Skin	7	122	122	35	87	21-79	I-IV	+	100	27-108
24	Spleen	2	6	6	1	5	36-48	I-IV	+	100	32-97
25	Stomach	6	245	245	123	122	36-72	I-IV	+	100	38-109
26	Testis	5	24	24	24		41-67	I-IV	+	100	37-111
27	Thymus	4	5	5	4	1	37-56	I-IV	+	100	35-107
28	Thyroid	5	17	17	10	7	29-61	I-IV	+	100	27-102
29	Uterus	5	26	26		26	35-56	I-IV	+	100	36-108
30	Vulva	3	13	13		13	32-55	I-IV	+	100	34-108
	Total	202	6837	6795	2669	4126			+	100	

(#: Details of 10 or more subtypes are shown in Table S2;* Details of a part of the samples are shown in Excel S1; ** Details are shown in Excel S2).

Fig.4

A

Clinical paracancer tissues of breast cancer

DAPI: CM-01: γ -actin

B

Cancer types	Cancer subtypes	Paracancer tissue specimen number	Number of paracancer tissues with CT	% of paracancer tissue with CT	CT density
Bladder	2	10	10	100	72-101
Breast	25	356	356	100	78-114
Esophagus	1	5	5	100	72-103
Colon	7	121	121	100	71-109
Intestine	1	3	3	100	78-107
Kidney	2	6	6	100	75-112
Liver	6	89	89	100	67-103
Lung	5	65	65	100	82-112
Ovary	2	12	12	100	79-114
Pancreas	6	96	96	100	81-107
Stomach	6	78	78	100	79-113
Uterus	1	5	5	100	81-102
Total	64	846	846	100	

Fig.5

A

Original cancer niche	Cancer metastasis to other organs	Patient number	Metastatic cancer tissue number	Number of metastatic cancer tissues with CT	% of metastatic cancer with CT	CT density (CT/mm ²)
Breast	lymph node	45	45	45	100	36-104
	lung	4	4	4	100	65-112
	liver	3	3	3	100	53-108
	bone	3	3	3	100	47-102
	Neck/head	5	5	5	100	68-113
Colon	lymph node	32	32	32	100	42-105
	liver	4	4	4	100	50-102
	epiploon	3	3	3	100	53-104
	stomach	4	4	4	100	82-113
	ovary	4	4	4	100	46-108
Esophagus	lymph node	23	23	23	100	37-98
Liver	lymph node	34	34	34	100	45-107
	spleen	5	5	5	100	51-109
Lung	lymph node	21	21	21	100	65-98
	abdominal cavity	3	3	3	100	62-101
Stomach	lymph node	25	25	25	100	52-106
	liver	8	8	8	100	56-99
	lung	7	7	7	100	47-104
Pancreas	lymph node	32	32	32	100	53-106
	mesentery	4	4	4	100	34-103
Prostate	lymph node	13	13	13	100	47-98
	stomach	4	4	4	100	54-105
Ovary	lymph node	21	21	21	100	44-101
	liver	4	4	4	100	56-109
Total		306	306	306	100	

B

Original cancer niche	Patient/ tissue number	CT density in cancer tissues	Paracancer tissue number	% of paracancer with CT	CT density in paracancer	Cancer metastasis to organs	Metastatic cancer tissue (MCT) number	% of metastatic cancer tissue with CT	CT density of MCT
Breast	3	35-101	3	100	81-112	head/neck	3	100	69-103
Colon	3	76-102	3	100	92-112	Stomach	3	100	96-113
Lung	3	69-110	3	100	94-113	Lymph	3	100	89-108
Liver	3	43-98	3	100	89-108	Spleen	3	100	85-107
Ovary	3	46-92	3	100	85-109	Liver	3	100	84-105
Pancreas	3	38-98	3	100	87-113	Stomach	3	100	61-104
Prostate	3	46-103	3	100	86-108	Liver	3	100	78-102
Stomach	3	52-106	3	100	89-113	Lung	3	100	81-105

Fig.S1

A

Bxpc3

DAPI

CM-01

EC

CM

EC

γ -actin

DAPI: CM-01: γ -actin

Cell

EC

CM

B

Clinical thyroid cancer

DAPI: CM-01: γ -actin

CT

CT

Fig.S2

Fig.S3

Fig.S4

A

Clinical oral cancer

DAPI: CM-01: γ -actin

B

Clinical thyroid cancer

DAPI: CM-01: γ -actin

Fig.S5

Fig. S6

clinical metastatic mucinous
adenocarcinoma from colon via CT in liver

clinical metastatic adenocarcinoma from ovary
via CT in epiploon

clinical metastatic breast adenocarcinoma CT
cluster invading into lymph node

clinical metastatic mucinous
adenocarcinoma from unknown site via
CT in epiploon

DAPI: CM-01: γ -actin

Fig. S7

Clinical breast cancer

A

DAPI: CM-01: γ -actin

Clinical breast cancer

B

DAPI: CM-01: γ -actin

Fig.S8

A

Clinical breast cancer

DAPI: CM-01: γ -actin

B

Clinical colon cancer

DAPI: CM-01: γ -actin

Fig.S9

Fig.S10

Clinical breast cancer

A

DAPI: CM-01: γ -actin

B

Clinical breast cancer

DAPI: CM-01: γ -actin

A

Clinical breast cancer

DAPI: CM-01: γ -actin

B

Clinical breast cancer

DAPI: CM-01: γ -actin

Fig.S12

Fig.S13

Fig.S14

Fig.S15

Clinical pancreas cancer

Fig.S16

Fig.S17

Fig.S18

Fig.S19

Fig.S20

A

Clinical prostate cancer

DAPI: CM-01: γ -actin

B

Clinical breast cancer

DAPI: CM-01: γ -actin

Fig.S21

Fig.S22

Fig.S23

Fig.S24

Fig. S25

A

Clinical prostate cancer

B

Comparison of cytocapsular tubes and humoral vessels in cancer, paracancer tissues and metastatic cancer.

Average ratios of numbers of cytocapsular tubes to numbers of blood vessels and lymph vessels			
Cancer types	Original cancer niche	Paracancer	metastatic cancer
Breast	1003 $\pm$ 12	1215 $\pm$ 25	1106 $\pm$ 17
Colon	987 $\pm$ 11	1112 $\pm$ 23	1056 $\pm$ 18
Lung	997 $\pm$ 21	1107 $\pm$ 14	1067 $\pm$ 23
Liver	1005 $\pm$ 18	1108 $\pm$ 22	991 $\pm$ 16
Ovary	1104 $\pm$ 23	1108 $\pm$ 17	1106 $\pm$ 15
Pancreas	1109 $\pm$ 25	1116 $\pm$ 14	1009 $\pm$ 24
Prostate	993 $\pm$ 17	1008 $\pm$ 22	997 $\pm$ 26
Stomach	1013 $\pm$ 18	1122 $\pm$ 27	1008 $\pm$ 16

Clinical prostate cancerDAPI: CM-01: γ -actin **Clinical lung cancer**DAPI: CM-01: γ -actin **Clinical prostate cancer**DAPI: CM-01: γ -actin

Fig.S27

Needle biopsy of suspicious breast tumor

Table S1. Clinical characteristics of cytocapsular tubes (CTs) in benign tumor tissues.

Benign tumor types	Subtypes	Patients/specimens	with CT	% with CT
Breast	Fibrosis and Simple Cysts	11		
	Ductal or Lobular Hyperplasia	13	3	
	Lobular Carcinoma in Situ	2		
	Adenosi	1		
	Fibroadenomas	1		
	Phyllodes Tumors	1	1	
	Intraductal Papillomas	8	1	
	Granular Cell Tumors	3	1	
	Fat Necrosis and Oil Cysts	1		
	Mastitis	2		
	Duct Ectasia	2		
Lung	Hamartomas	2		
	Bronchial adenomas	3		
	Papillomas	3		
Prostate	Benign prostatic hyperplasia	4	1	
Stomach	fundic gland polyp	12	4	
	hyperplastic polyp	1		
	inflammatory fibroid polyps	2		
	xanthoma	1		
	hamartomatous polyps	1		
	leiomyoma	1		
	lipoma	1		
	hemangioma	2		
	glomus tumour	2	1	
	cystic tumour	1		
Liver	Hemangioma	1		
	Focal nodular hyperplasia	1		
	Hepatocellular adenoma	2		
Colon	Hyperplastic polyps	15	3	
	Hamartomas	11	1	
	Juvenile polyps	4		
	Inflammatory polyps	2	1	
	Lymphoid polyps	4		
	Tubular adenomas	1		
	Villous adenomas	2		
	Tubulovillous adenomas	2		
Total		126	17	13.40%

Table S2. Subtypes of cancers with 10 (or more) kinds of investigated subtypes in Table 2.

Cancer types	Cancer subtypes	Cancer types	Cancer subtypes
Bone	1 Chondroblastic osteosarcoma of left thigh	1	Adenocarcinoma
	2 Chondrosarcoma of lower limb	2	Adenosquamous carcinoma
	3 Fibroblastic osteosarcoma of right lower femur	3	Atypical carcinoid
	4 Giant cell tumor of bone	4	Basal cell carcinoma
	5 Giant cell tumor of left femur	5	Bronchioloalveolar carcinoma
	6 Osteosarcoma of left knee (sparse)		Complexed small cell carcinoma and
	7 Osteosarcoma of left tibia	6	adenocarcinoma
	8 Osteosarcoma of right scapula	7	Giant cell carcinoma
	9 Osteoblastic osteosarcoma of left upper tibia	8	Invasive adenocarcinoma
	10 Osteosarcoma of right upper femur	9	Large cell carcinoma
	11 Osteoblastic osteosarcoma of left lower femur	10	Large cell neuroendocrine carcinoma
	12 Undifferentiated chondrosarcoma of pars sacralis	11	Large cell undifferentiated carcinoma
Breast	1 Acinic cell carcinoma	12	Mucinous adenocarcinoma
	2 Adenoid cystic carcinoma	13	Mucinous bronchioloalveolar carcinoma
	Bilateral breast carcinoma and non-synchronous breast carcinoma	14	Non-small cell carcinoma
	3 Carcinoma		Non-small cell carcinoma Squamous cell
	4 Carcinoid	15	carcinoma
	5 Carcinoma with apocrine differentiation		Non-small cell Invasive papillary
	6 Carcinoma with medullary features	16	adenocarcinoma
	7 Carcinoma with neuroendocrine features	17	Non-small cell lung adenocarcinoma
	8 Exceptionally rare types and variants	18	Papillary adenocarcinoma
	9 Glycogen-rich clear cell carcinoma	19	Pleomorphic carcinoma
	10 Inflammatory carcinoma	20	Sarcomatoid carcinoma
	11 Infiltrating ductal carcinoma,	21	Small cell carcinoma
	12 Invasive carcinoma of no special type	22	Solid adenocarcinoma
	13 Invasive lobular carcinoma	23	Squamous cell carcinoma
	14 Invasive micropapillary carcinoma	1	Acinar cell carcinoma
	15 Invasive papillary adenocarcinoma	2	Adenocarcinoma
	16 Invasive papillary carcinoma	3	Adenosquamous carcinoma
	17 Lipid-rich carcinoma	4	Carcinoid
	18 Medullary carcinoma	5	Cystic-solid pseudopapillary carcinoma
		6	Duct adenocarcinoma
		7	Islet cell carcinoma
			Low-grade malignant cystic - solid
	19 Metaplastic carcinoma	8	papillary tumor
	20 Mixed invasive lobular and ductal carcinoma	9	Mucous adenocarcinoma
	21 Mucinous adenocarcinoma	10	Neuroendocrine tumors of the pancreas
	Mucinous carcinoma and carcinoma with		
	22 Mucoepidermoid carcinoma	11	Papillary adenocarcinoma
	23 Neuroendocrine carcinoma	12	Squamous cell carcinoma
	24 Oncocytic carcinoma	13	Undifferentiated carcinoma
	25 Polymorphous carcinoma		
	26 Salivary gland/skin adnexal type tumours		
	27 Sebaceous carcinoma		
Kidney	1 Carcinoma sarcomatodes		
	2 Chromophobe carcinoma		
	3 Clear cell carcinoma		
	4 Collecting duct carcinoma		
	5 Granular cell carcinoma		
	6 High grade urothelial carcinoma		
	7 Low grade urothelial carcinoma		
	8 Nephroblastoma		
	9 Papillary renal cell carcinoma		
	10 Transitional cell carcinoma		

Table S3: Cytocapsular tube (CT) density and suggested cytocapsular tube-based cancer metastasis (CM) grades:

- No CT
- CM grade 1 (CT: 1-10/mm², with no CT degradation)
- CM grade 2 (CT: 11-40/mm², with no CT degradation)
- CM grade 3 (CT: 41-80/mm², with/without a few CT degradation)
- CM grade 4 (CT: >80/mm², or with many and severe CT degradation)

Table S4: Relationship between conventional cancer stages and cancer metastasis (CM) grades based on the results in involved in Table S1 and Table 2:

Cancer stage	Cancer Metastasis (CM) grade
0	0, 1, 2, 3, 4
I	1, 2, 3, 4
II	2, 3, 4
III	3, 4
IV	4

Movie.S1

Movie.S2

No.	Age	Sex	Organ/ Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	ER	PR	HER2	Cytocapsular tubes (CT)	CT/ mm 2	CT degra dation	Cancer metastasis grade
1	48	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+	-	-	+	6	-	1
2	64	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+++	-	-	+	9	-	1
3	64	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+++	-	-	+	6	-	1
4	50	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	-	*	1+	+	8	-	1
5	61	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	++	+	-	+	24	-	2
6	61	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	++	+	-	+	18	-	2
7	48	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+	-	-	+	12	-	2
8	50	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	-	*	1+	+	13	-	2
9	40	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+	*	0	+	16	-	2
10	40	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+	*	0	+	22	-	2
11	56	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+++	*	0	+	27	-	2
12	56	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+++	*	0	+	11	-	2
13	33	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+++	*	0	+	38	-	2
14	67	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	++	++	0	+	38	-	2
15	33	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+++	*	0	+	46	+	3
16	48	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+	-	0	+	51	-	3
17	48	F	Breast	Invasive ductal carcinoma	T1N0M0	1	I	malignant	+	*	0	+	42	+	3
18	55	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	-	+	45	-	3
19	55	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	-	+	34	-	2
20	69	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+++	+++	-	+	56	+	3
21	63	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	-	-	+	47	+	3
22	63	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	-	-	+	41	-	3
23	48	F	Breast	Mucinous carcinoma	T1N0M0	2	I	malignant	++	-	-	+	53	-	3
24	48	F	Breast	Mucinous carcinoma	T1N0M0	2	I	malignant	++	-	-	+	58	+	3
25	42	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	-	2+	+	36	-	2
26	42	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	-	2+	+	21	-	2
27	49	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	-	+	23	-	2
28	49	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	-	+	32	-	2
29	54	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	-	+	36	-	2
30	54	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	-	+	44	-	3
31	54	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	++	-	+	53	-	3
32	48	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	-	+	31	-	2
33	48	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	-	+	24	-	2
34	44	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+	+++	*	+	36	-	2
35	44	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	*	+++	0	+	42	-	3

36	65	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	++	++	0	+	33	-	2
37	65	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	++	++	0	+	52	-	3
38	38	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	-	-	0	+	22	-	2
39	38	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	-	-	0	+	38	-	2
40	43	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	+	0	+	31	-	2
41	43	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	+	0	+	46	-	3
42	39	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	-	-	0	+	49	-	3
43	39	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	-	-	0	+	60	-	3
44	51	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+	+	0	+	55	-	3
45	51	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+	+	0	+	32	-	2
46	57	F	Breast	Mucinous carcinoma	T1cN0M0	2	I	malignant	*	*	0	+	26	-	2
47	57	F	Breast	Mucinous carcinoma	T1cN0M0	2	I	malignant	*	*	0	+	29	-	2
48	62	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	35	-	2
49	62	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	32	-	2
50	48	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	46	-	3
51	48	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	36	-	2
52	48	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	++	0	+	47	-	3
53	48	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	++	0	+	41	-	3
54	50	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	0	+	52	-	3
55	50	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	0	+	49	-	3
56	51	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	++	0	+	55	-	3
57	51	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	++	0	+	36	-	2
58	52	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	-	0	+	32	-	2
59	52	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	-	0	+	46	-	3
60	31	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	0	+	48	-	3
61	31	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	0	+	44	-	3
62	51	F	Breast	Invasive ductal carcinoma (sparse)	T1N0M0	2	I	malignant	-	-	0	+	32	-	2
63	53	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+++	-	0	+	28	-	2
64	53	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+++	+	0	+	54	-	3
65	65	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	21	-	2
66	41	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	-	0	+	62	-	3
67	41	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	-	0	+	45	-	3
68	46	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	33	-	2
69	72	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+++	-	0	+	61	-	3
70	72	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+++	-	0	+	56	-	3
71	58	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	++	0	+	44	-	3
72	58	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	++	0	+	48	-	3
73	44	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	++	++	0	+	39	-	2
74	44	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	++	++	0	+	56	-	3
75	46	F	Breast	Invasive ductal carcinoma with necrosis	T1N0M0	2	I	malignant	+++	++	0	+	72	-	3

76	46	F	Breast	invasive ductal carcinoma with necro	T1N0M0	2	I	malignant	+++	++	0	+	77	-	3
77	35	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+++	0	+	79	-	3
78	35	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+++	0	+	68	-	3
79	63	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+	0	+	74	-	3
80	63	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+	0	+	36	-	2
81	48	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+	0	+	43	-	3
82	48	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+	0	+	39	-	2
83	46	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	-	+	0	+	32	-	2
84	60	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	++	0	+	56	-	3
85	60	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	++	0	+	62	-	3
86	58	F	Breast	nvasive ductal carcinoma (sparse	T1cN0M0	2	I	malignant	-	-	3+	+	55	-	3
87	58	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	-	-	3+	+	62	-	3
88	41	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	++	3+	+	65	-	3
89	41	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	++	3+	+	38	-	2
90	34	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+++	0	+	45	-	3
91	34	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+++	0	+	52	-	3
92	67	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	-	-	3+	+	62	-	3
93	67	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	-	-	3+	+	54	-	3
94	27	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+	+	2+	+	49	-	3
95	27	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+	+	2+	+	36	-	2
96	42	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+++	0	+	41	-	3
97	42	F	Breast	Invasive ductal carcinoma	T1cN0M0	2	I	malignant	+++	+++	0	+	53	-	3
98	47	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	+++	0	+	60	-	3
99	47	F	Breast	asive ductal carcinoma with necro	T1N0M0	2	I	malignant	++	+++	0	+	56	-	3
100	56	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	-	0	+	47	-	3
101	56	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	-	0	+	49	-	3
102	71	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	37	-	2
103	71	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	42	-	3
104	36	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	*	0	+	44	-	3
105	36	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	0	+	49	-	3
106	40	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	-	1+	+	34	-	2
107	40	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	-	1+	+	52	-	3
108	55	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	*	0	+	48	-	3
109	55	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	*	0	+	33	-	2
110	52	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	2+	+	25	-	2
111	52	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	2+	+	21	-	2
112	47	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	0	+	43	-	3
113	47	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	-	0	+	27	-	2
114	71	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+++	+	3+	+	54	-	3
115	71	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+++	+	3+	+	42	-	3

116	50	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	23	-	2
117	50	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	0	+	26	-	2
118	44	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	2+	+	34	-	2
119	44	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	2+	+	38	-	2
120	38	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	-	2+	+	32	-	2
121	38	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	-	2+	+	58	-	3
122	58	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	0	+	49	-	3
123	58	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+	+	0	+	38	-	2
124	44	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+++	-	0	+	32	-	2
125	44	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	+++	-	0	+	26	-	2
126	40	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	+	0	+	22	-	2
127	40	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	++	+	0	+	33	-	2
128	50	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	2+	+	28	-	2
129	50	F	Breast	Invasive ductal carcinoma	T1N0M0	2	I	malignant	-	-	2+	+	32	-	2
130	41	F	Breast	Invasive ductal carcinoma with necrosis	T1cN0M0	3	I	malignant	-	-	2+	+	37	-	2
131	41	F	Breast	Invasive ductal carcinoma with necrosis	T1cN0M0	3	I	malignant	-	-	2+	+	42	-	3
132	73	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	-	-	0	+	38	-	2
133	73	F	Breast	Invasive ductal carcinoma with necrosis	T1N0M0	3	I	malignant	-	-	0	+	33	-	2
134	49	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	+++	+++	0	+	56	-	3
135	40	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	++	++	0	+	57	-	3
136	40	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	++	++	0	+	41	-	3
137	32	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	-	-	0	+	65	-	3
138	32	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	-	-	0	+	57	-	3
139	43	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	-	*	3+	+	42	-	3
140	43	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	-	*	3+	+	44	-	3
141	66	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	-	-	3+	+	32	-	2
142	66	F	Breast	Invasive ductal carcinoma	T1N0M0	3	I	malignant	-	-	3+	+	21	-	2
143	56	F	Breast	Invasive ductal carcinoma (adenosin)	T1N0M0	-	I	malignant	*	*	-	+	26	-	2
144	56	F	Breast	Invasive ductal carcinoma (adenosin)	T1N0M0	-	I	malignant	*	*	-	+	33	-	2
145	67	F	Breast	Invasive ductal carcinoma (fibrous tissue and lymphovascular invasion)	T1N0M0	-	I	malignant	*	*	3+	+	38	-	2
146	67	F	Breast	Invasive ductal carcinoma (fibrous tissue and lymphovascular invasion)	T1N0M0	-	I	malignant	*	*	-	+	43	-	3
147	69	F	Breast	Invasive ductal carcinoma (sparse lymphovascular invasion)	T1N0M0	-	I	malignant	+++	+++	-	+	48	-	3
148	33	F	Breast	Invasive lobular carcinoma	T1N0M0	-	I	malignant	+	+	-	+	28	-	2
149	33	F	Breast	Invasive lobular carcinoma	T1N0M0	-	I	malignant	+	+	-	+	38	-	2
150	54	F	Breast	Invasive ductal carcinoma (sparse lymphovascular invasion)	T1N0M0	-	I	malignant	++	++	-	+	24	-	2
151	56	F	Breast	Invasive ductal carcinoma (fibrous tissue and lymphovascular invasion)	T1N0M0	-	I	malignant	*	*	-	+	52	-	3
152	56	F	Breast	Invasive ductal carcinoma (fibrous tissue and lymphovascular invasion)	T1N0M0	-	I	malignant	*	*	-	+	46	-	3
153	54	F	Breast	Invasive ductal carcinoma (chronic inflammation and lymphovascular invasion)	T1N0M0	-	I	malignant	*	*	0	+	37	-	2
154	54	F	Breast	Invasive ductal carcinoma (fibrofatty tissue and lymphovascular invasion)	T1N0M0	-	I	malignant	*	*	*	+	42	-	3
155	49	F	Breast	Invasive ductal carcinoma (breast tissue)	T1N0M0	-	I	malignant	*	*	0	+	27	-	2

156	49	F	Breast	invasive ductal carcinoma (breast tissue)	T1N0M0	-	I	malignant	*	*	*	+	38	-	2
157	53	F	Breast	invasive ductal carcinoma (sparse)	T1cN0M0	-	I	malignant	-	-	0	+	31	-	2
158	53	F	Breast	invasive ductal carcinoma (sparse)	T1cN0M0	-	I	malignant	-	-	2+	+	55	-	3
159	49	F	Breast	invasive ductal carcinoma (sparse)	T1N0M0	-	I	malignant	+++	+++	0	+	58	-	3
160	59	F	Breast	Medullary carcinoma	T1N0M0	-	I	malignant	-	-	0	+	43	-	3
161	59	F	Breast	Medullary carcinoma	T1N0M0	-	I	malignant	-	-	0	+	65	-	3
162	58	F	Breast	Papillary carcinoma	T1cN0M0	-	I	malignant	-	-	0	+	34	-	2
163	58	F	Breast	Papillary carcinoma	T1cN0M0	-	I	malignant	-	-	0	+	37	-	2
164	56	F	Breast	carcinoma (chronic inflammation of)	T1N0M0	-	I	malignant	*	*	*	+	42	-	3
165	56	F	Breast	carcinoma (chronic inflammation of)	T1N0M0	-	I	malignant	*	*	0	+	51	-	3
166	51	F	Breast	invasive ductal carcinoma (breast tissue)	T1N0M0	-	I	malignant	*	*	0	+	28	-	2
167	65	F	Breast	invasive ductal carcinoma (breast tissue)	T1N0M0	-	I	malignant	*	*	0	+	26	-	2
168	46	F	Breast	carcinoma (chronic inflammation of)	T1N0M0	-	I	malignant	*	*	0	+	21	-	2
169	39	F	Breast	ductal carcinoma (fibrous tissue and)	T1N0M0	-	I	malignant	*	*	0	+	33	-	2
170	39	F	Breast	invasive ductal carcinoma (breast tissue)	T1N0M0	-	I	malignant	*	*	0	+	43	-	3
171	67	F	Breast	carcinoma (chronic inflammation of)	T1N0M0	-	I	malignant	*	*	0	+	51	-	3
172	67	F	Breast	carcinoma (chronic inflammation of)	T1N0M0	-	I	malignant	*	*	0	+	34	-	2
173	45	F	Breast	Medullary carcinoma	T1N0M0	-	I	malignant	-	*	0	+	41	-	3
174	45	F	Breast	Medullary carcinoma	T1N0M0	-	I	malignant	-	*	0	+	46	-	3
175	46	F	Breast	invasive ductal carcinoma (sparse) with	T1cN0M0	-	I	malignant	-	-	*	+	53	-	3
176	57	F	Breast	Medullary carcinoma (sparse)	T1N0M0	-	I	malignant	-	-	0	+	58	-	3
177	57	F	Breast	Medullary carcinoma	T1N0M0	-	I	malignant	-	-	0	+	49	-	3
178	36	F	Breast	Medullary carcinoma	T1cN0M0	-	I	malignant	*	*	0	+	36	-	2
179	36	F	Breast	Medullary carcinoma	T1cN0M0	-	I	malignant	-	-	0	+	44	-	3
180	41	F	Breast	Adenosquamous carcinoma	T1N0M0	-	I	malignant	+	+++	0	+	51	-	3
181	41	F	Breast	Adenosquamous carcinoma	T1N0M0	-	I	malignant	+	+++	0	+	66	-	3
182	59	F	Breast	Lipid-rich carcinoma (sparse)	T1cN0M0	-	I	malignant	*	*	0	+	62	-	3
183	59	F	Breast	Lipid-rich carcinoma	T1cN0M0	-	I	malignant	+++	*	0	+	67	-	3
184	55	F	Breast	invasive ductal carcinoma (sparse)	T1N0M0	-	I	malignant	+++	*	0	+	58	-	3
185	67	F	Breast	ductal carcinoma (fibrous tissue and)	T1N0M0	-	I	malignant	*	*	0	+	33	-	2
186	32	F	Breast	invasive ductal carcinoma (sparse)	T1N0M0	-	I	malignant	+	-	3+	+	31	-	2
187	32	F	Breast	invasive ductal carcinoma (necrosis tissue)	T1N0M0	-	I	malignant	*	*	*	+	28	-	2
188	52	F	Breast	Medullary carcinoma	T1N0M0	-	I	malignant	-	-	0	+	49	-	3
189	52	F	Breast	Medullary carcinoma	T1N0M0	-	I	malignant	-	-	0	+	50	-	3
190	55	F	Breast	Medullary carcinoma	T1N0M0	-	I	malignant	-	-	0	+	28	-	2
191	55	F	Breast	Medullary carcinoma	T1N0M0	-	I	malignant	-	-	0	+	30	-	2
192	63	F	Breast	Invasive lobular carcinoma	T1N0M0	-	I	malignant	+	-	0	+	47	-	3
193	63	F	Breast	Invasive lobular carcinoma	T1N0M0	-	I	malignant	+	-	0	+	38	-	2
194	33	F	Breast	Invasive papillary carcinoma	T1N0M0	-	I	malignant	+++	-	0	+	44	-	3
195	33	F	Breast	Invasive papillary carcinoma	T1N0M0	-	I	malignant	+++	-	0	+	52	-	3

196	55	F	Breast	Invasive ductal carcinoma	T1N0M0	1--2	I	malignant	+++	*	0	+	58	-	3
197	57	F	breast	infiltrative ductal carcinoma	T1N0M0	2	Ia	Malignant				+	57	-	3
198	65	F	breast	infiltrative ductal carcinoma	T1N0M0	2	Ia	Malignant				+	62	-	3
199	62	F	breast	infiltrative ductal carcinoma	T1N0M0	2	Ia	Malignant				+	69	-	3
200	58	F	breast	infiltrative ductal carcinoma	T1N0M0	2	Ia	Malignant				+	46	-	3
201	62	F	breast	infiltrative ductal carcinoma	T1N0M0	2	Ia	Malignant				+	41	-	3
202	48	F	breast	infiltrative ductal carcinoma	T1N0M0	2	Ia	Malignant				+	63	-	3
203	61	F	breast	infiltrative ductal carcinoma	T1N0M0	2	Ia	Malignant				+	47	-	3
204	59	F	breast	infiltrative ductal carcinoma	T1N0M0	3	Ia	Malignant				+	55	-	3
205	59	F	breast	infiltrative ductal carcinoma	T1N0M0	2--3	Ia	Malignant				+	59	-	3
206	57	F	breast	infiltrative ductal carcinoma	T1N0M0	2--3	Ia	Malignant				+	46	-	3
207	33	F	breast	infiltrative ductal carcinoma	T1N1M0	2	Ila	Malignant				+	85	+	4
208	48	F	breast	infiltrative ductal carcinoma	T2N0M0	2	Ila	Malignant				+	82	+	4
209	53	F	breast	infiltrative ductal carcinoma	T2N0M0	2--3	Ila	Malignant				+	84	+	4
210	47	F	breast	infiltrative ductal carcinoma	T2N0M0	2--3	Ila	Malignant				+	87	+	4
211	47	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	-	-	1+	+	89	+	4
212	47	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	-	-	1+	+	91	+	4
213	48	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	++	++	-	+	92	+	4
214	48	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	++	++	-	+	96	+	4
215	86	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	+++	-	0	+	88	+	4
216	86	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	+++	-	0	+	84	+	4
217	50	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	+++	+++	0	+	89	+	4
218	50	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	+++	+++	0	+	92	+	4
219	55	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	+++	-	0	+	96	+	4
220	55	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	+++	-	0	+	97	+	4
221	50	F	Breast	Mucinous carcinoma	T2N0M0	1	Ila	malignant	++	++	0	+	93	+	4
222	50	F	Breast	Mucinous carcinoma	T2N0M0	1	Ila	malignant	++	++	0	+	89	+	4
223	39	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	-	*	2+	+	82	+	4
224	39	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	-	*	2+	+	84	+	4
225	47	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	++	*	0	+	98	+	4
226	47	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	++	*	0	+	92	+	4
227	46	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	++	++	0	+	91	+	4
228	46	F	Breast	Invasive ductal carcinoma	T2N0M0	1	Ila	malignant	++	++	0	+	95	+	4
229	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	102	+	4
230	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	99	+	4
231	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	2+	+	107	+	4

232	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	-	+	103	+	4
233	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	112	+	4
234	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	109	+	4
235	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	-	+	97	+	4
236	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	-	+	124	+	4
237	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	-	+	116	+	4
238	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	-	+	125	+	4
239	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	-	+	109	+	4
240	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	-	+	117	+	4
241	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	-	+	108	+	4
242	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	-	+	104	+	4
243	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	115	+	4
244	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	108	+	4
245	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	-	+	103	+	4
246	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	101	+	4
247	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	-	+	106	+	4
248	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	-	+	121	+	4
249	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	-	+	113	+	4
250	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	-	+	104	+	4
251	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	2+	+	107	+	4
252	54	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	-	+	113	+	4
253	54	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	-	+	115	+	4
254	32	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	98	+	4
255	32	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	99	+	4
256	31	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	95	+	4
257	31	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	107	+	4
258	58	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	114	+	4
259	58	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	109	+	4
260	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+++	1+	+	124	+	4
261	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+++	-	+	107	+	4
262	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	116	+	4
263	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	109	+	4
264	64	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	96	+	4
265	39	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	99	+	4

266	39	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	103	+	4
267	32	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	112	+	4
268	32	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	108	+	4
269	72	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	-	+	102	+	4
270	72	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	-	+	117	+	4
271	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	113	+	4
272	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	125	+	4
273	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	-	+	104	+	4
274	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	-	+	98	+	4
275	65	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	95	+	4
276	67	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	2+	+	112	+	4
277	67	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	3+	+	124	+	4
278	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	-	+	97	+	4
279	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	-	+	99	+	4
280	37	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	-	+	91	+	4
281	37	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	-	+	121	+	4
282	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	126	+	4
283	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	113	+	4
284	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	-	+	118	+	4
285	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	123	+	4
286	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	103	+	4
287	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	-	+	109	+	4
288	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	-	+	98	+	4
289	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	-	+	96	+	4
290	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	-	+	156	+	4
291	28	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	-	+	164	+	4
292	28	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	-	+	171	+	4
293	65	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	-	+	154	+	4
294	65	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	-	+	127	+	4
295	53	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	98	+	4
296	30	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	-	+	128	+	4
297	54	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	134	+	4
298	54	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	128	+	4
299	78	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	-	+	119	+	4

300	78	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	-	+	126	+	4
301	58	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	131	+	4
302	58	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	125	+	4
303	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	146	+	4
304	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	138	+	4
305	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	128	+	4
306	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	121	+	4
307	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	129	+	4
308	30	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	-	+	109	+	4
309	30	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	-	+	103	+	4
310	45	F	Breast	nvasive ductal carcinoma (sparse	T2N0M0	2	Ila	malignant	+	+	-	+	115	+	4
311	45	F	Breast	nvasive ductal carcinoma (sparse	T2N0M0	2	Ila	malignant	+	+	-	+	126	+	4
312	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	-	+	98	+	4
313	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	-	+	97	+	4
314	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	120	+	4
315	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	-	+	132	+	4
316	65	F	Breast	Mucinous carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	127	+	4
317	65	F	Breast	Mucinous carcinoma	T2N0M0	2	Ila	malignant	++	++	-	+	119	+	4
318	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	116	+	4
319	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	137	+	4
320	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+++	0	+	132	+	4
321	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+++	0	+	126	+	4
322	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+++	0	+	108	+	4
323	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+++	0	+	105	+	4
324	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+	0	+	98	+	4
325	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+	0	+	96	+	4
326	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+++	0	+	112	+	4
327	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+++	0	+	118	+	4
328	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	109	+	4
329	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	102	+	4
330	46	F	Breast	ductal carcinoma with intraductal c	T2N0M0	2	Ila	malignant	-	-	0	+	105	+	4
331	46	F	Breast	ductal carcinoma with intraductal c	T2N0M0	2	Ila	malignant	-	-	0	+	114	+	4
332	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+++	0	+	116	+	4
333	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+++	0	+	122	+	4

334	66	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	++	0	+	110	+	4
335	66	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	++	0	+	127	+	4
336	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	++	0	+	96	+	4
337	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	++	0	+	109	+	4
338	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+	0	+	105	+	4
339	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+	0	+	92	+	4
340	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+	0	+	156	+	4
341	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	-	0	+	126	+	4
342	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	163	+	4
343	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	-	0	+	102	+	4
344	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	134	+	4
345	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	137	+	4
346	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	119	+	4
347	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	97	+	4
348	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	2+	+	94	+	4
349	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	2+	+	132	+	4
350	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	141	+	4
351	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	135	+	4
352	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	146	+	4
353	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	139	+	4
354	69	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	167	+	4
355	69	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	182	+	4
356	65	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	175	+	4
357	65	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	79	+	4
358	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	3+	+	67	+	4
359	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	3+	+	174	+	4
360	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	86	+	4
361	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	72	+	4
362	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	68	+	4
363	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	152	+	4
364	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	127	+	4
365	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	138	+	4
366	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	142	+	4
367	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	153	+	4

368	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	68	+	4
369	39	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	89	+	4
370	39	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	99	+	4
371	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	103	+	4
372	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	107	+	4
373	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	89	+	4
374	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	86	+	4
375	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	187	+	4
376	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	176	+	4
377	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	117	+	4
378	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	118	+	4
379	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	87	+	4
380	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	65	+	4
381	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	173	+	4
382	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	182	+	4
383	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	97	+	4
384	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	96	+	4
385	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	87	+	4
386	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	92	+	4
387	59	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	91	+	4
388	59	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	103	+	4
389	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	104	+	4
390	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	117	+	4
391	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	96	+	4
392	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	87	+	4
393	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	157	+	4
394	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	135	+	4
395	34	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	99	+	4
396	34	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	101	+	4
397	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	89	+	4
398	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	81	++	4
399	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	103	+	4
400	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	108	+	4
401	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	0	+	125	+	4

402	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	0	+	129	+	4
403	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	132	+	4
404	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	141	+	4
405	35	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	167	+	4
406	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	67	++	4
407	69	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	79	++	4
408	69	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	81	+	4
409	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	113	+	4
410	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	109	+	4
411	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	86	+	4
412	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	82	+	4
413	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	67	++	4
414	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	75	++	4
415	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	77	++	4
416	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	81	+	4
417	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	82	+	4
418	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	92	+	4
419	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	*	+	98	+	4
420	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	87	+	4
421	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	103	+	4
422	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	109	+	4
423	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	121	+	4
424	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	0	+	118	+	4
425	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	0	+	105	+	4
426	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	*	0	+	109	+	4
427	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	176	+	4
428	35	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	182	+	4
429	35	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	189	+	4
430	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	98	+	4
431	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	112	+	4
432	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+++	0	+	106	+	4
433	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+++	0	+	89	+	4
434	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	*	+	81	+	4
435	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	*	+	162	+	4

436	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	176	+	4
437	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	106	+	4
438	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	101	+	4
439	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	78	++	4
440	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	85	+	4
441	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	87	+	4
442	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	89	+	4
443	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	82	+	4
444	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	89	+	4
445	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	*	+	106	+	4
446	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	3+	+	87	+	4
447	53	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	79	++	4
448	53	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	109	+	4
449	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	103	+	4
450	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	86	+	4
451	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	84	+	4
452	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	129	+	4
453	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	3+	+	134	+	4
454	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	3+	+	145	+	4
455	54	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	113	+	4
456	54	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	0	+	87	++	4
457	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	134	+	4
458	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	128	+	4
459	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	2+	+	131	+	4
460	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	2+	+	129	+	4
461	34	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	89	+	4
462	34	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	*	0	+	103	+	4
463	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	109	+	4
464	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	118	+	4
465	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	131	+	4
466	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	98	+	4
467	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	83	+	4
468	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	97	+	4
469	72	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	3+	+	153	+	4

470	72	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	3+	+	146	+	4
471	57	F	Breast	nvasive ductal carcinoma (sparse	T2N0M0	2	Ila	malignant	++	*	0	+	135	+	4
472	57	F	Breast		T2N0M0	2	Ila	malignant	++	*	0	+	128	+	4
473	41	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	119	+	4
474	41	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	106	+	4
475	58	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	132	+	4
476	58	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	127	+	4
477	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	118	+	4
478	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	103	+	4
479	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	104	+	4
480	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	*	+	87	+	4
481	64	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	97	+	4
482	64	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	1+	+	92	+	4
483	68	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	2+	+	126	+	4
484	68	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	2+	+	165	+	4
485	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	109	+	4
486	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	102	+	4
487	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	*	+	98	+	4
488	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	*	+	87	+	4
489	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	125	+	4
490	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	158	+	4
491	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	162	+	4
492	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	98	+	4
493	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	0	+	86	+	4
494	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	0	+	84	+	4
495	53	F	Breast	oma with carcinomatous change o	T2N0M0	2	Ila	malignant	-	*	0	+	82	+	4
496	53	F	Breast	oma with carcinomatous change o	T2N0M0	2	Ila	malignant	-	*	0	+	93	+	4
497	34	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	145	+	4
498	34	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	138	+	4
499	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	132	+	4
500	50	F	Breast	nvasive ductal carcinoma (sparse	T2N0M0	2	Ila	malignant	++	++	0	+	145	+	4
501	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	125	+	4
502	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	138	+	4
503	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	0	+	98	+	4

504	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	0	+	93	+	4
505	41	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	++	0	+	103	+	4
506	41	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	*	0	+	115	+	4
507	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	105	+	4
508	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	128	+	4
509	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	145	+	4
510	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	129	+	4
511	55	F	Breast	Invasive ductal carcinoma (sparse	T2N0M0	2	Ila	malignant	-	-	0	+	87	++	4
512	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	83	+	4
513	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	98	+	4
514	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	103	+	4
515	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	106	+	4
516	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	94	+	4
517	41	F	Breast	Invasive ductal carcinoma (sparse	T2N0M0	2	Ila	malignant	++	++	3+	+	109	+	4
518	41	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	3+	+	118	+	4
519	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	127	+	4
520	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	83	+	4
521	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	129	+	4
522	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	131	+	4
523	44	F	Breast	Invasive ductal carcinoma with necro	T2N0M0	2	Ila	malignant	+++	+++	0	+	167	+	4
524	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	172	+	4
525	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	109	+	4
526	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	132	+	4
527	44	F	Breast	Invasive ductal carcinoma with necro	T2N0M0	2	Ila	malignant	+++	++	0	+	138	+	4
528	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	97	+	4
529	63	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	86	++	4
530	63	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	83	+	4
531	70	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	102	+	4
532	70	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	107	+	4
533	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	115	+	4
534	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	93	+	4
535	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	1+	+	106	+	4
536	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	1+	+	99	+	4
537	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	86	+	4

538	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	128	+	4
539	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	3+	+	137	+	4
540	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	3+	+	128	+	4
541	57	F	Breast	Invasive ductal carcinoma with necrosis	T2N0M0	2	Ila	malignant	-	-	3+	+	102	+	4
542	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	117	+	4
543	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	94	+	4
544	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	129	+	4
545	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	132	+	4
546	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	96	+	4
547	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	87	+	4
548	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	103	+	4
549	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	107	+	4
550	72	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	86	++	4
551	72	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	92	+	4
552	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	103	+	4
553	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	118	+	4
554	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	87	++	4
555	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	82	++	4
556	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	96	+	4
557	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	137	+	4
558	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	89	++	4
559	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	92	+	4
560	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	94	+	4
561	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	96	+	4
562	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	3+	+	107	+	4
563	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	3+	+	104	+	4
564	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	2+	+	118	+	4
565	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	2+	+	126	+	4
566	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	0	+	96	+	4
567	66	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	95	+	4
568	66	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	82	++	4
569	64	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	98	+	4
570	64	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	127	+	4
571	35	F	Breast	Invasive ductal carcinoma with necrosis	T2N0M0	2	Ila	malignant	-	-	0	+	164	+	4

572	35	F	Breast	invasive ductal carcinoma with necrosis	T2N0M0	2	Ila	malignant	-	-	0	+	158	+	4
573	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	99	+	4
574	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	102	+	4
575	70	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	3+	+	86	+	4
576	70	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	3+	+	120	+	4
577	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	93	+	4
578	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	92	+	4
579	62	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	134	+	4
580	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	3+	+	142	+	4
581	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	3+	+	89	++	4
582	39	F	Breast	invasive ductal carcinoma (sparse)	T2N0M0	2	Ila	malignant	-	-	0	+	68	++	4
583	39	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	73	++	4
584	58	F	Breast	invasive ductal carcinoma with necrosis	T2N0M0	2	Ila	malignant	-	-	0	+	78	++	4
585	58	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	82	+	4
586	29	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	89	+	4
587	29	F	Breast	invasive ductal carcinoma with necrosis	T2N0M0	2	Ila	malignant	+	-	0	+	56	+	4
588	37	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	102	+	4
589	37	F	Breast	invasive ductal carcinoma (sparse)	T2N0M0	2	Ila	malignant	+++	-	0	+	104	+	4
590	42	F	Breast	invasive ductal carcinoma with necrosis	T2N0M0	2	Ila	malignant	-	-	0	+	126	+	4
591	42	F	Breast	invasive ductal carcinoma (sparse) with necrosis	T2N0M0	2	Ila	malignant	-	-	0	+	112	+	4
592	42	F	Breast	invasive ductal carcinoma (sparse)	T2N0M0	2	Ila	malignant	++	-	0	+	98	+	4
593	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	87	+	4
594	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	86	+	4
595	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	93	+	4
596	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	95	+	4
597	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	107	+	4
598	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	102	+	4
599	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	87	+	4
600	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	116	+	4
601	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	98	+	4
602	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	93	+	4
603	53	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	103	+	4
604	53	F	Breast	invasive ductal carcinoma (sparse)	T2N0M0	2	Ila	malignant	-	-	3+	+	128	+	4
605	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	96	+	4

606	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	83	++	4
607	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	112	+	4
608	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	86	+	4
609	51	F	Breast	Invasive ductal carcinoma with necrosis	T2N0M0	2	Ila	malignant	-	-	0	+	78	++	4
610	51	F	Breast	Invasive ductal carcinoma with necrosis	T2N0M0	2	Ila	malignant	-	-	0	+	125	+	4
611	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	3+	+	133	+	4
612	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	3+	+	83	+	4
613	65	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	92	+	4
614	65	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	75	++	4
615	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	82	++	4
616	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	86	+	4
617	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	92	+	4
618	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	0	+	98	+	4
619	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	*	+	0	+	103	+	4
620	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	86	+	4
621	57	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	2	Ila	malignant	-	-	*	+	92	+	4
622	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	118	+	4
623	64	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	2	Ila	malignant	++	+	0	+	127	+	4
624	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	83	+	4
625	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	91	+	4
626	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	103	+	4
627	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	109	+	4
628	72	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	116	+	4
629	72	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	108	+	4
630	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	128	+	4
631	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	132	+	4
632	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	0	+	116	+	4
633	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	0	+	85	+	4
634	40	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	2	Ila	malignant	*	*	0	+	156	+	4
635	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	131	+	4
636	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	108	+	4
637	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	83	+	4
638	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	78	++	4
639	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	0	+	65	++	4

640	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	0	+	72	++	4
641	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	63	++	4
642	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	79	+	4
643	41	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	92	+	4
644	41	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	75	+	4
645	67	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	2+	+	67	++	4
646	67	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	2+	+	65	++	4
647	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	54	++	4
648	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	68	++	4
649	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	2+	+	62	++	4
650	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	2+	+	71	+	4
651	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	83	+	4
652	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	93	+	4
653	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	81	+	4
654	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	107	+	4
655	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	122	+	4
656	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	+	2+	+	103	+	4
657	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	87	+	4
658	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	83	+	4
659	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	112	+	4
660	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	87	+	4
661	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	65	+	4
662	36	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	76	+	4
663	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	79	++	4
664	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	86	+	4
665	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	107	+	4
666	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	129	+	4
667	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	67	++	4
668	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	75	++	4
669	69	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	84	+	4
670	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	92	+	4
671	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	76	++	4
672	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	102	+	4
673	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	119	+	4

674	38	F	Breast	invasive ductal carcinoma (sparse	T2N0M0	2	Ila	malignant	-	-	0	+	83	+	4
675	76	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	2+	+	89	+	4
676	76	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	2+	+	73	++	4
677	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	67	++	4
678	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	63	++	4
679	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	79	+	4
680	46	F	Breast	invasive ductal carcinoma (sparse) with n	T2N0M0	2	Ila	malignant	+	-	0	+	91	+	4
681	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	83	+	4
682	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	87	+	4
683	67	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	72	+	4
684	67	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	64	+	4
685	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	58	+	4
686	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	63	++	4
687	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	3+	+	72	++	4
688	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	3+	+	119	+	4
689	32	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	127	+	4
690	32	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	65	++	4
691	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	71	++	4
692	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	73	++	4
693	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	2+	+	82	+	4
694	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	2+	+	84	+	4
695	60	F	Breast	invasive ductal carcinoma (sparse	T2N0M0	2	Ila	malignant	++	-	0	+	91	+	4
696	60	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	103	+	4
697	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	2+	+	106	+	4
698	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	127	+	4
699	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	135	+	4
700	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	87	+	4
701	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	82	++	4
702	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	79	++	4
703	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	81	++	4
704	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+++	0	+	64	++	4
705	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+++	0	+	53	++	4
706	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	48	++	4
707	38	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	42	++	4

708	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	3+	+	67	++	4
709	51	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	3+	+	82	+	4
710	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	71	++	4
711	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	103	+	4
712	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	127	+	4
713	55	F	Breast	Invasive ductal carcinoma (sparse	T2N0M0	2	Ila	malignant	+++	-	0	+	82	+	4
714	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	66	+	4
715	40	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	59	+	4
716	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	71	+	4
717	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	2+	+	87	+	4
718	55	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	*	+	82	+	4
719	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	117	+	4
720	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	1+	+	102	+	4
721	56	F	Breast	Papillary carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	119	+	4
722	56	F	Breast	Papillary carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	156	+	4
723	46	F	Breast	Adenocarcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	76	++	4
724	46	F	Breast	Adenocarcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	46	++	4
725	40	F	Breast	Adenocarcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	53	++	4
726	40	F	Breast	Adenocarcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	72	++	4
727	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	0	+	60	++	4
728	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	0	+	78	++	4
729	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	71	++	4
730	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	0	+	64	++	4
731	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	2+	+	82	++	4
732	61	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	2+	+	87	++	4
733	71	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	*	0	+	91	++	4
734	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	56	++	4
735	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	62	++	4
736	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	77	++	4
737	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	92	++	4
738	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	3+	+	45	++	4
739	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	*	3+	+	42	++	4
740	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	51	++	4
741	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	82	++	4

742	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	73	++	4
743	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	++	0	+	82	++	4
744	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	87	++	4
745	43	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	65	++	4
746	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	+	0	+	92	++	4
747	52	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	107	++	4
748	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	0	+	63	++	4
749	42	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	++	0	+	46	++	4
750	62	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	49	++	4
751	62	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	51	++	4
752	53	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	3+	+	58	++	4
753	53	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	3+	+	62	++	4
754	45	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	71	++	4
755	66	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	79	++	4
756	66	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	48	++	4
757	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	53	++	4
758	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	128	+	4
759	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	112	+	4
760	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+++	0	+	103	+	4
761	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	2+	+	76	++	4
762	56	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	-	2+	+	69	++	4
763	64	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	61	++	4
764	64	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	81	++	4
765	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	47	++	4
766	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	43	++	4
767	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	58	++	4
768	33	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	60	++	4
769	34	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	102	++	4
770	34	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	+	0	+	92	++	4
771	22	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	97	++	4
772	22	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	88	++	4
773	28	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	82	++	4
774	28	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	63	++	4
775	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	59	++	4

776	46	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	++	0	+	87	++	4
777	63	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	47	++	4
778	63	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+++	-	0	+	41	++	4
779	69	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	52	++	4
780	69	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	0	+	68	++	4
781	37	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	72	++	4
782	37	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	63	++	4
783	65	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	58	++	4
784	65	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	0	+	55	++	4
785	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	62	++	4
786	50	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	-	-	3+	+	69	++	4
787	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	2+	+	102	+	4
788	57	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	+	-	2+	+	48	++	4
789	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	40	++	4
790	48	F	Breast	Invasive ductal carcinoma	T2N0M0	2	Ila	malignant	++	+	0	+	52	++	4
791	62	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	Malignant				+	62	++	4
792	62	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIA	Malignant				+	48	++	4
793	56	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	-	+	51	++	4
794	56	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	-	+	55	++	4
795	60	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	-	+	56	++	4
796	60	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	-	+	73	++	4
797	60	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	-	+	64	++	4
798	60	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	-	+	55	++	4
799	60	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	-	+	71	++	4
800	60	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	-	+	79	++	4
801	56	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	81	++	4
802	56	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	76	++	4
803	51	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	3+	+	77	++	4
804	55	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	63	++	4
805	55	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	65	++	4
806	45	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	69	++	4
807	45	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	72	++	4
808	83	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	75	+	4
809	83	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	109	+	4

810	43	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	46	++	4
811	43	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	66	++	4
812	50	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	++	++	0	+	71	++	4
813	50	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	++	++	0	+	52	++	4
814	48	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	59	++	4
815	48	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	73	++	4
816	64	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	66	++	4
817	64	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	69	++	4
818	40	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	++	++	0	+	119	+	4
819	40	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	++	++	0	+	102	+	4
820	63	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	+++	+	0	+	67	++	4
821	63	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	+++	+	0	+	72	++	4
822	58	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	*	0	+	48	++	4
823	58	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	43	++	4
824	34	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	*	0	+	52	++	4
825	34	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	*	0	+	59	++	4
826	58	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	*	3+	+	61	++	4
827	58	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	*	3+	+	73	++	4
828	49	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	84	++	4
829	49	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	44	++	4
830	40	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	+	-	0	+	49	++	4
831	40	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	+	-	0	+	63	++	4
832	47	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	*	0	+	67	++	4
833	34	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	71	++	4
834	34	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	88	+	4
835	34	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	81	+	4
836	30	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	2+	+	92	+	4
837	30	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	2+	+	46	++	4
838	43	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	49	++	4
839	43	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	51	++	4
840	36	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	58	++	4
841	36	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	62	++	4
842	64	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	2+	+	88	++	4
843	64	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	2+	+	74	++	4

844	34	F	Breast	Invasive ductal carcinoma	T2N0M0	3	Ila	malignant	-	-	0	+	79	++	4
845	34	F	Breast	invasive ductal carcinoma with necrosis	T2N0M0	3	Ila	malignant	-	-	0	+	61	++	4
846	45	F	Breast	ductal carcinoma (fibrous tissue and lymphovascular invasion)	T2N0M0	-	Ila	malignant	*	*	-	+	54	++	4
847	45	F	Breast	invasive ductal carcinoma (breast tissue)	T2N0M0	-	Ila	malignant	*	*	-	+	41	++	4
848	51	F	Breast	invasive ductal carcinoma (breast tissue)	T2N0M0	-	Ila	malignant	*	*	-	+	48	++	4
849	51	F	Breast	invasive ductal carcinoma (sparse lymphovascular invasion)	T2N0M0	-	Ila	malignant	*	*	-	+	43	++	4
850	64	F	Breast	invasive ductal carcinoma (sparse lymphovascular invasion)	T2N0M0	-	Ila	malignant	*	*	-	+	68	++	4
851	64	F	Breast	carcinoma (chronic inflammation of breast tissue)	T2N0M0	-	Ila	malignant	*	*	2+	+	88	+	4
852	56	F	Breast	carcinoma (severe atypical hyperplasia)	T2N0M0	-	Ila	malignant	++	-	-	+	109	+	4
853	56	F	Breast	carcinoma (severe atypical hyperplasia)	T2N0M0	-	Ila	malignant	++	-	-	+	92	+	4
854	61	F	Breast	invasive ductal carcinoma (sparse lymphovascular invasion)	T2N0M0	-	Ila	malignant	++	+	-	+	93	+	4
855	33	F	Breast	invasive ductal carcinoma (sparse lymphovascular invasion)	T2N0M0	-	Ila	malignant	++	++	-	+	98	+	4
856	52	F	Breast	carcinoma (chronic inflammation of breast tissue)	T2N0M0	-	Ila	malignant	*	*	2+	+	118	+	4
857	64	F	Breast	invasive ductal carcinoma (sparse lymphovascular invasion)	T2N0M0	-	Ila	malignant	-	-	-	+	123	+	4
858	65	F	Breast	ductal carcinoma (fibrous tissue and lymphovascular invasion)	T2N0M0	-	Ila	malignant	*	*	-	+	146	+	4
859	57	F	Breast	invasive ductal carcinoma (fibrofatty tissue)	T2N0M0	-	Ila	malignant	*	*	-	+	156	+	4
860	53	F	Breast	invasive ductal carcinoma (sparse) with necrosis	T2N0M0	-	Ila	malignant	-	-	-	+	129	+	4
861	30	F	Breast	invasive ductal carcinoma (fibrofatty tissue)	T2N0M0	-	Ila	malignant	*	*	-	+	104	+	4
862	60	F	Breast	ductal carcinoma (cataplasia and necrosis)	T2N0M0	-	Ila	malignant	*	*	-	+	108	+	4
863	60	F	Breast	ductal carcinoma (cataplasia and necrosis)	T2N0M0	-	Ila	malignant	*	*	-	+	118	+	4
864	44	F	Breast	invasive ductal carcinoma (sparse lymphovascular invasion)	T2N0M0	-	Ila	malignant	-	-	-	+	102	+	4
865	50	F	Breast	Invasive lobular carcinoma	T2N0M0	-	Ila	malignant	+	-	-	+	87	++	4
866	50	F	Breast	Invasive lobular carcinoma	T2N0M0	-	Ila	malignant	+	-	-	+	75	++	4
867	46	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	++	+	-	+	64	++	4
868	46	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	++	+	-	+	48	++	4
869	61	F	Breast	medullary carcinoma (sparse) with necrosis	T2N0M0	-	Ila	malignant	-	-	-	+	53	++	4
870	61	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	-	+	56	++	4
871	58	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	-	+	71	++	4
872	58	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	-	+	78	++	4
873	64	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	-	+	92	++	4
874	64	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	-	+	67	++	4
875	39	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	*	-	-	+	79	++	4
876	39	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	+	-	-	+	54	+	4
877	49	F	Breast	Mixed lobular and ductal carcinoma	T2N0M0	-	Ila	malignant	+++	-	-	+	87	+	4

878	49	F	Breast	Mixed lobular and ductal carcinoma	T2N0M0	-	Ila	malignant	+++	-	-	+	89	+	4
879	20	F	Breast	Apocrine carcinoma (fibrous tissue)	T2N0M0	-	Ila	malignant	*	*	-	+	43	++	4
880	20	F	Breast	Apocrine carcinoma	T2N0M0	-	Ila	malignant	-	*	-	+	52	++	4
881	45	F	Breast	Invasive ductal carcinoma (breast tissue)	T2N0M0	-	Ila	malignant	*	*	0	+	45	++	4
882	51	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	-	Ila	malignant	-	-	3+	+	55	++	4
883	49	F	Breast	Invasive ductal carcinoma	T2N0M0	-	Ila	malignant	*	*	0	+	52	++	4
884	49	F	Breast	Invasive ductal carcinoma (breast tissue)	T2N0M0	-	Ila	malignant	*	*	0	+	63	++	4
885	42	F	Breast	Invasive mixed ductal and lobular carcinoma	T2N0M0	-	Ila	malignant	+++	+++	0	+	124	+	4
886	42	F	Breast	Invasive mixed ductal and lobular carcinoma	T2N0M0	-	Ila	malignant	+++	+++	0	+	105	+	4
887	52	F	Breast	Invasive mixed ductal and lobular carcinoma	T2N0M0	-	Ila	malignant	++	++	0	+	99	+	4
888	52	F	Breast	Invasive mixed ductal and lobular carcinoma	T2N0M0	-	Ila	malignant	++	++	0	+	78	++	4
889	51	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	71	++	4
890	51	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	43	++	4
891	34	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	51	++	4
892	34	F	Breast	Carcinoma tissue (sparse)	T2N0M0	-	Ila	malignant	-	-	0	+	57	++	4
893	40	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	62	++	4
894	40	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	68	++	4
895	55	F	Breast	Papillary carcinoma	T2N0M0	-	Ila	malignant	-	-	3+	+	54	++	4
896	55	F	Breast	Papillary carcinoma	T2N0M0	-	Ila	malignant	-	-	3+	+	77	++	4
897	67	F	Breast	Papillary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	85	++	4
898	67	F	Breast	Papillary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	44	++	4
899	35	F	Breast	Invasive ductal carcinoma (breast tissue)	T2N0M0	-	Ila	malignant	*	*	0	+	49	++	4
900	42	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	-	Ila	malignant	-	-	0	+	53	++	4
901	48	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	-	Ila	malignant	++	++	0	+	87	++	4
902	67	F	Breast	Ductal carcinoma (blood vessel and axillary)	T2N0M0	-	Ila	malignant	*	*	3+	+	102	++	4
903	67	F	Breast	Ductal carcinoma (blood vessel and axillary)	T2N0M0	-	Ila	malignant	*	*	*	+	118	++	4
904	50	F	Breast	Ductal carcinoma (fibrous tissue and lymph nodes)	T2N0M0	-	Ila	malignant	*	*	0	+	67	++	4
905	47	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	-	Ila	malignant	-	-	0	+	61	++	4
906	47	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	-	Ila	malignant	-	-	0	+	53	++	4
907	62	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	-	Ila	malignant	+++	-	0	+	49	++	4
908	62	F	Breast	Invasive ductal carcinoma (breast duct)	T2N0M0	-	Ila	malignant	*	*	0	+	114	+	4
909	47	F	Breast	Ductal carcinoma (inflammatory necrosis)	T2N0M0	-	Ila	malignant	-	*	0	+	129	+	4
910	55	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	++	-	3+	+	107	+	4
911	55	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	++	*	3+	+	67	++	4

912	61	F	Breast	invasive ductal carcinoma (sparse	T2N0M0	-	Ila	malignant	+++	+++	0	+	73	++	4
913	50	F	Breast	invasive ductal carcinoma (breast tiss	T2N0M0	-	Ila	malignant	*	*	0	+	105	+	4
914	43	F	Breast	al carcinoma (fibrofatty tissue and	T2N0M0	-	Ila	malignant	*	*	0	+	109	+	4
915	43	F	Breast	al carcinoma (fibrofatty tissue and	T2N0M0	-	Ila	malignant	*	*	*	+	76	++	4
916	43	F	Breast	invasive ductal carcinoma (sparse	T2N0M0	-	Ila	malignant	*	*	*	+	89	+	4
917	43	F	Breast	al carcinoma (fibrofatty tissue and	T2N0M0	-	Ila	malignant	*	*	*	+	47	++	4
918	57	F	Breast	al carcinoma (fibrofatty tissue and	T2N0M0	-	Ila	malignant	*	*	3+	+	53	++	4
919	52	F	Breast	al (chronic inflammation of fibrofatty	T2N0M0	-	Ila	malignant	*	*	0	+	116	+	4
920	62	F	Breast	al carcinoma (fibrous tissue and l	T2N0M0	-	Ila	malignant	*	*	0	+	103	+	4
921	44	F	Breast	al carcinoma (blood vessel and ac	T2N0M0	-	Ila	malignant	*	*	2+	+	87	++	4
922	44	F	Breast	invasive ductal carcinoma (sparse	T2N0M0	-	Ila	malignant	++	+	2+	+	82	++	4
923	61	F	Breast	al (chronic inflammation of fibrous	T2N0M0	-	Ila	malignant	-	-	0	+	45	++	4
924	51	F	Breast	invasive ductal carcinoma (tumoral nec	T2N0M0	-	Ila	malignant	*	*	*	+	42	++	4
925	51	F	Breast	invasive ductal carcinoma (tumoral nec	T2N0M0	-	Ila	malignant	*	*	*	+	55	++	4
926	43	F	Breast	al carcinoma (fibrofatty tissue and	T2N0M0	-	Ila	malignant	*	*	*	+	58	++	4
927	43	F	Breast	invasive lobular carcinoma (breast tis	T2N0M0	-	Ila	malignant	*	*	0	+	62	++	4
928	48	F	Breast	invasive ductal carcinoma (sparse	T2N0M0	-	Ila	malignant	+	-	0	+	68	++	4
929	40	F	Breast	al carcinoma (fibrofatty tissue and	T2N0M0	-	Ila	malignant	*	*	*	+	42	++	4
930	64	F	Breast	invasive ductal carcinoma (tumoral nec	T2N0M0	-	Ila	malignant	*	*	*	+	49	++	4
931	40	F	Breast	al carcinoma (fibrous tissue and l	T2N0M0	-	Ila	malignant	*	*	0	+	51	++	4
932	46	F	Breast	intraductal carcinoma with early infiltra	T2N0M0	-	Ila	malignant	+	-	2+	+	48	++	4
933	46	F	Breast	intraductal carcinoma with early infiltra	T2N0M0	-	Ila	malignant	+	-	2+	+	58	++	4
934	69	F	Breast	intraductal carcinoma (duct of breast	T2N0M0	-	Ila	malignant	*	*	0	+	64	++	4
935	52	F	Breast	al carcinoma (fibrous tissue and l	T2N0M0	-	Ila	malignant	*	*	*	+	59	++	4
936	46	F	Breast	intraductal carcinoma with early infiltra	T2N0M0	-	Ila	malignant	-	-	2+	+	48	++	4
937	46	F	Breast	intraductal carcinoma with early infiltra	T2N0M0	-	Ila	malignant	-	-	2+	+	44	++	4
938	34	F	Breast	al carcinoma (fibrous tissue and l	T2N0M0	-	Ila	malignant	*	*	0	+	52	++	4
939	46	F	Breast	invasive ductal carcinoma (sparse	T2N0M0	-	Ila	malignant	*	*	2+	+	55	++	4
940	49	F	Breast	al carcinoma (fibrofatty tissue and	T2N0M0	-	Ila	malignant	*	*	0	+	48	++	4
941	48	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	63	++	4
942	48	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	72	++	4
943	50	F	Breast	Atypical medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	42	++	4
944	50	F	Breast	Atypical medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	76	++	4
945	51	F	Breast	Mixed lobular and ductal carcinoma	T2N0M0	-	Ila	malignant	++	-	0	+	66	++	4

946	51	F	Breast	Mixed lobular and ductal carcinoma	T2N0M0	-	Ila	malignant	++	-	0	+	63	++	4
947	31	F	Breast	Invasive adenocarcinoma (duct of breast)	T2N0M0	-	Ila	malignant	*	*	*	+	78	++	4
948	31	F	Breast	Invasive adenocarcinoma (sparse)	T2N0M0	-	Ila	malignant	+++	+	0	+	53	++	4
949	40	F	Breast	Apocrine carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	58	++	4
950	40	F	Breast	Apocrine carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	60	++	4
951	42	F	Breast	Carcinoid	T2N0M0	-	Ila	malignant	-	-	0	+	70	++	4
952	42	F	Breast	Carcinoid	T2N0M0	-	Ila	malignant	-	-	0	+	62	++	4
953	42	F	Breast	Invasive cribriform carcinoma	T2N0M0	-	Ila	malignant	+++	+++	0	+	67	++	4
954	42	F	Breast	Invasive cribriform carcinoma	T2N0M0	-	Ila	malignant	+++	+++	0	+	69	++	4
955	58	F	Breast	Lipid-rich carcinoma (breast tissue)	T2N0M0	-	Ila	malignant	*	*	*	+	54	++	4
956	58	F	Breast	Carcinoma (fibrofatty tissue and blood vessels)	T2N0M0	-	Ila	malignant	*	*	*	+	59	++	4
957	40	F	Breast	Lipid-rich carcinoma (breast tissue)	T2N0M0	-	Ila	malignant	*	*	0	+	103	+	4
958	40	F	Breast	Carcinoma (fibrofatty tissue and blood vessels)	T2N0M0	-	Ila	malignant	*	*	0	+	89	+	4
959	71	F	Breast	Invasive ductal carcinoma (sparse)	T2N0M0	-	Ila	malignant	+++	*	*	+	115	+	4
960	45	F	Breast	Invasive ductal carcinoma (breast tissue)	T2N0M0	-	Ila	malignant	*	*	0	+	98	+	4
961	44	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	47	++	4
962	44	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	49	++	4
963	52	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	51	++	4
964	52	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	-	-	0	+	57	++	4
965	43	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	++	++	0	+	63	++	4
966	43	F	Breast	Medullary carcinoma	T2N0M0	-	Ila	malignant	++	++	0	+	72	++	4
967	58	F	Breast	Invasive lobular carcinoma	T2N0M0	-	Ila	malignant	+++	-	0	+	70	++	4
968	58	F	Breast	Invasive lobular carcinoma	T2N0M0	-	Ila	malignant	+++	+	0	+	83	++	4
969	49	F	Breast	Mixed lobular and duct carcinoma	T2N0M0	-	Ila	malignant	+	+	0	+	87	++	4
970	49	F	Breast	Mixed lobular and duct carcinoma	T2N0M0	-	Ila	malignant	+	+	0	+	93	+	4
971	54	F	Breast	Invasive papillary carcinoma	T2N0M0	-	Ila	malignant	++	+	0	+	96	+	4
972	54	F	Breast	Invasive papillary carcinoma	T2N0M0	-	Ila	malignant	++	+	0	+	54	++	4
973	53	F	Breast	Invasive papillary carcinoma	T2N0M0	-	Ila	malignant	+++	+	0	+	48	++	4
974	53	F	Breast	Invasive papillary carcinoma	T2N0M0	-	Ila	malignant	+++	+	0	+	67	++	4
975	59	F	Breast	Invasive lobular carcinoma (cataplasia type)	T2N0M0		IIA	malignant				+	63	++	4
976	49	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant				+	75	++	4
977	46	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant				+	82	++	4
978	37	F	Breast	Invasive lobular carcinoma (cataplasia type)	T2N0M0		IIA	malignant				+	89	++	4
979	50	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant				+	65	++	4

980	47	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant				+	81	++	4
981	69	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant				+	41	++	4
982	58	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant				+	44	++	4
983	60	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant				+	50	++	4
984	57	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant				+	52	++	4
985	53	F	breast	infiltrative ductal carcinoma, mucinous ca	T2N1M0	3	IIb	Malignant				+	63	++	4
986	50	F	breast	infiltrative ductal carcinoma	T2N1M0	3	IIb	Malignant				+	143	++	4
987	45	F	breast	infiltrative ductal carcinoma	T2N1M0	3	IIb	Malignant				+	125	++	4
988	43	F	breast	infiltrative ductal carcinoma	T2N1M0	2--3	IIb	Malignant				+	116	++	4
989	54	F	breast	infiltrative ductal carcinoma	T2N1M0	2	IIb	Malignant				+	72	++	4
990	40	F	breast	infiltrative ductal carcinoma	T2N1M0	2	IIb	Malignant				+	89	+++	4
991	41	F	breast	infiltrative ductal carcinoma	T2N1M0	2	IIb	Malignant				+	54	+++	4
992	41	F	breast	infiltrative ductal carcinoma	T2N1M0	2	IIb	Malignant				+	58	++	4
993	46	F	breast	infiltrative ductal carcinoma	T2N1M0	2	IIb	Malignant				+	47	++	4
994	46	F	breast	infiltrative ductal carcinoma	T2N1M0	2	IIb	Malignant				+	112	+	4
995	52	F	breast	infiltrative ductal carcinoma	T2N1M0	2	IIb	Malignant				+	107	+	4
996	51	F	breast	infiltrative ductal carcinoma	T2N1M0	2	IIb	Malignant				+	113	+	4
997	49	F	breast	infiltrative ductal carcinoma	T2N1M0	3	IIb	Malignant				+	67	+++	4
998	44	F	breast	infiltrative ductal carcinoma	T2N1M0	3	IIb	Malignant				+	43	+++	4
999	44	F	breast	infiltrating lobular carcinoma	T2N1M0	3	IIb	Malignant				+	49	+++	4
1000	49	F	breast	infiltrating lobular carcinoma	T2N1M0	3	IIb	Malignant				+	52	+++	4
1001	46	F	Breast	Invasive ductal carcinoma	T3N0M0	1	IIb	malignant	-	+++	0	+	78	++	4
1002	46	F	Breast	Invasive ductal carcinoma	T3N0M0	1	IIb	malignant	-	+++	0	+	84	++	4
1003	56	F	Breast	Invasive ductal carcinoma	T3N0M0	1	IIb	malignant	++	+	0	+	57	++	4
1004	40	F	Breast	Invasive ductal carcinoma	T3N0M0	1	IIb	malignant	+	*	0	+	51	++	4
1005	36	F	Breast	Invasive ductal carcinoma	T3N0M0	1	IIb	malignant	+++	*	0	+	60	++	4
1006	37	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIb	malignant	-	-	2+	+	72	++	4
1007	37	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIb	malignant	-	-	2+	+	81	++	4
1008	58	F	Breast	Invasive ductal carcinoma	T2N0M0	1	IIb	malignant	-	-	2+	+	46	++	4
1009	52	F	Breast	Invasive ductal carcinoma	T3N0M0	1	IIb	malignant	-	*	2+	+	49	++	4
1010	52	F	Breast	Invasive ductal carcinoma	T3N0M0	1	IIb	malignant	-	*	2+	+	55	++	4
1011	44	F	Breast	Invasive ductal carcinoma	T3N1M0	1	IIb	malignant	+	-	0	+	43	++	4
1012	44	F	Breast	Invasive ductal carcinoma	T3N1M0	1	IIb	malignant	+	-	0	+	48	++	4
1013	49	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+	-	+	87	++	4

1014	49	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+	-	+	82	++	4
1015	48	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+	+	-	+	91	++	4
1016	48	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+	+	-	+	67	++	4
1017	40	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+++	+	-	+	73	++	4
1018	40	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+++	+	-	+	56	++	4
1019	78	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	++	-	-	+	48	++	4
1020	78	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	++	-	-	+	52	++	4
1021	46	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	-	-	+	54	++	4
1022	46	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	-	-	+	68	++	4
1023	50	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	-	+	49	++	4
1024	53	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	1+	+	51	++	4
1025	53	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	2+	+	62	++	4
1026	65	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	3+	+	67	++	4
1027	65	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	3+	+	72	++	4
1028	80	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	-	-	+	84	++	4
1029	80	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	*	-	+	103	++	4
1030	49	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	*	++	0	+	118	++	4
1031	49	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	*	++	0	+	47	++	4
1032	45	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	87	++	4
1033	45	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	92	++	4
1034	62	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	++	++	0	+	46	++	4
1035	62	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	++	++	0	+	55	++	4
1036	34	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	2+	+	43	++	4
1037	34	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	2+	+	48	++	4
1038	48	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+++	0	+	96	++	4
1039	48	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+++	0	+	108	++	4
1040	38	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+	-	0	+	87	++	4
1041	38	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+	-	0	+	73	++	4
1042	48	F	Breast	nvasive ductal carcinoma (sparse	T2N1M0	2	IIb	malignant	-	-	0	+	49	++	4
1043	48	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	54	++	4
1044	61	F	Breast	asive ductal carcinoma with necro	T2N1M0	2	IIb	malignant	-	-	0	+	57	++	4
1045	61	F	Breast	asive ductal carcinoma with necro	T2N1M0	2	IIb	malignant	-	-	*	+	64	++	4
1046	50	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	42	++	4
1047	50	F	Breast	nvasive ductal carcinoma (sparse	T2N1M0	2	IIb	malignant	-	-	0	+	48	++	4

1048	73	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	56	++	4
1049	73	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	52	++	4
1050	56	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	43	++	4
1051	56	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	98	++	4
1052	46	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	94	+	4
1053	46	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	103	+	4
1054	39	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+	+	0	+	109	+	4
1055	39	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+	+	0	+	89	++	4
1056	32	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	83	++	4
1057	32	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	74	++	4
1058	47	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	++	0	+	108	+	4
1059	47	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	++	0	+	103	+	4
1060	48	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	98	+	4
1061	48	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	101	+	4
1062	35	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	+++	2+	+	84	++	4
1063	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIb	malignant	-	-	1+	+	98	++	4
1064	49	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIb	malignant	-	-	1+	+	93	++	4
1065	60	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	1+	+	87	+	4
1066	60	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	1+	+	85	+	4
1067	35	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIb	malignant	++	-	0	+	73	++	4
1068	35	F	Breast	Invasive ductal carcinoma	T2N0M0	2	IIb	malignant	++	-	0	+	76	++	4
1069	43	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	++	-	0	+	53	++	4
1070	43	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	++	-	0	+	49	++	4
1071	41	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+++	-	2+	+	47	++	4
1072	41	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+++	-	2+	+	53	++	4
1073	38	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIb	malignant	-	-	3+	+	64	+	4
1074	38	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIb	malignant	-	-	3+	+	78	+	4
1075	36	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	++	0	+	108	+	4
1076	36	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	++	0	+	116	+	4
1077	28	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	++	0	+	94	+	4
1078	61	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+	-	0	+	44	++	4
1079	61	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	52	++	4
1080	44	F	Breast	Invasive ductal carcinoma with necro	T2N1M0	2	IIb	malignant	++	++	3+	+	67	++	4
1081	44	F	Breast	Invasive ductal carcinoma with necro	T2N1M0	2	IIb	malignant	++	++	3+	+	54	++	4

1082	54	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+	0	+	68	++	4
1083	54	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+	0	+	73	++	4
1084	41	F	Breast	nvasive ductal carcinoma (sparse	T3N0M0	2	IIb	malignant	-	-	*	+	77	++	4
1085	41	F	Breast	nvasive ductal carcinoma (sparse	T3N0M0	2	IIb	malignant	-	-	0	+	63	++	4
1086	47	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+++	0	+	66	++	4
1087	47	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+++	0	+	58	++	4
1088	41	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	++	2+	+	62	++	4
1089	41	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	++	++	2+	+	49	++	4
1090	54	F	Breast	e ductal carcinoma (sparse) with n	T3N0M0	2	IIb	malignant	+++	-	0	+	47	++	4
1091	54	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+	0	+	58	++	4
1092	51	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+	-	0	+	64	++	4
1093	51	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	+	-	0	+	69	++	4
1094	54	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+	-	3+	+	42	++	4
1095	54	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+	-	3+	+	48	++	4
1096	53	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	2+	+	51	++	4
1097	53	F	Breast	asive ductal carcinoma with necro	T3N0M0	2	IIb	malignant	-	-	2+	+	54	++	4
1098	52	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	48	++	4
1099	52	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	55	++	4
1100	44	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	69	++	4
1101	44	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	0	+	89	++	4
1102	54	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	2+	+	92	++	4
1103	54	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	2+	+	96	++	4
1104	58	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	2+	+	42	++	4
1105	58	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	2+	+	44	++	4
1106	46	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	+	2+	+	53	++	4
1107	46	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	+	2+	+	87	++	4
1108	81	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	++	-	0	+	94	++	4
1109	81	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	++	+	0	+	66	++	4
1110	60	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+	+	1+	+	57	++	4
1111	60	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+	+	1+	+	85	++	4
1112	43	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	47	++	4
1113	44	F	Breast	Invasive ductal carcinoma	T2N1M0	2	IIb	malignant	-	-	3+	+	88	++	4
1114	46	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	46	++	4
1115	60	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+	0	+	98	++	4

1116	60	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+++	+	0	+	105	++	4
1117	63	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	98	++	4
1118	63	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	116	++	4
1119	57	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIb	malignant	+	-	0	+	78	++	4
1120	57	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIb	malignant	+	-	0	+	83	++	4
1121	60	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	79	++	4
1122	60	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	47	++	4
1123	46	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	52	++	4
1124	46	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	-	-	0	+	56	++	4
1125	41	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIb	malignant	++	+	0	+	64	++	4
1126	41	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIb	malignant	++	+	0	+	78	++	4
1127	48	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIb	malignant	+	+++	0	+	66	++	4
1128	66	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	Malignant				+	41	++	4
1129	48	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	Malignant				+	46	++	4
1130	66	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	Malignant				+	76	++	4
1131	48	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	Malignant				+	73	++	4
1132	45	F	Breast	Invasive ductal carcinoma	T2N1M0	3	IIb	malignant	-	-	3+	+	56	++	4
1133	45	F	Breast	Invasive ductal carcinoma	T2N1M0	3	IIb	malignant	-	-	3+	+	45	++	4
1134	39	F	Breast	Invasive ductal carcinoma	T3N0M0	3	IIb	malignant	+	+	3+	+	85	++	4
1135	39	F	Breast	Invasive ductal carcinoma	T3N0M0	3	IIb	malignant	+	+	3+	+	93	++	4
1136	33	F	Breast	Invasive ductal carcinoma	T2N1M0	3	IIb	malignant	-	-	0	+	102	++	4
1137	33	F	Breast	Invasive ductal carcinoma	T2N1M0	3	IIb	malignant	-	-	0	+	99	++	4
1138	45	F	Breast	Invasive ductal carcinoma	T3N0M0	3	IIb	malignant	-	-	0	+	117	++	4
1139	45	F	Breast	Invasive ductal carcinoma	T3N0M0	3	IIb	malignant	-	*	0	+	106	++	4
1140	34	F	Breast	Invasive ductal carcinoma	T3N0M0	3	IIb	malignant	-	*	0	+	102	++	4
1141	34	F	Breast	Invasive ductal carcinoma	T3N0M0	3	IIb	malignant	*	*	0	+	94	++	4
1142	34	F	Breast	Invasive ductal carcinoma	T3N0M0	3	IIb	malignant	-	-	0	+	116	++	4
1143	34	F	Breast	Invasive ductal carcinoma	T3N0M0	3	IIb	malignant	-	-	0	+	108	++	4
1144	45	F	Breast	Invasive ductal carcinoma	T2N1M0	3	IIb	malignant	++	+	2+	+	127	++	4
1145	45	F	Breast	Invasive ductal carcinoma	T2N1M0	3	IIb	malignant	++	+	2+	+	118	++	4
1146	52	F	Breast	asive ductal carcinoma (breast tiss	T2N1M0	-	IIb	malignant	*	*	-	+	103	++	4
1147	52	F	Breast	asive ductal carcinoma (breast tiss	T2N1M0	-	IIb	malignant	*	*	2+	+	98	++	4
1148	50	F	Breast	nvasive ductal carcinoma (sparse	T2N1M0	-	IIb	malignant	-	-	-	+	46	++	4
1149	51	F	Breast	nvasive ductal carcinoma (sparse	T2N1M0	-	IIb	malignant	+	+	0	+	48	++	4

1150	51	F	Breast	invasive ductal carcinoma (sparse	T2N1M0	-	IIb	malignant	+	+	0	+	51	++	4
1151	48	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIb	malignant	-	-	0	+	63	++	4
1152	48	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIb	malignant	-	-	0	+	77	++	4
1153	35	F	Breast	invasive ductal carcinoma (sparse	T3N0M0	-	IIb	malignant	++	+++	2+	+	98	++	4
1154	39	F	Breast	Medullary carcinoma	T2N1M0	-	IIb	malignant	-	-	0	+	48	++	4
1155	39	F	Breast	Medullary carcinoma	T2N1M0	-	IIb	malignant	-	-	0	+	57	++	4
1156	49	F	Breast	Medullary carcinoma	T3N0M0	-	IIb	malignant	-	*	0	+	55	++	4
1157	49	F	Breast	Medullary carcinoma	T3N0M0	-	IIb	malignant	-	*	0	+	43	++	4
1158	28	F	Breast	al carcinoma (fibrofatty tissue and	T3N0M0	-	IIb	malignant	*	*	*	+	62	++	4
1159	44	F	Breast	Invasive lobular carcinoma	T3N0M0	-	IIb	malignant	+	+	0	+	67	++	4
1160	44	F	Breast	Invasive lobular carcinoma	T3N0M0	-	IIb	malignant	+	+	0	+	68	++	4
1161	56	F	Breast	asive ductal carcinoma (breast tiss	T3N0M0	-	IIb	malignant	*	*	0	+	72	++	4
1162	43	F	Breast	al carcinoma (fibrofatty tissue and	T3N0M0	-	IIb	malignant	*	*	*	+	83	++	4
1163	44	F	Breast	al carcinoma (fibrofatty tissue and	T2N1M0	-	IIb	malignant	*	*	*	+	109	++	4
1164	46	F	Breast	vasive ductal carcinoma (sparse) with n	T3N0M0	-	IIb	malignant	-	-	0	+	112	++	4
1165	55	F	Breast	Medullary carcinoma	T3N0M0	-	IIb	malignant	-	-	0	+	94	++	4
1166	55	F	Breast	Medullary carcinoma	T3N0M0	-	IIb	malignant	-	-	0	+	47	++	4
1167	52	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIb	malignant	-	-	0	+	63	++	4
1168	52	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIb	malignant	-	-	0	+	52	++	4
1169	40	F	Breast	tal carcinoma (fibrous tissue and t	T3N0M0	-	IIb	malignant	*	*	0	+	43	++	4
1170	58	F	Breast	al carcinoma (adipose tissue and	T2N0M0	-	IIb	malignant	*	*	*	+	68	++	4
1171	48	F	Breast	Invasive ductal carcinoma	T3N0M0	-	IIb	malignant	*	*	0	+	84	++	4
1172	52	F	Breast	Mixed lobular and duct carcinoma	T2N1M0	-	IIb	malignant	+++	+	0	+	47	++	4
1173	52	F	Breast	Mixed lobular and duct carcinoma	T2N1M0	-	IIb	malignant	+++	+	0	+	43	++	4
1174	37	F	Breast	Sarcoma phyllodes	T2N0M0	-	IIb	malignant	-	-	0	+	63	++	4
1175	37	F	Breast	Sarcoma phyllodes	T2N0M0	-	IIb	malignant	-	-	0	+	67	++	4
1176	31	F	Breast	Sarcoma phyllodes	T2N0M0	-	IIb	malignant	-	-	0	+	69	++	4
1177	31	F	Breast	Sarcoma phyllodes	T2N0M0	-	IIb	malignant	-	-	0	+	72	++	4
1178	40	F	Breast	Sarcoma phyllodes	T2N0M0	-	IIb	malignant	-	*	0	+	73	++	4
1179	40	F	Breast	Sarcoma phyllodes	T2N0M0	-	IIb	malignant	-	*	0	+	84	++	4
1180	50	F	Breast	Mucinous carcinoma	T2N1M0	1--2	IIb	malignant	-	-	-	+	89	++	4
1181	50	F	Breast	Mucinous carcinoma	T2N1M0	1--2	IIb	malignant	+	+	-	+	63	++	4
1182	36	F	Breast	Invasive ductal carcinoma	T3N0M0	1--2	IIb	malignant	+++	*	0	+	71	++	4
1183	58	F	Breast	Invasive ductal carcinoma	T3N0M0	1--2	IIB	Malignant				+	66	++	4

1184	58	F	Breast	Invasive ductal carcinoma	T3N0M0	1--2	IIB	Malignant				+	42	++	4
1185	47	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant				+	73	++	4
1186	35	F	Breast	Invasive lobular carcinoma	T3N0M0		IIB	malignant				+	68	++	4
1187	19	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant				+	75	++	4
1188	45	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant				+	58	++	4
1189	49	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant				+	56	++	4
1190	63	F	Breast	Invasive lobular carcinoma	T3N0M0		IIB	malignant				+	64	++	4
1191	42	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant				+	68	++	4
1192	50	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant				+	56	++	4
1193	25	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	Malignant	+++	-	3+	+	45	++	4
1194	39	F	Breast	Invasive ductal carcinoma	T2N1M0	1	IIB	Malignant	+++	++	3+	+	43	++	4
1195	25	F	Breast	Invasive ductal carcinoma	T3N0M0	2	IIB	Malignant	+++	-	3+	+	56	++	4
1196	39	F	Breast	Invasive ductal carcinoma	T2N1M0	-	IIB	Malignant	*	*	*	+	73	++	4
1197	35	F	Breast	Invasive ductal carcinoma	T3N2M0	2	IIla	malignant	++	++	0	+	182	++	4
1198	35	F	Breast	Invasive ductal carcinoma	T3N2M0	2	IIla	malignant	++	++	0	+	167	++	4
1199	73	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIla	malignant	-	-	0	+	96	++	4
1200	73	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIla	malignant	-	-	0	+	103	++	4
1201	41	F	Breast	Invasive ductal carcinoma	T2N2M0	2	IIla	malignant	-	-	0	+	119	++	4
1202	41	F	Breast	Invasive ductal carcinoma	T2N2M0	2	IIla	malignant	-	-	0	+	87	++	4
1203	57	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIla	malignant	++	-	0	+	93	++	4
1204	57	F	Breast	Invasive ductal carcinoma	T3N1M0	2	IIla	malignant	++	-	0	+	104	++	4
1205	63	F	Breast	Invasive ductal carcinoma with necrosis	T3N1M0	2	IIla	malignant	-	-	0	+	117	++	4
1206	63	F	Breast	Invasive ductal carcinoma with necrosis	T3N1M0	2	IIla	malignant	-	-	0	+	101	++	4
1207	44	F	Breast	Invasive ductal carcinoma	T2N2M0	2	IIla	malignant	-	-	0	+	113	++	4
1208	44	F	Breast	Invasive ductal carcinoma	T2N2M0	2	IIla	malignant	-	-	0	+	87	++	4
1209	33	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIla	malignant	++	-	0	+	96	++	4
1210	33	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIla	malignant	++	-	0	+	90	++	4
1211	40	F	Breast	Invasive ductal carcinoma	T3N2M0	2	IIla	malignant	-	-	0	+	103	++	4
1212	40	F	Breast	Invasive ductal carcinoma	T3N2M0	2	IIla	malignant	-	-	0	+	108	++	4
1213	44	F	Breast	Invasive ductal carcinoma	T3N2M0	3	IIla	malignant	-	-	0	+	112	++	4
1214	44	F	Breast	Invasive ductal carcinoma	T3N2M0	3	IIla	malignant	-	-	0	+	117	++	4
1215	49	F	Breast	Invasive lobular carcinoma	T3N2M0	-	IIla	malignant	-	-	0	+	137	++	4
1216	49	F	Breast	Invasive lobular carcinoma	T3N2M0	-	IIla	malignant	-	-	0	+	125	++	4
1217	50	F	Breast	Invasive lobular carcinoma	T2N2M0		IIIA	malignant				+	128	++	4

1218	84	F	Breast	Invasive ductal carcinoma	T4N0M0	1	IIIb	malignant	*	++	0	+	120	++	4
1219	84	F	Breast	Invasive ductal carcinoma	T4N0M0	1	IIIb	malignant	*	++	0	+	113	++	4
1220	52	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	++	-	+	132	++	4
1221	52	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	++	-	+	143	++	4
1222	48	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	+++	-	+	145	++	4
1223	48	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	+++	-	+	187	++	4
1224	69	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	-	-	+	165	++	4
1225	69	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	+	-	+	152	+	4
1226	45	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	-	-	3+	+	132	+	4
1227	45	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	-	-	3+	+	128	+	4
1228	32	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+	++	-	+	133	+	4
1229	32	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+	++	-	+	144	+	4
1230	66	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	-	-	2+	+	162	+	4
1231	66	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	-	-	2+	+	102	+	4
1232	60	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+	-	2+	+	97	+	4
1233	60	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+	-	2+	+	104	+	4
1234	64	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+++	+++	-	+	118	+	4
1235	64	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+++	+++	-	+	103	+	4
1236	52	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	-	++	0	+	67	++	4
1237	52	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	-	++	0	+	58	++	4
1238	46	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	-	0	+	102	++	4
1239	46	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	-	0	+	98	+++	4
1240	65	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	*	++	0	+	93	+++	4
1241	65	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	*	++	0	+	86	+++	4
1242	71	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	-	-	0	+	77	+++	4
1243	71	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	-	-	0	+	57	+++	4
1244	45	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	++	-	0	+	49	+++	4
1245	45	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	++	-	0	+	84	+++	4
1246	40	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	++	0	+	76	+++	4
1247	40	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	++	0	+	79	+++	4
1248	82	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	-	0	+	58	+++	4
1249	82	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	-	0	+	53	+++	4
1250	59	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+++	-	0	+	103	++	4
1251	59	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+++	-	0	+	124	++	4

1252	63	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	*	-	0	+	73	+++	4
1253	63	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	*	-	0	+	81	+++	4
1254	40	F	Breast	Invasive ductal carcinoma with necrosis	T4N0M0	2	IIIb	malignant	++	++	0	+	99	+++	4
1255	40	F	Breast	Invasive ductal carcinoma with necrosis	T4N0M0	2	IIIb	malignant	++	++	0	+	94	+++	4
1256	81	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	-	0	+	103	++	4
1257	81	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	-	0	+	108	+	4
1258	49	F	Breast	Invasive ductal carcinoma (sparse)	T4N0M0	2	IIIb	malignant	++	-	0	+	83	+++	4
1259	49	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	-	0	+	75	+++	4
1260	69	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	+	0	+	77	+++	4
1261	69	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	+	0	+	82	+++	4
1262	57	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	-	+	0	+	97	+++	4
1263	57	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+	+	0	+	67	+++	4
1264	61	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	-	0	+	83	+++	4
1265	61	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	-	0	+	93	+++	4
1266	42	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	-	-	0	+	98	+	4
1267	42	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	-	-	1+	+	102	+	4
1268	52	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+	-	3+	+	117	+	4
1269	52	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+	-	3+	+	126	+	4
1270	41	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	++	-	0	+	88	+++	4
1271	41	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+	-	0	+	83	+++	4
1272	42	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIb	malignant	++	+	0	+	92	+++	4
1273	42	F	Breast	Invasive ductal carcinoma with necrosis	T4N2M0	2	IIIb	malignant	++	+	0	+	106	+++	4
1274	53	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	++	*	0	+	94	+++	4
1275	53	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	++	*	0	+	81	+++	4
1276	60	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIb	malignant	-	-	0	+	74	+++	4
1277	60	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIb	malignant	-	-	0	+	66	+++	4
1278	52	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	-	0	+	58	+++	4
1279	52	F	Breast	Invasive ductal carcinoma	T4N0M0	2	IIIb	malignant	+++	-	0	+	87	+++	4
1280	49	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+	+	0	+	95	+++	4
1281	49	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIb	malignant	+	+	0	+	102	++	4
1282	49	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIb	malignant	-	-	0	+	111	++	4
1283	49	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIb	malignant	-	-	0	+	102	++	4
1284	52	F	Breast	Invasive ductal carcinoma	T4cN2M0	2	IIIb	malignant	-	-	0	+	98	+++	4
1285	52	F	Breast	Invasive ductal carcinoma	T4cN2M0	2	IIIb	malignant	-	-	0	+	73	+++	4

1286	62	F	Breast	Invasive ductal carcinoma	T4N0M0	3	IIIb	malignant	-	-	2+	+	79	+++	4
1287	62	F	Breast	Invasive ductal carcinoma	T4N0M0	3	IIIb	malignant	-	-	2+	+	58	+++	4
1288	74	F	Breast	Invasive papillary carcinoma	T4N0M0	-	IIIb	malignant	+++	-	-	+	52	+++	4
1289	74	F	Breast	Invasive papillary carcinoma	T4N0M0	-	IIIb	malignant	+++	-	-	+	67	+++	4
1290	47	F	Breast	Invasive lobular carcinoma	T4N0M0	-	IIIb	malignant	++	++	0	+	108	+++	4
1291	47	F	Breast	Invasive lobular carcinoma	T4N0M0	-	IIIb	malignant	++	++	0	+	156	+++	4
1292	73	F	Breast	ive mixed lobular and ductal carci	T4N0M0	-	IIIb	malignant	-	*	0	+	201	+++	4
1293	73	F	Breast	ive mixed lobular and ductal carci	T4N0M0	-	IIIb	malignant	-	*	0	+	187	+++	4
1294	48	F	Breast	Squamous cell carcinoma	T4N0M0	2--3	IIIb	malignant	-	-	0	+	184	+	4
1295	48	F	Breast	Squamous cell carcinoma	T4N0M0	2--3	IIIb	malignant	-	-	0	+	177	+	4
1296	37	F	Breast	Invasive lobular carcinoma	T4N1M0		IIIB	malignant				+	153	+	4
1297	73	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant				+	122	+	4
1298	51	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant				+	86	++	4
1299	41	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant				+	66	++	4
1300	53	F	Breast	nvasive lobular carcinoma (sparse	T4N1M0		IIIB	malignant				+	79	++	4
1301	32	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIB	Malignant	++	-	3+	+	118	+	4
1302	60	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIB	Malignant	-	-	3+	+	105	+	4
1303	32	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IIIB	Malignant	++	-	3+	+	101	+	4
1304	60	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IIIB	Malignant	-	-	3+	+	162	+	4
1305	44	F	Breast	Invasive ductal carcinoma	T2N3M0	2	IV	malignant	-	-	2+	+	191	+++	4
1306	44	F	Breast	Invasive ductal carcinoma	T2N3M0	2	IV	malignant	-	-	2+	+	156	+++	4
1307	31	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IV	malignant	+++	+++	0	+	153	+++	4
1308	31	F	Breast	Invasive ductal carcinoma	T4N2M0	2	IV	malignant	+++	+++	0	+	126	+++	4
1309	57	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IV	malignant	-	-	0	+	115	+++	4
1310	57	F	Breast	Invasive ductal carcinoma	T4N1M0	2	IV	malignant	-	-	0	+	103	+++	4
1311	73	F	Breast	arcinoma (chronic inflammation of	T4N1M1	-	IV	malignant	*	*	0	+	108	+++	4
1312	73	F	Breast	arcinoma (chronic inflammation of	T4N1M1	-	IV	malignant	*	*	0	+	99	+++	4
1313	32	F	Breast	Neuroendocrine carcinoma	T2N3M0	-	IV	malignant	-	+	0	+	126	+++	4
1314	32	F	Breast	Neuroendocrine carcinoma	T2N3M0	-	IV	malignant	-	+	0	+	89	+++	4
1315	50	F	Breast	Invasive ductal carcinoma	T4N3M1	1--2	IV	malignant	++	*	0	+	72	+++	4
1316	50	F	Breast	Invasive ductal carcinoma	T4N3M1	1--2	IV	malignant	++	*	0	+	85	+++	4
1317	54	F	Breast	Invasive ductal carcinoma	T3N0M0	1--2		Malignant				+	92	+	4
1318	38	F	Breast	Invasive ductal carcinoma	T3N0M0	1--2		Malignant	+++	+++	3+	+	101	+	4
1319	38	F	Breast	Invasive ductal carcinoma	T3N0M0	1--2		Malignant	+++	+++	3+	+	67	+	4

1320	41	F	Breast	Invasive ductal carcinoma	T2N0M0	1--2	Malignant	+	+	0	+	73	+	4
1321	41	F	Breast	Invasive ductal carcinoma	T2N0M0	1--2	Malignant	++	++	0	+	78	+	4
1322	35	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant				+	82	+	4
1323	32	F	Breast	Invasive ductal carcinoma	T1N1M0	2--3	Malignant				+	65	+	4
1324	38	F	Breast	Invasive ductal carcinoma	T3N0M0	2--3	Malignant				+	47	+	4
1325	52	F	Breast	Invasive ductal carcinoma	T3N0M0	2--3	Malignant				+	58	+	4
1326	31	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant				+	69	+	4
1327	30	F	Breast	Invasive ductal carcinoma	T4N0M0	2--3	Malignant	+++	+++	0	+	91	+	4
1328	30	F	Breast	Invasive ductal carcinoma	T4N0M0	2--3	Malignant	+++	+++	0	+	107	+	4
1329	33	F	Breast	Invasive ductal carcinoma	T1N0M0	2--3	Malignant	+	+	0	+	116	+	4
1330	33	F	Breast	Invasive ductal carcinoma	T1N0M0	2--3	Malignant	+	+	0	+	67	+	4
1331	35	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant	-	-	0	+	73	+	4
1332	35	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant	-	-	0	+	82	+	4
1333	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant	-	++	0	+	91	+	4
1334	44	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant	-	++	0	+	103	+	4
1335	43	F	Breast	Invasive ductal carcinoma	T2N1M0	2--3	Malignant	+	+++	2+	+	105	+	4
1336	43	F	Breast	Invasive ductal carcinoma	T2N1M0	2--3	Malignant	+	+++	2+	+	117	+	4
1337	41	F	Breast	Invasive ductal carcinoma	T3N1M0	2--3	Malignant	-	-	0	+	88	+	4
1338	41	F	Breast	Invasive ductal carcinoma	T3N1M0	2--3	Malignant	-	-	0	+	82	+	4
1339	59	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant	++	+++	0	+	74	+	4
1340	59	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant	++	+++	0	+	109	+	4
1341	34	F	Breast	Invasive ductal carcinoma	T4N0M0	2--3	Malignant	+	+++	0	+	116	+	4
1342	34	F	Breast	Invasive ductal carcinoma	T4N0M0	2--3	Malignant	+	+++	0	+	58	+	4
1343	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant	++	+	0	+	78	+	4
1344	47	F	Breast	Invasive ductal carcinoma	T2N0M0	2--3	Malignant	++	+	0	+	67	+	4
1345		F	breast	breast tissue			NAT				+	128	+	4
1346		F	breast	breast tissue			NAT				+	115	+	4
1347		F	breast	breast tissue			NAT				+	136	+	4
1348		F	breast	breast tissue			NAT				+	98	+	4
1349		F	breast	breast tissue			NAT				+	176	+	4
1350		F	breast	breast tissue			NAT				+	182	+	4
1351		F	breast	breast tissue			NAT				+	201	+	4
1352		F	breast	breast tissue			NAT				+	153	+	4
1353		F	breast	breast tissue			NAT				+	166	+	4

1354		F	breast	breast tissue			NAT				+	204	+	4
1355		F	breast	breast tissue			NAT				+	183	+	4
1356		F	breast	breast tissue			NAT				+	162	+	4
1357		F	breast	breast tissue			NAT				+	188	+	4
1358		F	breast	breast tissue			NAT				+	117	+	4
1359		F	breast	breast tissue			NAT				+	103	+	4
1360		F	breast	breast tissue			NAT				+	98	++	4
1361		F	breast	breast tissue			NAT				+	92	++	4
1362		F	breast	breast tissue			NAT				+	132	+	4
1363		F	breast	breast tissue			NAT				+	148	+	4
1364		F	breast	breast tissue			NAT				+	126	+	4
1365		F	breast	breast tissue			NAT				+	115	+	4
1366		F	breast	breast tissue			NAT				+	108	+	4
1367		F	breast	breast tissue			NAT				+	101	+	4
1368		F	breast	breast tissue			NAT				+	136	+	4
1369		F	breast	breast tissue			NAT				+	89	++	4
1370		F	breast	breast tissue			NAT				+	96	++	4
1371		F	breast	breast tissue			NAT				+	88	+	4
1372		F	breast	breast tissue			NAT				+	102	+	4
1373		F	breast	breast tissue			NAT				+	117	+	4
1374		F	breast	breast tissue			NAT				+	159	+	4
1375	49	F	Breast	Adjacent normal breast tissue	-	-	NAT				+	132	+	4
1376	38	F	Breast	Adjacent normal breast tissue	-	-	NAT				+	119	+	4
1377	43	F	Breast	Adjacent normal breast tissue	-	-	NAT				+	124	+	4
1378	46	F	Breast	Adjacent normal breast duct tissue	-	-	NAT	+	+	0	+	95	+	4
1379	46	F	Breast	Adjacent normal breast tissue	-	-	NAT	+	+	0	+	105	+	4
1380	42	F	Breast	Adjacent normal breast tissue	-	-	NAT	-	++	0	+	97	++	4
1381	42	F	Breast	Adjacent normal breast tissue(fibrous ti	-	-	NAT	*	*	*	+	86	++	4
1382	43	F	Breast	Adjacent normal breast tissue (fibrous t	-	-	NAT	*	*	*	+	149	+	4
1383	43	F	Breast	Adjacent normal breast tissue	-	-	NAT	+	+	0	+	133	+	4
1384	46	F	Lymph node	Metastatic adenocarcinoma of oter from breast	2		Metastasis				+	87	++	4
1385	40	F	Lymph node	Metastatic adenocarcinoma of oter from breast	3		Metastasis				+	103	+	4
1386	48	F	Lymph node	Metastatic adenocarcinoma of oter from breast	2		Metastasis				+	114	+	4
1387	53	F	Lymph node	Metastatic adenocarcinoma of oter from breast	2		Metastasis				+	128	+	4

1388	46	F	Lymph node	static adenocarcinoma of oter from breast	2	Metastasis				+	156	+	4
1389	40	F	Lymph node	static adenocarcinoma of oter from breast	3	Metastasis				+	142	+	4
1390	53	F	Lymph node	static adenocarcinoma of oter from breast	2	Metastasis				+	108	+	4
1391	42	F	Lymph node	static adenocarcinoma of oter from breast	2	Metastasis				+	127		4
1392	48	F	Lymph node	static adenocarcinoma of oter from breast	2	Metastasis				+	114		4
1393	66	M	Lymph node	static adenocarcinoma of oter from breast	2	Metastasis				+	98	+	4
1394	58	F	Lymph node	static adenocarcinoma of oter from breast	3	Metastasis				+	107	+	4
1395	42	F	Lymph node	static adenocarcinoma of oter from breast	2	Metastasis				+	142	+	4
1396	66	M	Lymph node	static adenocarcinoma of oter from breast	2	Metastasis				+	158	+	4
1397	58	F	Lymph node	static adenocarcinoma of oter from breast	3	Metastasis				+	192		4
1398	70	F	Brain	static adenocarcinoma from breast	3	Metastasis				+	187	++	4
1399	43	F	Brain	static adenocarcinoma from breast	2	Metastasis				+	156	++	4
1400	55	F	Lung	undifferentiated adenocarcinoma from breast	-	Metastasis				+	192	+	4
1401	34	F	Liver	static adenocarcinoma from breast	3	Metastasis				+	177	+	4
1402	34	F	Liver	static adenocarcinoma from breast	3	Metastasis				+	184	+	4
1403	75	F	Chest wall	static adenocarcinoma from breast	3	Metastasis				+	179	++	4
1404	49	F	Ovary	static adenocarcinoma from breast	3	Metastasis				+	168	++	4
1405	48	F	Breast	Fibroadenoma	-	Benign	++	+	0	-			0
1406	48	F	Breast	Fibroadenoma	-	Benign	++	+	0	-			0
1407	19	F	Breast	Fibroadenoma	-	Benign	+++	+++	0	-			0
1408	19	F	Breast	Fibroadenoma	-	Benign	+++	+++	0	-			0
1409	54	F	Breast	Fibroadenoma	-	Benign	-	-	0	-			0
1410	54	F	Breast	Fibroadenoma	-	Benign	-	-	0	+	9		1
1411		F	Breast	breast tissue		Normal tissue				-			
1412		F	Breast	breast tissue		Normal tissue				-			
1413		F	Breast	breast tissue		Normal tissue				-			
1414		F	Breast	breast tissue		Normal tissue				-			
1415		F	Breast	breast tissue		Normal tissue				-			
China													
1416	54	F	Liver	static adenocarcinoma from breast		III Metastasis	-	-	-	+	103	+	4
1417	61	F	Liver	static adenocarcinoma from breast		III Metastasis	-	-	-	+	126	+	4
1418	52	F	Liver	static adenocarcinoma from breast		III Metastasis	-	-	-	+	134		4
1419	48	F	Lung	static adenocarcinoma from breast		III Metastasis	-	-	-	+	98	++	4
1420	71	F	Lung	static adenocarcinoma from breast		III Metastasis	-	-	+	+	107	++	4

1421	33	F	Lung	metastasis adenocarcinoma from breast			III	Metastasis	-	-	3+	+	112	+	4
1422	51	F	Breast	Invasive ductal carcinoma			III	Malignant	+	+	-	+	156	+	4
1423	33	F	Breast	Invasive ductal carcinoma			III	Malignant	+	+	-	+	128	+	4
1424	34	F	Breast	Invasive ductal carcinoma			II	Malignant	+	+	-	+	109	++	4
1425	45	F	Breast	Invasive ductal carcinoma			III	Malignant	+	+	-	+	133	+	4
1426	46	F	Breast	Invasive ductal carcinoma			II	Malignant	+	+	-	+	125	+	4
1427		F	Breast	breast tissue				Normal tissue				-			
1428		F	Breast	breast tissue				Normal tissue				-			
1429		F	Breast	breast tissue				Normal tissue				-			
Vietnam															
1430	55	F	Breast	Infiltrating ductal carcinoma			I	Metastasis			-	+	82	+	4
1431	55	F	Breast	cancer breast tissue of above sample				NAT			-	+	105	+	4
1432	45	F	Breast	Ductal carcinoma			III	Metastasis			-	+	116	+	4
1433	45	F	Breast	cancer breast tissue of above sample				NAT			-	+	162	+	4
1434	47	F	Breast	Infiltrating ductal carcinoma			I	Metastasis	-	-	-	+	86	+	4
1435	47	F	Breast	cancer breast tissue of above sample				NAT				+	125	+	4
1436	64	F	Breast	Infiltrating ductal carcinoma			III	Metastasis				+	108	+	4
1437	64	F	Breast	cancer breast tissue of above sample				NAT				+	147	+	4
Ukraine															
1438	37	F	Breast	Invasive breast carcinoma	T3N0Mx	3	IIB	Malignant				+	87	++	4
1439	45	F	Breast	Invasive breast carcinoma	T3N0M0	3	IIB	Malignant				+	101	+	4
1440	54	F	Breast	Invasive breast carcinoma	T2N0M0	3	IIB	Malignant				+	115	+	4
1441	48	F	Breast	Invasive breast carcinoma	T2N1M0	3	IIB	Malignant				+	96	+	4
1442	60	F	Breast	Invasive breast carcinoma	T2N0M0	2	IIB	Malignant				+	92	++	4

No.	Age	Sex	Organ/ Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Cytocapsular tubes (CT)	CT/ mm2	CT degradation	Cancer metastasis grade
1	49	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	23	+	2
2	24	F	Colon	Mucinous adenocarcinoma	T2N0M0	1	I	malignant	+	18	+	2
3	30	M	Colon	Adenocarcinoma	T1N0M0	1	I	malignant	+	27	+	2
4	27	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	31	+	2
5	69	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	27	+	2
6	51	M	Colon	Mucinous adenocarcinoma	T2N0M0	1	I	malignant	+	39	+	2
7	68	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	43	+	3
8	45	M	Colon	Mucinous adenocarcinoma	T2N0M0	1	I	malignant	+	52	+	3
9	63	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	33	+	2
10	69	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	29	+	2
11	49	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	46	+	3
12	67	F	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	31	+	2
13	53	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	44	+	3
14	69	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	38	+	2
15	64	M	Colon	Mucinous adenocarcinoma	T2N0M0	3	I	malignant	+	52	+	3
16	61	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	63	+	3
17	70	F	Colon	Mucinous adenocarcinoma	T3N0M0	1	I	malignant	+	46	+	3
18	57	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	38	+	2
19	43	M	Colon	Mucinous adenocarcinoma	T2N0M0	1	I	malignant	+	29	+	2
20	51	M	Colon	Mucinous adenocarcinoma	T2N0M0	2	I	malignant	+	35	+	2
21	16	M	Colon	Adenocarcinoma	T3N0M0	3	I	malignant	+	39	+	2
22	52	M	Colon	Mucinous adenocarcinoma	T2N0M0	3	I	malignant	+	45	+	3
23	38	M	Colon	Signet ring cell carcinoma	T3N0M0	-	I	malignant	+	52	+	3
24	50	M	Colon	Carcinoid	T2N0M0	-	I	malignant	+	38	+	2
25	64	F	Colon	Adenocarcinoma (sparse)	T2N0M0	-	I	Malignant	+	36	+	2
26	42	F	Colon	Adenocarcinoma	T2N0M0	1	I	Malignant	+	47	+	3
27	77	M	Colon	Adenocarcinoma	T1N0M0	1	I	Malignant	+	53	+	3
28	78	F	Colon	Adenocarcinoma	T1N0M0	1	I	Malignant	+	61	+	3
29	58	F	Colon	Adenocarcinoma (sparse)	T2N0M0	-	I	Malignant	+	68	+	3
30	31	M	Colon	Adenocarcinoma	T2N0M0	2	I	Malignant	+	49	+	3
31	52	M	Colon	Mucinous adenocarcinoma	T2N0M0	1	I	Malignant	+	54	+	3
32	36	M	Colon	Mucinous adenocarcinoma	T1N0M0	1	I	Malignant	+	37	+	2
33	55	F	Colon	Mucinous adenocarcinoma	T2N0M0	3	I	Malignant	+	66	+	3
34	57	F	Colon	Mucinous adenocarcinoma	T2N0M0	2	I	Malignant	+	42	+	3
35	44	F	Colon	Mucinous adenocarcinoma	T1N0M0	2	I	Malignant	+	71	+	3
36	63	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	28	+	2

37	63	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	36	+	2
38	40	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	41	+	3
39	40	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	72	+	3
40	66	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	43	+	3
41	66	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	36	+	2
42	51	F	Colon	Adenocarcinoma (chronic inflammatory)	T2N0M0	-	I	malignant	+	53	+	3
43	51	F	Colon	Adenocarcinoma (chronic inflammatory)	T2N0M0	-	I	malignant	+	47	+	3
44	55	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	38	+	2
45	55	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	29	+	2
46	70	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	40	+	2
47	70	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	53	+	3
48	48	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	59	+	3
49	48	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	25	+	2
50	47	F	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	32	+	2
51	47	F	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	44	+	3
52	66	F	Colon	Adenocarcinoma (chronic inflammatory)	T2N0M0	-	I	malignant	+	58	+	3
53	66	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	75	+	3
54	56	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	27	+	2
55	56	M	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	31	+	2
56	45	F	Colon	Adenocarcinoma (sparse)	T2N0M0	-	I	malignant	+	33	+	2
57	45	F	Colon	Adenocarcinoma	T2N0M0	1	I	malignant	+	42	+	3
58	72	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	45	+	3
59	72	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	39	+	2
60	39	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	31	+	2
61	39	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	26	+	2
62	46	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	34	+	2
63	46	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	55	+	2
64	61	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	64	+	3
65	61	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	57	+	3
66	70	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	61	+	3
67	70	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	72	+	3
68	44	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	43	+	3
69	44	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	37	+	2
70	64	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	35	+	2
71	64	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	43	+	3
72	75	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	49	+	3
73	75	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	36	+	2

74	51	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	40	+	2
75	51	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	57	+	3
76	75	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	69	+	3
77	75	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	70	+	3
78	72	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	54	+	3
79	72	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	43	+	3
80	90	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	37	+	2
81	90	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	62	+	3
82	77	F	Colon	Adenocarcinoma (smooth muscle)	T2N0M0	-	I	malignant	+	56	+	3
83	77	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	51	+	3
84	26	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	48	+	3
85	26	F	Colon	Adenocarcinoma (colon tissue)	T2N0M0	-	I	malignant	+	37	+	2
86	46	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	52	+	3
87	46	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	27	+	2
88	64	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	45	+	3
89	64	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	48	+	3
90	78	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	53	+	3
91	78	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	58	+	3
92	81	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	64	+	3
93	81	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	71	+	3
94	29	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	26	+	2
95	29	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	35	+	2
96	57	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	33	+	2
97	57	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	42	+	3
98	46	M	Colon	Adenocarcinoma (sparse)	T2N0M0	-	I	malignant	+	48	+	3
99	46	M	Colon	Adenocarcinoma (chronic inflammatory)	T2N0M0	-	I	malignant	+	56	+	3
100	62	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	43	+	3
101	62	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	33	+	2
102	68	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	51	+	3
103	68	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	57	+	3
104	60	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	35	+	2
105	60	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	43	+	3
106	80	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	36	+	2
107	80	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	58	+	3
108	81	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	65	+	3
109	81	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	45	+	3

110	58	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	41	+	3
111	58	F	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	30	+	2
112	60	F	Colon	Mucinous adenocarcinoma	T2N0M0	1	I	malignant	+	27	+	2
113	60	F	Colon	Mucinous adenocarcinoma	T2N0M0	1	I	malignant	+	23	+	2
114	62	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	33	+	2
115	62	M	Colon	Adenocarcinoma	T2N0M0	2	I	malignant	+	36	+	2
116	51	M	Colon	Adenocarcinoma	T2N0M0	2--3	I	malignant	+	47	+	3
117	51	M	Colon	Adenocarcinoma	T2N0M0	2--3	I	malignant	+	51	+	3
118	80	F	Colon	Adenocarcinoma	T2N0M0	2--3	I	malignant	+	55	+	3
119	80	F	Colon	Adenocarcinoma	T2N0M0	2--3	I	malignant	+	63	+	3
120	56	F	Colon	Adenocarcinoma	T2N0M0	2--3	I	malignant	+	58	+	3
121	56	F	Colon	Adenocarcinoma	T2N0M0	2--3	I	malignant	+	49	+	3
122	48	M	Colon	Adenocarcinoma (sparse)	T2N0M0	3	I	malignant	+	32	+	2
123	48	M	Colon	Adenocarcinoma	T2N0M0	3	I	malignant	+	42	+	3
124	65	F	Colon	Adenocarcinoma	T2N0M0	3	I	malignant	+	47	+	3
125	65	F	Colon	Adenocarcinoma	T2N0M0	3	I	malignant	+	34	+	2
126	39	M	Colon	Undifferentiated carcinoma	T2N0M0	-	I	malignant	+	56	+	3
127	39	M	Colon	Undifferentiated carcinoma	T2N0M0	-	I	malignant	+	68	+	3
128	56	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	83	+	4
129	56	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	92	+	4
130	41	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	83	+	4
131	61	M	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	76	+	3
132	40	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	69	+	3
133	64	M	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	84	+	4
134	73	F	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	81	+	4
135	69	M	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	94	+	4
136	64	M	Colon	Adenocarcinoma(fibrous tissue)	T4N0M0	-	II	malignant	+	87	+	4
137	51	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	76	+	3
138	75	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	96	+	4
139	59	M	Colon	Mucinous adenocarcinoma	T4N0M0	1	II	malignant	+	102	+	4
140	73	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	113	+	4
141	53	M	Colon	Adenocarcinoma(colonic mucosa tiss	T3N0M0	-	II	malignant	+	98	+	4
142	50	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	84	+	4
143	38	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	87	+	4
144	51	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	93	+	4
145	46	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	103	+	4

146	40	F	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	malignant	+	108	+	4
147	50	M	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	malignant	+	99	+	4
148	44	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	87	+	4
149	54	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	92	+	4
150	45	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	84	+	4
151	73	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	86	+	4
152	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	94	+	4
153	41	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	106	+	4
154	62	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	115	+	4
155	73	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	97	+	4
156	74	F	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	malignant	+	89	+	4
157	39	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	82	+	4
158	68	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	78	+	3
159	76	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	73	+	3
160	73	M	Colon	Mucinous adenocarcinoma	T4N0M0	2	II	malignant	+	84	+	4
161	62	F	Colon	Adenocarcinoma(sparse)	T4N0M0	2	II	malignant	+	91	+	4
162	51	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	104	+	4
163	55	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	118	+	4
164	48	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	82	+	4
165	40	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	91	+	4
166	72	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	86	+	4
167	59	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	93	+	4
168	53	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	97	+	4
169	50	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	105	+	4
170	50	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	116	+	4
171	70	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	108	+	4
172	53	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	96	+	4
173	63	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	103	+	4
174	41	M	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	126	+	4
175	53	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	117	+	4
176	62	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	132	+	4
177	50	M	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	malignant	+	105	+	4
178	26	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	112	+	4
179	70	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	94	+	4
180	69	M	Colon	Adenocarcinoma(fibrous tissue)	T3N0M0	-	II	malignant	+	96	+	4
181	49	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	89	+	4

182	78	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	86	+	4
183	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	98	+	4
184	55	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	102	+	4
185	31	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	115	+	4
186	64	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	84	+	4
187	62	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	128	+	4
188	65	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	132	+	4
189	71	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	84	+	4
190	66	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	90	+	4
191	41	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	105	+	4
192	53	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	101	+	4
193	53	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	93	+	4
194	62	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	97	+	4
195	69	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	117	+	4
196	42	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	86	+	4
197	68	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	93	+	4
198	30	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	117	+	4
199	82	M	Colon	Adenocarcinoma(fibrous tissue)	T4N0M0	-	II	malignant	+	103	+	4
200	71	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	107	+	4
201	65	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	96	+	4
202	53	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	127	+	4
203	57	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	115	+	4
204	50	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	103	+	4
205	78	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	92	+	4
206	49	M	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	malignant	+	86	+	4
207	70	F	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	malignant	+	79	++	4
208	34	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	83	++	4
209	47	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	94	+	4
210	34	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	102	+	4
211	55	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	114	+	4
212	73	F	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	148	+	4
213	51	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	96	+	4
214	76	F	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	93	+	4
215	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	88	+	4
216	51	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	109	+	4
217	72	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	112	+	4

218	42	F	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	125	+	4
219	64	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	132	+	4
220	38	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	85	+	4
221	60	F	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	94	+	4
222	48	F	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	90	+	4
223	39	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	84	+	4
224	74	F	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	126	+	4
225	53	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	107	+	4
226	46	M	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	malignant	+	118	+	4
227	49	F	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	malignant	+	98	+	4
228	51	F	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	malignant	+	101	+	4
229	41	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	88	+	4
230	35	M	Colon	Mucinous adenocarcinoma	T4N0M0	2	II	malignant	+	83	++	4
231	24	M	Colon	Mucinous adenocarcinoma(colonic m	T3N0M0	-	II	malignant	+	103	+	4
232	53	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	116	+	4
233	72	M	Colon	Mucinous adenocarcinoma(colonic m	T3N0M0	-	II	malignant	+	108	+	4
234	58	F	Colon	Signet ring cell carcinoma	T3N0M0	-	II	malignant	+	127	+	4
235	42	M	Colon	Signet ring cell carcinoma	T3N0M0	-	II	malignant	+	123	+	4
236	49	F	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	malignant	+	102	+	4
237	49	F	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	93	+	4
238	35	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	97	+	4
239	62	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	86	+	4
240	59	M	Colon	Adenosquamous carcinoma	T4N0M0	-	II	malignant	+	124	+	4
241	59	M	Colon	Adenosquamous carcinoma	T3N0M0	-	II	malignant	+	117	+	4
242	67	F	Colon	Adenosquamous carcinoma	T3N0M0	-	II	malignant	+	102	+	4
243	37	F	Colon	Signet ring cell carcinoma	T3N0M0	-	II	malignant	+	99	+	4
244	71	M	Colon	Signet ring cell carcinoma	T4N0M0	-	II	malignant	+	102	+	4
245	35	F	Colon	Atypical carcinoid	T4N0M0	-	II	malignant	+	104	+	4
246	27	M	Colon	Adenocarcinoma	T4N0M0	1	II	Malignant	+	116	+	4
247	43	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	83	+	4
248	41	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	86	+	4
249	54	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	81	+	4
250	67	F	Colon	Adenocarcinoma (smooth muscle)	T3N0M0	-	II	Malignant	+	94	+	4
251	43	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	92	+	4
252	73	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	97	+	4
253	53	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	87	+	4

254	45	M	Colon	Mucinous adenocarcinoma	T3N0M0	1--2	II	Malignant	+	85	+	4
255	51	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	103	+	4
256	60	F	Colon	Adenocarcinoma	T4N0M0	1	II	Malignant	+	119	+	4
257	68	M	Colon	Adenocarcinoma	T4N0M0	1	II	Malignant	+	96	+	4
258	48	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	109	+	4
259	60	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	92	+	4
260	75	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	87	+	4
261	64	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	102	+	4
262	68	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	82	++	4
263	46	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	81	++	4
264	43	M	Colon	Adenocarcinoma	T4N0M0	1	II	Malignant	+	80	+	4
265	38	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	93	+	4
266	49	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	94	+	4
267	71	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	91	+	4
268	46	M	Colon	Adenocarcinoma	T4N0M0	1	II	Malignant	+	87	+	4
269	49	M	Colon	Adenocarcinoma	T4N0M0	1	II	Malignant	+	84	+	4
270	70	M	Colon	Adenocarcinoma	T4N0M0	1	II	Malignant	+	89	+	4
271	53	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	86	+	4
272	43	M	Colon	Adenocarcinoma (sparse)	T3N0M0	1	II	Malignant	+	93	+	4
273	52	F	Colon	Adenocarcinoma (fibrous tissue and I	T3N0M0	-	II	Malignant	+	98	+	4
274	69	M	Colon	Mucinous adenocarcinoma	T3N0M0	1--2	II	Malignant	+	104	+	4
275	34	M	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	Malignant	+	115	+	4
276	36	F	Colon	Adenocarcinoma (smooth muscle)	T3N0M0	-	II	Malignant	+	97	+	4
277	65	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	93	+	4
278	62	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	87	+	4
279	69	M	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	Malignant	+	89	+	4
280	65	M	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	Malignant	+	103	+	4
281	56	M	Colon	Adenocarcinoma (sparse) with necro:	T3N0M0	1	II	Malignant	+	112	+	4
282	40	M	Colon	Adenocarcinoma (sparse)	T3N0M0	2	II	Malignant	+	109	+	4
283	53	F	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	Malignant	+	94	+	4
284	66	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	97	+	4
285	50	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	84	+	4
286	63	F	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	87	++	4
287	64	F	Colon	Adenocarcinoma	T4N0M0	1	II	Malignant	+	81	++	4
288	32	M	Colon	Mucinous adenocarcinoma	T3N0M0	1--2	II	Malignant	+	92	+	4
289	68	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	98	+	4

290	58	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	102	+	4
291	34	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	121	+	4
292	57	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	132	+	4
293	52	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	139	+	4
294	72	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	103	+	4
295	61	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	114	+	4
296	71	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	106	+	4
297	58	M	Colon	Adenocarcinoma	T4N0M0	2	II	Malignant	+	96	+	4
298	56	F	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	90	+	4
299	36	M	Colon	Adenocarcinoma	T3N0M0	1	II	Malignant	+	88	+	4
300	51	M	Colon	Adenocarcinoma	T4N0M0	2	II	Malignant	+	83	+	4
301	78	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	86	+	4
302	52	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	92	+	4
303	52	M	Colon	Adenocarcinoma	T4N0M0	2	II	Malignant	+	87	+	4
304	51	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	89	+	4
305	77	M	Colon	Mucinous adenocarcinoma (colonic ti	T3N0M0	-	II	Malignant	+	123	+	4
306	64	M	Colon	Adenocarcinoma	T4N0M0	2	II	Malignant	+	125	+	4
307	84	F	Colon	Mucinous adenocarcinoma	T3N0M0	1--2	II	Malignant	+	114	+	4
308	43	F	Colon	Adenocarcinoma	T4N0M0	2	II	Malignant	+	106	+	4
309	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	87	+	4
310	60	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	89	+	4
311	68	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	90	+	4
312	44	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	95	+	4
313	70	M	Colon	Adenocarcinoma (sparse)	T3N0M0	-	II	Malignant	+	84	+	4
314	80	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	75	++	4
315	75	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	70	++	4
316	65	F	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	86	+	4
317	22	M	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	Malignant	+	88	+	4
318	60	F	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	Malignant	+	94	+	4
319	50	F	Colon	Mucinous adenocarcinoma	T4N0M0	2	II	Malignant	+	93	+	4
320	49	F	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	Malignant	+	115	+	4
321	46	M	Colon	Mucinous adenocarcinoma (chronic ii	T3N0M0	-	II	Malignant	+	108	+	4
322	79	F	Colon	Mucinous adenocarcinoma	T4N0M0	3	II	Malignant	+	97	+	4
323	79	F	Colon	Mucinous adenocarcinoma	T4N0M0	3	II	Malignant	+	94	+	4
324	68	M	Colon	Mucinous adenocarcinoma	T4N0M0	2	II	Malignant	+	89	+	4
325	32	M	Colon	Adenocarcinoma	T3N0M0	2	II	Malignant	+	81	++	4

326	30	F	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	Malignant	+	88	+	4
327	28	M	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	Malignant	+	83	+	4
328	47	M	Colon	Mucinous adenocarcinoma	T4N0M0	2	II	Malignant	+	91	+	4
329	58	M	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	118	+	4
330	82	F	Colon	Adenocarcinoma	T4N0M0	3	II	Malignant	+	103	+	4
331	58	F	Colon	Adenocarcinoma (fibrous tissue and I	T3N0M0	-	II	Malignant	+	105	+	4
332	47	F	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	76	+	4
333	46	M	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	93	+	4
334	40	F	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	89	+	4
335	74	M	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	86	+	4
336	49	M	Colon	Adenocarcinoma	T4N0M0	3	II	Malignant	+	84	+	4
337	33	M	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	85	+	4
338	38	M	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	87	+	4
339	33	M	Colon	Adenocarcinoma	T4N0M0	3	II	Malignant	+	96	+	4
340	31	M	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	92	+	4
341	70	F	Colon	Adenocarcinoma	T3N0M0	3	II	Malignant	+	84	++	4
342	54	M	Colon	Adenocarcinoma (fibrofatty tissue)	T3N0M0	-	II	Malignant	+	103	+	4
343	32	M	Colon	Mucinous adenocarcinoma	T4N0M0	3	II	Malignant	+	115	+	4
344	33	F	Colon	Mucinous adenocarcinoma	T4N0M0	3	II	Malignant	+	153	+	4
345	60	F	Colon	Signet ring cell carcinoma	T4N0M0	-	II	Malignant	+	126	+	4
346	45	M	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	Malignant	+	124	+	4
347	50	M	Colon	Signet ring cell carcinoma	T3N0M0	-	II	Malignant	+	98	+	4
348	75	F	Colon	Signet ring cell carcinoma	T3N0M0	-	II	Malignant	+	92	+	4
349	50	M	Colon	Signet ring cell carcinoma	T3N0M0	-	II	Malignant	+	87	+	4
350	57	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	89	+	4
351	57	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	93	+	4
352	61	M	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	97	+	4
353	61	M	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	90	+	4
354	27	M	Colon	Adenocarcinoma (chronic inflammatio	T4N0M0	-	II	malignant	+	83	+	4
355	27	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	105	+	4
356	65	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	111	+	4
357	65	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	124	+	4
358	46	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	127	+	4
359	46	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	102	+	4
360	32	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	107	+	4
361	32	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	98	+	4

362	58	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	96	+	4
363	58	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	89	+	4
364	54	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	80	+	4
365	54	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	99	+	4
366	46	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	103	+	4
367	46	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	108	+	4
368	39	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	113	+	4
369	39	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	121	+	4
370	43	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	127	+	4
371	43	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	108	+	4
372	57	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	103	+	4
373	57	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	99	+	4
374	59	F	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	84	++	4
375	59	F	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	81	++	4
376	44	F	Colon	Adenocarcinoma (sparse) with necro:	T3N0M0	2	II	malignant	+	93	+	4
377	44	F	Colon	Adenocarcinoma (necrotic tissue)	T3N0M0	-	II	malignant	+	102	+	4
378	57	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	109	+	4
379	57	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	114	+	4
380	60	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	106	+	4
381	60	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	109	+	4
382	50	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	112	+	4
383	50	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	126	+	4
384	82	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	132	+	4
385	82	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	134	+	4
386	37	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	138	+	4
387	37	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	106	+	4
388	72	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	97	+	4
389	72	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	82	+	4
390	29	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	84	+	4
391	29	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	90	+	4
392	50	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	93	+	4
393	50	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	104	+	4
394	26	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	108	+	4
395	26	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	117	+	4
396	82	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	89	+	4
397	82	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	92	+	4

398	63	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	95	+	4
399	63	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	86	+	4
400	73	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	84	+	4
401	73	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	82	+	4
402	70	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	81	+	4
403	70	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	83	+	4
404	61	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	96	+	4
405	61	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	92	+	4
406	41	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	103	+	4
407	41	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	118	+	4
408	44	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	99	+	4
409	44	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	80	+	4
410	33	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	76	+++	4
411	33	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	83	+	4
412	75	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	102	+	4
413	75	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	118	+	4
414	50	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	97	+	4
415	50	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	92	+	4
416	75	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	89	+	4
417	75	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	83	+	4
418	44	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	138	+	4
419	44	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	125	+	4
420	52	F	Colon	Adenocarcinoma (sparse)	T3N0M0	-	II	malignant	+	128	+	4
421	52	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	87	+	4
422	57	F	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	malignant	+	88	+	4
423	57	F	Colon	Mucinous adenocarcinoma	T3N0M0	1	II	malignant	+	90	+	4
424	51	F	Colon	Mucinous adenocarcinoma (sparse)	T4N0M0	2	II	malignant	+	93	+	4
425	51	F	Colon	Mucinous adenocarcinoma	T4N0M0	2	II	malignant	+	107	+	4
426	56	M	Colon	Squamous cell carcinoma	T3N0M0	1	II	malignant	+	119	+	4
427	56	M	Colon	Squamous cell carcinoma	T3N0M0	1	II	malignant	+	120	+	4
428	62	F	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	98	+	4
429	62	F	Colon	Adenocarcinoma	T4N0M0	1	II	malignant	+	95	+	4
430	41	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	85	+	4
431	41	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	83	+	4
432	68	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	91	+	4
433	68	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	82	+	4

434	34	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	73	+	4
435	34	M	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	78	+	4
436	72	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	76	+	4
437	72	F	Colon	Adenocarcinoma	T3N0M0	1	II	malignant	+	82	+	4
438	51	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	93	+	4
439	51	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	97	+	4
440	52	M	Colon	Adenocarcinoma (smooth muscle)	T4N0M0	-	II	malignant	+	102	+	4
441	52	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	116	+	4
442	72	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	113	+	4
443	72	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	128	+	4
444	73	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	124	+	4
445	73	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	108	+	4
446	42	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	89	+	4
447	42	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	92	+	4
448	45	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	94	+	4
449	45	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	90	+	4
450	43	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	97	+	4
451	43	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	88	+	4
452	32	M	Colon	Adenocarcinoma (necrotic tissue)	T3N0M0	-	II	malignant	+	93	+	4
453	32	M	Colon	Adenocarcinoma (necrotic tissue)	T3N0M0	-	II	malignant	+	125	+	4
454	46	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	118	+	4
455	46	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	109	+	4
456	79	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	102	+	4
457	79	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	89	+	4
458	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	93	+	4
459	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	96	+	4
460	36	F	Colon	Adenocarcinoma with necrosis	T3N0M0	2	II	malignant	+	97	+	4
461	36	F	Colon	Adenocarcinoma (fibrous tissue and I	T3N0M0	-	II	malignant	+	102	+	4
462	32	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	117	+	4
463	32	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	103	+	4
464	62	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	98	+	4
465	62	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	95	+	4
466	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	90	+	4
467	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	83	+	4
468	38	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	87	+	4
469	38	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	82	+	4

470	48	F	Colon	Adenocarcinoma with necrosis	T4N0M0	-	II	malignant	+	93	+	4
471	48	F	Colon	Adenocarcinoma with necrosis	T4N0M0	-	II	malignant	+	98	+	4
472	43	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	87	+	4
473	43	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	105	+	4
474	63	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	127	+	4
475	63	F	Colon	Adenocarcinoma (sparse)	T4N0M0	2	II	malignant	+	119	+	4
476	58	F	Colon	Adenocarcinoma with necrosis	T3N0M0	2	II	malignant	+	134	+	4
477	58	F	Colon	Adenocarcinoma (necrotic tissue)	T3N0M0	-	II	malignant	+	135	+	4
478	62	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	128	+	4
479	62	F	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	124	+	4
480	57	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	103	+	4
481	57	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	116	+	4
482	47	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	98	+	4
483	47	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	92	+	4
484	60	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	86	+	4
485	60	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	93	+	4
486	64	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	85	+	4
487	64	M	Colon	Adenocarcinoma	T4N0M0	2	II	malignant	+	92	+	4
488	32	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	98	+	4
489	32	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	84	+	4
490	46	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	87	+	4
491	46	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	103	+	4
492	57	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	119	+	4
493	57	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	124	+	4
494	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	107	+	4
495	67	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	104	+	4
496	55	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	89	+	4
497	55	F	Colon	Adenocarcinoma (sparse) with necro:	T3N0M0	-	II	malignant	+	82	+	4
498	69	F	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	84	+	4
499	69	F	Colon	Adenocarcinoma (chronic inflammati	T3N0M0	-	II	malignant	+	87	+	4
500	74	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	90	+	4
501	74	M	Colon	Adenocarcinoma (fibrofatty tissue)	T3N0M0	-	II	malignant	+	99	+	4
502	53	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	102	+	4
503	53	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	106	+	4
504	40	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	113	+	4
505	40	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	94	+	4

506	73	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	86	+	4
507	73	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	88	+	4
508	65	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	90	+	4
509	65	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	91	+	4
510	56	F	Colon	Adenocarcinoma	T4N0M0	2--3	II	malignant	+	97	+	4
511	56	F	Colon	Adenocarcinoma	T4N0M0	2--2	II	malignant	+	81	+	4
512	78	M	Colon	Adenocarcinoma	T3N0M0	2--3	II	malignant	+	110	+	4
513	78	M	Colon	Adenocarcinoma	T3N0M0	2--3	II	malignant	+	124	+	4
514	74	F	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	malignant	+	128	+	4
515	74	F	Colon	Mucinous adenocarcinoma	T3N0M0	2	II	malignant	+	135	+	4
516	47	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	84	+	4
517	47	M	Colon	Adenocarcinoma	T3N0M0	2	II	malignant	+	83	+	4
518	50	F	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	109	+	4
519	50	F	Colon	Adenocarcinoma (chronic inflammatory)	T4N0M0	-	II	malignant	+	87	+	4
520	39	F	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	112	+	4
521	39	F	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	105	+	4
522	74	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	89	+	4
523	74	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	93	+	4
524	46	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	128	+	4
525	46	M	Colon	Adenocarcinoma	T4N0M0	3	II	malignant	+	103	+	4
526	52	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	106	+	4
527	52	M	Colon	Adenocarcinoma	T3N0M0	3	II	malignant	+	97	+	4
528	72	M	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	malignant	+	92	+	4
529	72	M	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	malignant	+	84	+	4
530	59	M	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	malignant	+	76	+	4
531	59	M	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	malignant	+	84	+	4
532	55	F	Colon	Adenocarcinoma (mucosa of colon)	T4N0M0	-	II	malignant	+	143	+	4
533	55	F	Colon	Mucinous adenocarcinoma	T4N0M0	3	II	malignant	+	135	+	4
534	35	M	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	malignant	+	127	+	4
535	35	M	Colon	Mucinous adenocarcinoma	T3N0M0	3	II	malignant	+	138	+	4
536	72	M	Colon	Signet-ring cell carcinoma	T3N0M0	-	II	malignant	+	106	+	4
537	72	M	Colon	Signet-ring cell carcinoma	T3N0M0	-	II	malignant	+	117	+	4
538	47	M	Colon	Mucinous adenocarcinoma	T2 N0 M0		IIA	tumor	+	86	+	4
539	44	M	Colon	Mucinous adenocarcinoma	T3 N0 M0		IIA	tumor	+	83	+	4
540	33	M	Colon	Partly mucinous adenocarcinoma	T3 N0 M0		IIA	tumor	+	92	+	4
541	70	M	Colon	Partly mucinous adenocarcinoma	T3 N0 M0		IIA	tumor	+	84	+	4

542	70	F	Colon	Partly mucinous adenocarcinoma	T3 N0 M0		IIA	tumor	+	91	+	4
543	72	M	Colon	Mucinous adenocarcinoma	T3 N0 M0		IIA	tumor	+	90	+	4
544	70	M	Colon	Partly mucinous adenocarcinoma	T3 N0 M0		IIA	tumor	+	87	+	4
545	78	F	Colon	Partly mucinous adenocarcinoma	T3 N0 M0		IIA	tumor	+	83	+	4
546	75	M	Colon	Partly mucinous adenocarcinoma	T3 N0 M0		IIA	tumor	+	102	+	4
547	60	F	Colon	Mucinous adenocarcinoma	T3 N0 M0		IIA	tumor	+	107	+	4
548	56	F	Colon	Partly mucinous adenocarcinoma	T4a N0 M0		IIB	tumor	+	96	+	4
549	75	M	Colon	Mucinous adenocarcinoma	T4b N0 M0		IIC	tumor	+	95	+	4
550	69	M	Colon	Partly mucinous adenocarcinoma	N1b M0		III	tumor	+	127	+	4
551	57	M	Colon	Mucinous adenocarcinoma	N2b M0		III	tumor	+	136	+	4
552	55	F	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	142	+	4
553	61	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	148	+	4
554	68	F	Colon	Adenocarcinoma	T4N2M0	1	III	malignant	+	135	+	4
555	74	M	Colon	Adenocarcinoma	T4N2M0	1	III	malignant	+	126	+	4
556	46	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	117	+	4
557	50	M	Colon	Adenocarcinoma	T4N1M0	1	III	malignant	+	129	+	4
558	60	F	Colon	Adenocarcinoma	T2N1M0	2	III	malignant	+	135	+	4
559	70	M	Colon	Adenocarcinoma	T3N2M0	2	III	malignant	+	127	+	4
560	58	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	136	+	4
561	48	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	108	+	4
562	68	F	Colon	Mucinous adenocarcinoma	T3N1M0	2	III	malignant	+	83	+	4
563	51	M	Colon	Adenocarcinoma	T2N1M0	1	III	malignant	+	97	+	4
564	56	F	Colon	Adenocarcinoma	T2N1M0	1	III	malignant	+	85	+	4
565	52	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	102	+	4
566	76	M	Colon	Adenocarcinoma	T4N2M0	1	III	malignant	+	113	+	4
567	56	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	87	+	4
568	61	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	92	+	4
569	41	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	84	+	4
570	49	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	109	+	4
571	60	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	137	+	4
572	80	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	128	+	4
573	49	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	139	+	4
574	42	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	93	+	4
575	51	M	Colon	Adenocarcinoma(fibrous tissue)	T3N1M0	-	III	malignant	+	97	+	4
576	41	M	Colon	Mucinous adenocarcinoma	T4N1M0	2	III	malignant	+	82	+	4
577	62	F	Colon	Adenocarcinoma(sparse)	T4N1M0	2	III	malignant	+	87	+	4

578	38	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	80	+	4
579	65	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	137	+	4
580	58	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	135	+	4
581	41	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	128	+	4
582	48	F	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	116	+	4
583	78	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	109	+	4
584	72	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	105	+	4
585	47	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	142	+	4
586	64	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	147	+	4
587	54	F	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	137	+	4
588	52	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	129	+	4
589	45	M	Colon	Adenocarcinoma	T4N1M0	1	III	malignant	+	108	+	4
590	70	F	Colon	Adenocarcinoma(necrosis)	T3N1M0	2	III	malignant	+	86	+	4
591	69	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	88	+	4
592	61	M	Colon	Adenocarcinoma	T3N2M0	2	III	malignant	+	92	+	4
593	74	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	90	+	4
594	46	M	Colon	Mucinous adenocarcinoma	T3N2M0	1	III	malignant	+	93	+	4
595	53	F	Colon	Mucinous adenocarcinoma	T3N1M0	2	III	malignant	+	82	+	4
596	37	F	Colon	Mucinous adenocarcinoma	T4N2M0	3	III	malignant	+	91	+	4
597	57	M	Colon	Mucinous adenocarcinoma	T3N1M0	2	III	malignant	+	99	+	4
598	45	F	Colon	Adenocarcinoma	T4N2M0	1	III	malignant	+	83	+++	4
599	62	F	Colon	Adenocarcinoma	T3N1M0	3	III	malignant	+	89	+	4
600	40	M	Colon	Adenocarcinoma	T4N2M0	3	III	malignant	+	103	+	4
601	73	F	Colon	Adenocarcinoma	T4N1M0	3	III	malignant	+	83	+	4
602	20	F	Colon	Adenocarcinoma	T4N1M0	3	III	malignant	+	89	+	4
603	38	F	Colon	Adenocarcinoma	T4N1M0	3	III	malignant	+	91	+	4
604	34	M	Colon	Mucinous adenocarcinoma	T3N1M0	3	III	malignant	+	98	+	4
605	56	M	Colon	Signet ring cell carcinoma	T4N2M0	-	III	malignant	+	106	+	4
606	56	F	Colon	Signet ring cell carcinoma	T3N1M0	-	III	malignant	+	109	+	4
607	81	F	Colon	Signet ring cell carcinoma	T4N2M0	-	III	malignant	+	112	+	4
608	68	M	Colon	Squamous cell carcinoma	T4N1M0	2	III	malignant	+	86	+	4
609	73	F	Colon	Adenocarcinoma	T3N1M0	1	III	Malignant	+	89	+	4
610	55	M	Colon	Adenocarcinoma	T3N2M0	1	III	Malignant	+	93	+	4
611	59	F	Colon	Adenocarcinoma	T3N2M0	1	III	Malignant	+	95	+	4
612	43	F	Colon	Adenocarcinoma	T4N1M0	2	III	Malignant	+	104	+	4
613	60	M	Colon	Adenocarcinoma	T4N2M0	1	III	Malignant	+	124	+	4

614	65	M	Colon	Adenocarcinoma	T4N1M0	2	III	Malignant	+	128	+	4
615	45	M	Colon	Adenocarcinoma	T3N1M0	1	III	Malignant	+	109	+	4
616	30	F	Colon	Adenocarcinoma	T3N2M0	1	III	Malignant	+	114	+	4
617	78	M	Colon	Adenocarcinoma	T4N1M0	2	III	Malignant	+	87	+	4
618	49	F	Colon	Adenocarcinoma	T4N1M0	2	III	Malignant	+	89	+	4
619	51	F	Colon	Adenocarcinoma	T4N1M0	1	III	Malignant	+	93	+	4
620	55	M	Colon	Adenocarcinoma	T3N2M0	1	III	Malignant	+	97	+	4
621	39	F	Colon	Mucinous adenocarcinoma	T3N2M0	2	III	Malignant	+	81	+	4
622	60	M	Colon	Adenocarcinoma	T3N1M0	1	III	Malignant	+	127	+	4
623	50	M	Colon	Mucinous adenocarcinoma (smooth r	T3N1M0	-	III	Malignant	+	109	+	4
624	70	F	Colon	Mucinous adenocarcinoma	T2N1M0	1	III	Malignant	+	102	+	4
625	45	F	Colon	Mucinous adenocarcinoma	T3N2M0	1	III	Malignant	+	87	+	4
626	51	M	Colon	Mucinous adenocarcinoma	T3N1M0	1	III	Malignant	+	93	+	4
627	40	F	Colon	Adenocarcinoma	T3N1M0	1	III	Malignant	+	94	+	4
628	54	M	Colon	Mucinous adenocarcinoma	T3N1M0	3	III	Malignant	+	98	+	4
629	55	M	Colon	Mucinous adenocarcinoma (sparse)	T3N2M0	1	III	Malignant	+	103	+	4
630	56	F	Colon	Mucinous adenocarcinoma	T4N1M0	2	III	Malignant	+	108	+	4
631	83	F	Colon	Adenocarcinoma	T3N2M0	3	III	Malignant	+	117	+	4
632	40	M	Colon	Adenocarcinoma	T4N1M0	2	III	Malignant	+	88	+	4
633	60	F	Colon	Adenocarcinoma	T4N1M0	2	III	Malignant	+	84	+++	4
634	55	M	Colon	Adenocarcinoma	T3N2M0	2	III	Malignant	+	92	+	4
635	56	M	Colon	Adenocarcinoma	T3N2M0	3	III	Malignant	+	90	+	4
636	61	F	Colon	Adenocarcinoma	T3N1M0	2	III	Malignant	+	87	+	4
637	64	F	Colon	Adenocarcinoma	T4N1M0	2	III	Malignant	+	84	+	4
638	60	F	Colon	Adenocarcinoma	T3N1M0	2	III	Malignant	+	78	+	4
639	73	F	Colon	Adenocarcinoma	T4N2M0	2	III	Malignant	+	94	+	4
640	42	M	Colon	Adenocarcinoma (sparse)	T3N2M0	2	III	Malignant	+	81	+	4
641	43	M	Colon	Adenocarcinoma	T3N1M0	2	III	Malignant	+	84	+	4
642	50	F	Colon	Adenocarcinoma	T3N2M0	2	III	Malignant	+	87	+	4
643	43	M	Colon	Adenocarcinoma	T4N1M0	2	III	Malignant	+	93	+	4
644	51	M	Colon	Adenocarcinoma	T3N1M0	2	III	Malignant	+	98	+	4
645	35	F	Colon	Adenocarcinoma	T3N1M0	2	III	Malignant	+	96	+	4
646	35	M	Colon	Adenocarcinoma	T4N1M0	2	III	Malignant	+	84	+++	4
647	52	F	Colon	Adenocarcinoma	T3N2M0	2	III	Malignant	+	88	+	4
648	61	M	Colon	Adenocarcinoma (fibrous tissue and I	T3N1M0	-	III	Malignant	+	91	+	4
649	47	F	Colon	Adenocarcinoma	T3N1M0	2	III	Malignant	+	94	+	4

650	64	F	Colon	Adenocarcinoma	T3N2M0	2	III	Malignant	+	98	+	4
651	70	F	Colon	Adenocarcinoma	T3N2M0	2	III	Malignant	+	104	+	4
652	43	M	Colon	Adenocarcinoma	T3N1M0	1	III	Malignant	+	112	+	4
653	39	M	Colon	Adenocarcinoma	T4N2M0	2	III	Malignant	+	115	+	4
654	68	F	Colon	Adenocarcinoma	T2N1M0	2	III	Malignant	+	109	+	4
655	57	F	Colon	Adenocarcinoma	T3N2M0	2	III	Malignant	+	107	+	4
656	40	F	Colon	Adenocarcinoma (fibrous tissue and l	T2N2M0	-	III	Malignant	+	124	+	4
657	84	F	Colon	Adenocarcinoma (degeneration tissu	T2N2M0	-	III	Malignant	+	126	+	4
658	65	M	Colon	Adenocarcinoma	T3N1M0	2	III	Malignant	+	108	+	4
659	30	M	Colon	Adenocarcinoma	T2N1M0	2	III	Malignant	+	105	+	4
660	58	M	Colon	Mucinous adenocarcinoma (smooth r	T3N1M0	-	III	Malignant	+	94	+	4
661	48	M	Colon	Adenocarcinoma	T3N1M0	2	III	Malignant	+	85	+	4
662	39	M	Colon	Mucinous adenocarcinoma	T3N1M0	2	III	Malignant	+	89	+	4
663	67	M	Colon	Mucinous adenocarcinoma	T4N2M0	2	III	Malignant	+	93	+	4
664	28	F	Colon	Mucinous adenocarcinoma	T2N1M0	1	III	Malignant	+	94	+	4
665	56	M	Colon	Mucinous adenocarcinoma	T3N2M0	2	III	Malignant	+	96	+	4
666	42	M	Colon	Adenocarcinoma	T3N1M0	3	III	Malignant	+	103	+	4
667	49	F	Colon	Adenocarcinoma	T3N2M0	1	III	Malignant	+	105	+	4
668	41	M	Colon	Adenocarcinoma	T3N2M0	2	III	Malignant	+	109	+	4
669	70	M	Colon	Adenocarcinoma	T3N1M0	3	III	Malignant	+	115	+	4
670	45	M	Colon	Mucinous adenocarcinoma	T4N2M0	2	III	Malignant	+	127	+	4
671	51	M	Colon	Adenocarcinoma	T4N1M0	3	III	Malignant	+	147	+	4
672	57	F	Colon	Adenocarcinoma (degeneration tissu	T3N1M0	-	III	Malignant	+	152	+	4
673	65	M	Colon	Adenocarcinoma	T3N1M0	3	III	Malignant	+	137	+	4
674	28	F	Colon	Mucinous adenocarcinoma	T4N1M0	3	III	Malignant	+	128	+	4
675	33	F	Colon	Adenocarcinoma (smooth muscle)	T4N1M0	-	III	Malignant	+	84	+	4
676	51	M	Colon	Adenocarcinoma	T3N2M0	3	III	Malignant	+	97	+	4
677	52	F	Colon	Adenocarcinoma	T3N1M0	3	III	Malignant	+	81	+	4
678	43	F	Colon	Adenocarcinoma	T3N1M0	3	III	Malignant	+	90	+	4
679	55	M	Colon	Adenocarcinoma	T4N1M0	3	III	Malignant	+	94	+	4
680	59	F	Colon	Mucinous adenocarcinoma	T3N1M0	3	III	Malignant	+	97	+	4
681	43	M	Colon	Mucinous adenocarcinoma	T4N1M0	3	III	Malignant	+	99	+	4
682	38	F	Colon	Signet ring cell carcinoma	T3N1M0	-	III	Malignant	+	120	+	4
683	22	M	Colon	Mucinous adenocarcinoma	T4N1M0	3	III	Malignant	+	118	+	4
684	56	M	Colon	Mucinous adenocarcinoma	T4N1M0	3	III	Malignant	+	84	+	4
685	56	M	Colon	Mucinous adenocarcinoma	T3N1M0	3	III	Malignant	+	86	+	4

686	73	F	Colon	Mucinous adenocarcinoma	T3N1M0	3	III	Malignant	+	98	+	4
687	28	F	Colon	Signet ring cell carcinoma	T4N1M0	-	III	Malignant	+	83	+	4
688	27	F	Colon	Signet ring cell carcinoma	T3N1M0	-	III	Malignant	+	89	+	4
689	59	M	Colon	Carcinoid	T3N1M0	-	III	Malignant	+	94	+	4
690	69	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	105	+	4
691	69	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	109	+	4
692	59	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	141	+	4
693	59	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	128	+	4
694	60	F	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	125	+	4
695	60	F	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	112	+	4
696	44	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	109	+	4
697	44	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	106	+	4
698	46	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	98	+	4
699	46	M	Colon	Adenocarcinoma (sparse)	T3N1M0	2	III	malignant	+	91	+	4
700	62	F	Colon	Adenocarcinoma	T4N1M0	1	III	malignant	+	89	+	4
701	62	F	Colon	Adenocarcinoma	T4N1M0	1	III	malignant	+	87	+	4
702	57	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	86	+	4
703	57	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	94	+	4
704	46	F	Colon	Adenocarcinoma (smooth muscle)	T3N1M0	-	III	malignant	+	90	+	4
705	46	F	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	93	+	4
706	71	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	99	+	4
707	71	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	106	+	4
708	78	F	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	103	+	4
709	78	F	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	89	+	4
710	76	F	Colon	Adenocarcinoma (chronic inflammatory)	T3N1M0	-	III	malignant	+	83	+	4
711	76	F	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	82	+	4
712	56	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	87	+	4
713	56	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	90	+	4
714	42	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	96	+	4
715	42	M	Colon	Adenocarcinoma	T3N1M0	1	III	malignant	+	93	+	4
716	42	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	85	+	4
717	42	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	128	+	4
718	50	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	137	+	4
719	50	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	142	+	4
720	42	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	129	+	4
721	42	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	139	+	4

722	53	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	137	+	4
723	53	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	126	+	4
724	56	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	118	+	4
725	56	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	109	+	4
726	63	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	101	+	4
727	63	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	91	+	4
728	56	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	97	+	4
729	56	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	98	+	4
730	60	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	96	+	4
731	60	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	86	+	4
732	41	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	85	+	4
733	41	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	84	+	4
734	33	M	Colon	Adenocarcinoma (sparse)	T3N1M0	-	III	malignant	+	93	+	4
735	33	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	109	+	4
736	58	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	118	+	4
737	58	F	Colon	Adenocarcinoma (sparse)	T3N1M0	2	III	malignant	+	87	+	4
738	52	F	Colon	Adenocarcinoma	T3N1M0	3	III	malignant	+	96	+	4
739	52	F	Colon	Adenocarcinoma	T3N1M0	3	III	malignant	+	82	+	4
740	51	M	Colon	Adenosquamous carcinoma	T3N1M0	-	III	malignant	+	84	+	4
741	51	M	Colon	Adenosquamous carcinoma	T3N1M0	-	III	malignant	+	83	+	4
742	80	M	Colon	Adenocarcinoma	T4N2M0	2	III	malignant	+	97	+	4
743	80	M	Colon	Adenocarcinoma	T4N2M0	2	III	malignant	+	99	+	4
744	60	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	90	+	4
745	60	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	93	+	4
746	75	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	87	+	4
747	75	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	167	+	4
748	68	F	Colon	Adenocarcinoma (chronic inflammatory)	T3N1M0	-	III	malignant	+	156	+	4
749	68	F	Colon	Adenocarcinoma (smooth muscle)	T3N1M0	-	III	malignant	+	152	+	4
750	50	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	148	+	4
751	50	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	135	+	4
752	69	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	162	+	4
753	69	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	128	+	4
754	76	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	97	+	4
755	76	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	92	+	4
756	30	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	90	+	4
757	30	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	88	+	4

758	66	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	85	+	4
759	66	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	93	+	4
760	42	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	96	+	4
761	42	F	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	107	+	4
762	65	F	Colon	Adenocarcinoma	T3N1M0	3	III	malignant	+	109	+	4
763	65	F	Colon	Adenocarcinoma	T3N1M0	3	III	malignant	+	84	+	4
764	60	M	Colon	Adenocarcinoma	T3N1M0	2--3	III	malignant	+	89	+	4
765	60	M	Colon	Adenocarcinoma (sparse)	T3N1M0	2--3	III	malignant	+	96	+	4
766	68	M	Colon	Adenocarcinoma	T4N1M0	3	III	malignant	+	163	+	4
767	68	M	Colon	Adenocarcinoma	T4N1M0	3	III	malignant	+	152	+	4
768	37	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	148	+	4
769	37	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	139	+	4
770	72	F	Colon	Adenocarcinoma	T4N1M0	2--3	III	malignant	+	135	+	4
771	72	F	Colon	Adenocarcinoma	T4N1M0	2--3	III	malignant	+	112	+	4
772	24	M	Colon	Mucinous adenocarcinoma	T3N2M0	3	III	malignant	+	118	+	4
773	24	M	Colon	Mucinous adenocarcinoma	T3N2M0	3	III	malignant	+	127	+	4
774	60	F	Colon	Mucinous adenocarcinoma	T3N1M0	2	III	malignant	+	124	+	4
775	60	F	Colon	Mucinous adenocarcinoma	T3N1M0	2	III	malignant	+	105	+	4
776	42	M	Colon	Mucinous adenocarcinoma (sparse)	T3N1M0	1	III	malignant	+	101	+	4
777	42	M	Colon	Mucinous adenocarcinoma (sparse)	T3N1M0	1	III	malignant	+	89	+	4
778	59	F	Colon	Mucinous adenocarcinoma	T3N1M0	1	III	malignant	+	87	+	4
779	59	F	Colon	Mucinous adenocarcinoma	T3N1M0	1	III	malignant	+	90	+	4
780	48	F	Colon	Mucinous adenocarcinoma	T3N1M0	3	III	malignant	+	96	+	4
781	48	F	Colon	Mucinous adenocarcinoma	T3N1M0	3	III	malignant	+	99	+	4
782	45	F	Colon	Adenocarcinoma	T4N2M0	2	III	malignant	+	136	+	4
783	45	F	Colon	Adenocarcinoma	T4N2M0	2	III	malignant	+	128	+	4
784	52	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	109	+	4
785	52	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	117	+	4
786	42	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	110	+	4
787	42	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	104	+	4
788	52	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	98	+	4
789	52	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	87	+	4
790	47	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	84	+++	4
791	47	M	Colon	Adenocarcinoma	T4N1M0	2	III	malignant	+	93	+	4
792	60	M	Colon	Adenocarcinoma	T3N1M0	2	III	malignant	+	91	+	4
793	60	M	Colon	Adenocarcinoma (sparse)	T3N1M0	2	III	malignant	+	98	+	4

794	46	M	Colon	Mucinous adenocarcinoma	T3N1M0	2	III	malignant	+	108	+	4
795	46	M	Colon	Mucinous adenocarcinoma	T3N1M0	2	III	malignant	+	104	+	4
796	48	M	Colon	Mucinous adenocarcinoma	T3 N1a M0		IIIB	tumor	+	115	+	4
797	85	F	Colon	Mucinous adenocarcinoma	4a N1b M0		IIIB	tumor	+	128	+	4
798	73	F	Colon	Partly mucinous adenocarcinoma	T3 N2a M0		IIIB	tumor	+	93	+	4
799	80	M	Colon	Mucinous adenocarcinoma	T3 N1b M0		IIIB	tumor	+	95	+	4
800	67	M	Colon	Partly mucinous adenocarcinoma	T3 N1a M0		IIIB	tumor	+	89	+	4
801	60	F	Colon	Mucinous adenocarcinoma	T3 N1a M0		IIIB	tumor	+	86	+	4
802	32	M	Colon	Adenocarcinoma	T4N0M1	1	IV	malignant	+	81	+	4
803	51	F	Colon	Adenocarcinoma	T4N0M1	2	IV	malignant	+	137	+	4
804	70	F	Colon	Adenocarcinoma	T4N1M1	2	IV	malignant	+	125	+	4
805	58	F	Colon	Adenocarcinoma	T3N0M1	2	IV	malignant	+	126	+	4
806	51	F	Colon	Adenocarcinoma	T4N1M1	2	IV	malignant	+	162	+	4
807	48	F	Colon	Adenocarcinoma	T4N0M1	2	IV	malignant	+	174	+	4
808	48	F	Colon	Adenocarcinoma	T4N1M1	3	IV	malignant	+	178	+	4
809	48	M	Colon	Adenocarcinoma	T4N2M1	3	IV	malignant	+	165	+	4
810	53	M	Colon	Adenocarcinoma	T3N2M1	3	IV	malignant	+	119	+	4
811	40	M	Colon	Mucinous adenocarcinoma	T4N0M1	1	IV	Malignant	+	127	+	4
812	63	F	Colon	Mucinous adenocarcinoma	T4N2M1	1	IV	Malignant	+	172	+	4
813	53	M	Colon	Adenocarcinoma	T3N2M1	1	IV	Malignant	+	165	+	4
814	50	M	Colon	Adenocarcinoma	T2N1M1	2	IV	Malignant	+	173	+	4
815	55	F	Colon	Adenocarcinoma	T4N1M1	2	IV	Malignant	+	153	+	4
816	48	M	Colon	Adenocarcinoma	T3N0M1	2	IV	Malignant	+	149	+	4
817	49	F	Colon	Mucinous adenocarcinoma	T4N1M1	2	IV	Malignant	+	138	+	4
818	67	M	Colon	Adenocarcinoma (sparse)	T3N0M1	3	IV	Malignant	+	137	+	4
819	62	M	Colon	Adenocarcinoma	T4N0M1	3	IV	Malignant	+	155	+	4
820	68	F	Colon	Adenocarcinoma	T3N1M1	3	IV	Malignant	+	167	+	4
821	42	F	Colon	Adenocarcinoma	T4N0M1	3	IV	Malignant	+	144	+	4
822	50	M	Colon	Atypical carcinoid	T2N2M1	-	IV	Malignant	+	128	+	4
823	52	M	Colon	Adenocarcinoma	T3N1M1	2	IV	malignant	+	120	+	4
824	52	M	Colon	Adenocarcinoma	T3N1M1	2	IV	malignant	+	132	+	4
825	26	M	Colon	Adenocarcinoma (fibrous tissue and I	T3N2M1	-	IV	malignant	+	121	+	4
826	26	M	Colon	Adenocarcinoma (fibrous tissue and I	T3N2M1	-	IV	malignant	+	143	+	4
827	64	M	Colon	Adenocarcinoma	T4N0M1	2	IV	malignant	+	154	+	4
828	64	M	Colon	Adenocarcinoma	T4N0M1	2	IV	malignant	+	133	+	4
829	74	M	Colon	Adenocarcinoma	T3N0M1	2	IV	malignant	+	122	+	4

830	74	M	Colon	Adenocarcinoma	T3N0M1	2	IV	malignant	+	134	+	4
831	56	M	Colon	Adenocarcinoma	T3N0M1	3	IV	malignant	+	98	+	4
832	56	M	Colon	Adenocarcinoma	T3N0M1	3	IV	malignant	+	87	+	4
833	77	M	Colon	Mucinous adenocarcinoma	M1a		IVA	tumor	+	156	+	4
834	38	F	Colon	Partly mucinous adenocarcinoma	N2a M1a		IVA	tumor	+	163	+	4
835	31	M	Colon	Mucinous adenocarcinoma	lb N1b M1a		IVA	tumor	+	161	+	4
836	70	M	Colon	Mucinous adenocarcinoma	T3 M1b		IVB	tumor	+	98	+	4
837	70	M	Colon	NAT (colon mucosal tissue)					+	95	+	4
838	53	F	Colon	Mucinous adenocarcinoma	M0			tumor	+	108	+	4
839	53	F	Colon	NAT (colon mucosal tissue)					+	167	+	4
840	77	M	Colon	NAT (colon mucosal tissue)					+	189	+	4
841	47	M	Colon	NAT (colon mucosal tissue)					+	172	+	4
842	54	F	Colon	Partly mucinous adenocarcinoma	T4a M0			tumor	+	163	+	4
843	54	F	Colon	NAT (colon mucosal tissue)					+	102	+	4
844	79	F	Colon	Mucinous adenocarcinoma	T3 M0			tumor	+	104	+	4
845	79	F	Colon	NAT (colon mucosal tissue)					+	189	+	4
846	48	M	Colon	NAT (colon mucosal tissue)					+	183	+	4
847	85	F	Colon	NAT (colon mucosal tissue)					+	192	+	4
848	44	M	Colon	NAT (colon mucosal tissue)					+	194	+	4
849	33	M	Colon	NAT (colon mucosal tissue)					+	178	+	4
850	38	F	Colon	NAT (colon mucosal tissue)					+	167	+	4
851	31	M	Colon	NAT (colon mucosal tissue)					+	182	+	4
852	75	M	Colon	NAT (colon mucosal tissue)					+	93	+	4
853	70	M	Colon	NAT (colon mucosal tissue)					+	109	+	4
854	70	F	Colon	NAT (colon mucosal tissue)					+	128	+	4
855	72	M	Colon	NAT (colon mucosal tissue)					+	124	+	4
856	70	M	Colon	NAT (colon mucosal tissue)					+	167	+	4
857	78	F	Colon	NAT (colon mucosal tissue)					+	173	+	4
858	73	F	Colon	NAT (colon mucosal tissue)					+	190	+	4
859	75	M	Colon	NAT (colon mucosal tissue)					+	184	+	4
860	80	M	Colon	NAT (colon mucosal tissue)					+	98	+	4
861	67	M	Colon	NAT (colon mucosal tissue)					+	97	+	4
862	56	F	Colon	NAT (colon mucosal tissue)					+	112	+	4
863	40	M	Colon	Partly mucinous adenocarcinoma	N0 M0			tumor	+	104	+	4
864	40	M	Colon	NAT (colon mucosal tissue)					+	107	+	4
865	69	M	Colon	NAT (colon mucosal tissue)					+	118	+	4

866	63	M	Colon	Partly mucinous adenocarcinoma	N0 M0		tumor	+	126	+	4
867	63	M	Colon	NAT (colon mucosal tissue)				+	134	+	4
868	78	F	Colon	Little mucinous adenocarcinoma	N0 M0		tumor	+	128	+	4
869	78	F	Colon	NAT (colon mucosal tissue)				+	145	+	4
870	57	M	Colon	NAT (colon mucosal tissue)				+	156	+	4
871	72	M	Colon	Partly mucinous adenocarcinoma	N0 M0		tumor	+	178	+	4
872	72	M	Colon	NAT (colon mucosal tissue)				+	182	+	4
873	60	F	Colon	NAT (colon mucosal tissue)				+	180	+	4
874	60	F	Colon	NAT (colon mucosal tissue)				+	176	+	4
875	27	M	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	84	+	4
876	61	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	89	+	4
877	62	F	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	94	+	4
878	55	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	90	+	4
879	44	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	83	+	4
880	46	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	85	+	4
881	68	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	91	+	4
882	70	M	Colon	Adenocarcinoma	T3N1M0	3	Malignant	+	103	+	4
883	39	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	87	+	4
884	82	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	83	+	4
885	58	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	89	+	4
886	73	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	93	+	4
887	65	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	91	+	4
888	49	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	99	+	4
889	40	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	102	+	4
890	34	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	108	+	4
891	61	M	Colon	Mucinous adenocarcinoma	T3N0M0	1	Malignant	+	83	+	4
892	59	M	Colon	Adenocarcinoma	T2N0M0	-	Malignant	+	87	+	4
893	68	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	98	+	4
894	62	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	88	+	4
895	60	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	91	+	4
896	64	M	Colon	Adenocarcinoma	T3N1M0	1	Malignant	+	94	+	4
897	47	F	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	85	+	4
898	75	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	87	+	4
899	69	F	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	96	+	4
900	55	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	94	+	4
901	68	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	89	+	4

902	36	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	90	+	4
903	72	F	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	97	+	4
904	47	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	103	+	4
905	32	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	112	+	4
906	51	M	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	109	+	4
907	66	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	87	+	4
908	72	M	Colon	Mucinous adenocarcinoma	T2N0M0	1	Malignant	+	89	+	4
909	51	F	Colon	Mucinous adenocarcinoma	T4N0M0	1	Malignant	+	90	+	4
910	58	F	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	85	+	4
911	66	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	84	+	4
912	46	M	Colon	Mucinous adenocarcinoma	T2N1M0	1	Malignant	+	67	+	4
913	67	F	Colon	Mucinous adenocarcinoma	T3N0M0	1	Malignant	+	58	+	3
914	39	M	Colon	Mucinous adenocarcinoma	T3N0M0	1	Malignant	+	43	+++	4
915	65	F	Colon	Mucinous adenocarcinoma	T3N0M0	1	Malignant	+	78	+	3
916	74	F	Colon	Mucinous adenocarcinoma	T3N0M0	1	Malignant	+	79	+	3
917	37	M	Colon	Mucinous adenocarcinoma	T3N0M0	1	Malignant	+	96	+	4
918	58	M	Colon	Mucinous adenocarcinoma	T4N1M1	1	Malignant	+	103	+	4
919	74	M	Colon	Mucinous adenocarcinoma	T4N0M0	1	Malignant	+	88	+	4
920	59	F	Colon	Mucinous adenocarcinoma	T4N0M0	1	Malignant	+	85	+	4
921	60	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	93	+	4
922	45	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	90	+	4
923	68	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	83	+++	4
924	43	F	Colon	Adenocarcinoma	T4N0M0	*	Malignant	+	89	+	4
925	72	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	93	+	4
926	36	M	Colon	Adenocarcinoma	T4N0M0	-	Malignant	+	92	+	4
927	44	F	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	67	+	3
928	37	M	Colon	Adenocarcinoma	T4N1M0	1	Malignant	+	54	+	3
929	77	F	Colon	Adenocarcinoma	T2N0M0	-	Malignant	+	63	+	3
930	52	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	83	+	4
931	26	M	Colon	Adenocarcinoma	T3N2M1	1	Malignant	+	87	+	4
932	55	F	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	90	+	4
933	37	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	93	+	4
934	73	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	89	+	4
935	57	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	87	+	4
936	57	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	94	+	4
937	57	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	103	+	4

938	59	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	112	+	4
939	57	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	98	+	4
940	61	F	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	94	+	4
941	63	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	86	+	4
942	30	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	89	+	4
943	77	M	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	81	+	4
944	52	M	Colon	Adenocarcinoma	T2N0M0	3	Malignant	+	92	+	4
945	62	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	83	+	4
946	61	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	88	+	4
947	54	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	87	+	4
948	90	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	94	+	4
949	70	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	103	+	4
950	73	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	109	+	4
951	72	F	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	117	+	4
952	74	M	Colon	Adenocarcinoma	T3N0M1	1	Malignant	+	86	+	4
953	53	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	83	+	4
954	54	F	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	92	+	4
955	62	M	Colon	Adenocarcinoma	T1N0M0	1	Malignant	+	90	+	4
956	44	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	97	+	4
957	60	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	89	+	4
958	49	F	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	88	+	4
959	56	F	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	108	+	4
960	64	F	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	105	+	4
961	29	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	115	+	4
962	48	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	110	+	4
963	60	M	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	121	+	4
964	47	M	Colon	Adenocarcinoma	T4N1M0	2	Malignant	+	87	+	4
965	67	F	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	89	+	4
966	48	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	93	+	4
967	64	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	97	+	4
968	54	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	86	+	4
969	75	F	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	107	+	4
970	68	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	114	+	4
971	46	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	123	+	4
972	78	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	108	+	4
973	42	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	105	+	4

974	52	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	82	+	4
975	81	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	81	+	4
976	32	M	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	93	+	4
977	36	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	107	+	4
978	47	M	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	88	+	4
979	43	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	81	+	4
980	81	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	93	+	4
981	63	F	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	129	+	4
982	60	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	121	+	4
983	62	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	81	+	4
984	64	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	83	+	4
985	65	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	92	+	4
986	86	M	Colon	Adenocarcinoma	T4N1M0	2	Malignant	+	98	+	4
987	48	F	Colon	Adenocarcinoma	T4N1M0	2	Malignant	+	97	+	4
988	44	M	Colon	Adenocarcinoma	T4N0M0	3	Malignant	+	109	+	4
989	75	M	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	105	+	4
990	60	M	Colon	Adenocarcinoma	T3N1M0	2	Malignant	+	89	+	4
991	70	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	82	+	4
992	67	M	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	94	+	4
993	57	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	98	+	4
994	33	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	103	+	4
995	75	M	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	94	+	4
996	31	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	87	+	4
997	67	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	83	+	4
998	66	F	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	92	+	4
999	72	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	97	+	4
1000	53	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	83	+	4
1001	76	F	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	104	+	4
1002	69	M	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	109	+	4
1003	35	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	127	+	4
1004	60	M	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	135	+	4
1005	62	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	121	+	4
1006	48	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	101	+	4
1007	55	F	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	109	+	4
1008	64	F	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	97	+	4
1009	58	M	Colon	Adenocarcinoma	T2N0M0	-	Malignant	+	98	+	4

1010	41	F	Colon	Adenocarcinoma	T2N0M0	-	Malignant	+	81	+	4
1011	46	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	87	+	4
1012	63	F	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	86	+	4
1013	57	F	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	105	+	4
1014	48	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	118	+	4
1015	66	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	137	+	4
1016	66	M	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	129	+	4
1017	64	F	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	103	+	4
1018	77	F	Colon	Adenocarcinoma	T3N1M0	2	Malignant	+	84	+	4
1019	74	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	98	+	4
1020	61	F	Colon	Adenocarcinoma	T2N1M0	-	Malignant	+	87	+	4
1021	64	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	94	+	4
1022	45	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	103	+	4
1023	50	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	89	+	4
1024	63	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	87	+	4
1025	46	F	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	96	+	4
1026	60	M	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	104	+	4
1027	62	F	Colon	Adenocarcinoma	T3N0M0	1	Malignant	+	108	+	4
1028	80	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	117	+	4
1029	48	M	Colon	Adenocarcinoma	T2N0M0	1	Malignant	+	124	+	4
1030	23	M	Colon	Mucinous adenocarcinoma	T3N0M0	1	Malignant	+	132	+	4
1031	46	M	Colon	Mucinous adenocarcinoma	T3N1M0	-	Malignant	+	143	+	4
1032	60	F	Colon	Mucinous adenocarcinoma	T2N0M0	-	Malignant	+	88	+	4
1033	74	F	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	89	+	4
1034	59	F	Colon	Mucinous adenocarcinoma	T3N1M0	-	Malignant	+	93	+	4
1035	69	F	Colon	Adenocarcinoma	T4N0M0	1	Malignant	+	94	+	4
1036	53	M	Colon	Mucinous adenocarcinoma	T3N0M0	2	Malignant	+	90	+	4
1037	51	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	102	+	4
1038	60	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	104	+	4
1039	56	F	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	107	+	4
1040	56	M	Colon	Adenocarcinoma	T3N0M0	2	Malignant	+	83	+	4
1041	80	F	Colon	Adenocarcinoma	T2N0M0	3	Malignant	+	87	+	4
1042	47	M	Colon	Adenocarcinoma	T2N0M0	2	Malignant	+	91	+	4
1043	68	M	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	94	+	4
1044	78	M	Colon	Adenocarcinoma	T3N0M0	3	Malignant	+	128	+	4
1045	50	M	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	116	+	4

1046	47	M	Colon	Mucinous adenocarcinoma	T3N0M0	2	Malignant	+	109	+	4
1047	46	M	Colon	Adenocarcinoma	T4N0M0	3	Malignant	+	129	+	4
1048	52	M	Colon	Adenocarcinoma	T3N0M0	3	Malignant	+	135	+	4
1049	50	M	Colon	Adenocarcinoma	T4N0M0	2	Malignant	+	142	+	4
1050	68	M	Colon	Mucinous adenocarcinoma	T3N0M0	2	Malignant	+	144	+	4
1051	37	M	Colon	Adenocarcinoma	T4N1M1	2	Malignant	+	138	+	4
1052	67	F	Colon	Adenocarcinoma	T3N0M0	-	Malignant	+	127	+	4
1053	48	M	Colon	Adenocarcinoma	T2N0M0	3	Malignant	+	126	+	4
1054	38	M	Colon	Adenocarcinoma	T4N1M0	3	Malignant	+	138	+	4
1055	46	M	Colon	Adenocarcinoma	T3N0M0	3	Malignant	+	87	+	4
1056	77	M	Colon	Adenocarcinoma	T4N0M0	3	Malignant	+	94	+	4
1057	39	M	Colon	Adenocarcinoma	T2N0M0	3	Malignant	+	97	+	4
1058	35	M	Colon	Adenocarcinoma	T2N0M0	3	Malignant	+	81	+	4
1059	65	F	Colon	Adenocarcinoma	T2N0M0	3	Malignant	+	104	+	4
1060	74	M	Colon	Adenocarcinoma	T3N0M0	3	Malignant	+	107	+	4
1061	56	M	Colon	Adenocarcinoma	T3N0M1	3	Malignant	+	67	+	3
1062	50	F	Colon	Adenocarcinoma	T2N0M0	3	Malignant	+	85	+	4
1063	35	M	Colon	Signet ring cell carcinoma	T3N0M0	-	Malignant	+	108	+	4
1064	31	M	Colon	Adenocarcinoma	T4N0M0	3	Malignant	+	127	+	4
1065	59	M	Colon	Mucinous adenocarcinoma	T3N0M0	*	Malignant	+	106	+	4
1066	51	M	Colon	Cancer adjacent colon tissue	-	-	NAT	+	134	+	4
1067	68	M	Colon	Cancer adjacent colon tissue	-	-	NAT	+	156	+	4
1068	52	M	Colon	Cancer adjacent colon tissue	-	-	NAT	+	167	+	4
1069	35	M	Colon	Cancer adjacent colon tissue	-	-	NAT	+	103	+	4
1070		M	Colon	Colon tissue			Normal	-			
1071		M	Colon	Colon tissue			Normal	-			
1072		M	Colon	Colon tissue			Normal	-			
1073		M	Colon	Colon tissue			Normal	-			
1074		M	Colon	Colon tissue			Normal	-			
1075		M	Colon	Colon tissue			Normal	-			